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Abstract
Understanding the brain in both health and disease is of critical practical impor-
tance as well as fundamental scientific interest. The acute neural tissue slice is a
widely used experimental preparation, it facilitates treatments and measurements
not practical in vivo while preserving a largely connected network representative of
the true in vivo structure. This thesis presents the development of two techniques for
the study of the acute neural tissue slice, both particularly well suited to the study
of epilepsy, followed by an application of one of these techniques. A slice chamber is
presented that allows extended regions of a tissue slice to be exposed, in isolation,
to changes in ionic environment or pharmacological manipulation, readily providing
an entirely in vitro model of focal epilepsy. Secondly, a transformation is derived
that converts the slow dynamics of the intrinsic optical signal (IOS) associated with
neuronal activity both in vivo and in vitro to the form of the associated local field
potential, allowing the advantages of the IOS to be exploited while mitigating the
primary disadvantage - the lack of direct correspondence between the IOS and the
associated network dynamics. Finally a study is presented that employs the transfor-
mation of the IOS to facilitate a quantitative characterisation of the spatio-temporal
dynamics of adenosine release in response to electrographic seizure activity.
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Chapter 1
Introduction
Epilepsy is a disorder of the nervous system that is characterised by paroxysmal
episodes of abnormal brain activity. In this thesis two techniques for the study
of brain function in health and disease, both particularly suited to the study of
epilepsy, will be presented. The first is a fluidic device that allows an extended
region of a tissue slice to be exposed, in isolation, to changes in environment while
preserving the ability to record from the slice. This readily provides a model of focal
epilepsy - by exposing a region of tissue to a pro-convulsant while maintaining the
remainder of the slice in a physiological medium. The second method transforms
the slow temporal dynamics of the intrinsic optical signal (IOS) associated with
neuronal activity in vitro to a form that accurately mimics the more fundamental
dynamics of the local field potential (LFP). This transformation overcomes the pri-
mary disadvantage of the use of the IOS as a proxy for recording neuronal activity,
allowing the many advantages to be fully exploited. The result is a technique for
recording the spatio-temporal dynamics of neuronal activity particularly well suited
to the study of the propagation of focal seizure activity. Finally, the transformation
of the IOS is applied to the study of the spatiotemporal dynamics of adenosine, a po-
tent neuromodulator implicated in a number of physiological and pathophysiological
processes, and that plays a particularly important role in epilepsy.
In this chapter aspects of neurophysiology and neuropharmacology relevant
to the studies presented in later chapters will be briefly summarised, a number of
techniques for the study of the nervous system will be reviewed and the relevant
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Figure 1.1: The structure of a typical neuron showing branching processes. From Briar et al.
(2003). The figure has been redacted from this version to avoid copyright infringement.
disease processes will be discussed.
1.1 Brain anatomy and physiology
The brain processes sensory input, stores information and coordinates responses.
The current understanding of the cellular basis of these processes will be briefly
summarised here, however, for a more thorough review see Kandel et al. (2013).
Cellular composition
The three main components of brain tissue that are thought to be involved in infor-
mation processing and storage are neurons, astrocytes and oligodendrocytes. Neu-
rons consist of a cell body (soma) that gives rise to a number of processes that
connect to other neurons, receive sensory input or transmit output to other parts
of the body. Fig 1.1 shows the branching structure of a typical neuron. Input to
the neuron is received by the processes termed dendrites and output is conveyed
to other neurons along the axon. Neurons are electrically excitable cells, at rest
active transport of ions leads to a potential across the membrane ∼ -65 mV. How-
ever, if a combination of depolarising inputs causes the membrane potential to cross
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Figure 1.2: The membrane potential of a typical neuron during an action potential. From
Bean (2007). The figure has been redacted from this version to avoid copyright infringement.
a threshold potential (typically ∼ -55 mV), the membrane potential undergoes a
large transient depolarisation, followed by repolarisation. Such an event is termed
an action potential (Fig. 1.2). At their simplest, action potentials are caused by
the opening of a large number of voltage gated Na+ channels in response to initial
depolarisation. The resulting influx of Na+ ions leads to further depolarisation, be-
fore the channels inactivate. Voltage gated K+ channels then open, K+ ions enter
the cell, causing it to repolarise (for a more thorough summary see Bean (2007)).
Action potentials are binary events that propagate along the processes of neurons.
It is the rate and relative timing of action potentials, in addition to the connectivity
of the network that is thought to encode information in the brain. The speed of
propagation of action potentials strongly affects brain function. Lower membrane
conductance and capacitance both lead to increased propagation speed. To reduce
membrane conductance and capacitance other cells, oligodendrocytes in the central
nervous system and Schwann cells in the peripheral nervous system, can form an
insulating layer, known as myelin, around the axons of neurons. This insulation
results in much faster signal propagation. Some diseases, such as Guillain-Barre´
syndrome and multiple schlerosis, are associated with loss of myelin and cause sig-
nificant neurological problems.
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Figure 1.3: The structure of a typical chemical synapse showing both presynaptic and
postsynaptic neurons and an astrocyte. From Briar et al. (2003). The figure has been
redacted from this version to avoid copyright infringement.
There are three known forms of coupling between neurons, chemical synapses,
gap junctions and ephaptic coupling. Chemical synapses are junctions between the
terminal boutons of neurons and their target cells. When an action potential reaches
the terminal the depolarisation causes the opening of voltage gated Ca2+ channels.
As a result, Ca2+ ions enter the terminal and cause vesicles of neurotransmitter to
stochastically (Ribrault et al., 2011) fuse with the membrane and release their con-
tents in to the synaptic cleft (Fig. 1.3). The neurotransmitter then diffuses across
the cleft and binds to receptors on the post-synaptic cell and, potentially, on the
pre-synaptic cell and adjacent astrocytes, effecting some change, for a review see
Lisman et al. (2007). Most simply, the binding of neurotransmitter to ligand gated
ion channels causes them to open channels, ions then move across the membrane of
the post-synaptic cell, causing a change in membrane potential. If the combination
of synaptic inputs to the post-synaptic neuron causes its membrane to depolarise
above its threshold, an action potential will occur. The released transmitter is then
removed by astrocytes, cells that surround synapses (for reviews of astrocytic func-
tions see Haydon (2001); Volterra and Meldolesi (2005); Clarke and Barres (2013)).
Modulation of synaptic strength is implicated in learning and memory, for reviews
see Lamprecht and LeDoux (2004) and Sohl et al. (2005).
In addition to chemical synapses, neurons can be coupled by gap junctions.
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Figure 1.4: Golgi stained cortex of a human infant, showing the typical layered structure.
From Cajal (1899). The figure has been redacted from this version to avoid copyright
infringement.
These are groups of channels that directly connect the cytoplasm of two neurons.
Ions can move through the channels and so when the potentials of the connected
regions of the two cells are unequal, ions move so as reduce the difference in potential.
If, for example, an action potential occurs in one cell, a transient depolarisation
occurs in cells to which it is gap junction coupled. For a review see Pereda (2014).
The final way in which neurons are known to couple is by direct field effects,
known as ephaptic coupling (Anastassiou et al., 2011). Neurons are electrochemical
systems, their dynamics give rise to time varying electric fields, these fields then
affect other cells. These effects, although relatively small, are sufficient to entrain
the firing of action potentials in adjacent cells (Anastassiou et al., 2011).
Tissue structure
The brain is formed of a number of functionally and structurally distinct regions.
The structure of the regions discussed in this thesis will be briefly summarised here,
for a more complete discussion see Kandel et al. (2013).
The majority of the results presented in this thesis relate to the neocortex.
The neocortex is the outer-most region of the cerebrum, it is responsible for many
higher cognitive processes such as perception and the generation of motor com-
mands. The neocortex is comprised of six layers (Fig. 1.4) that lie parallel to the
pial surface.
Layer I, the outer most layer, is termed the molecular layer and contains few
neuronal somata, the majority that are present are inhibitory. Additionally, Layer
I is composed of dendritic tufts, axons and glia. Layer II/III receives strong feed-
forward input from layer IV, which in turn receives strong input from the thalamus.
Layer V is the main output layer, projecting to sub-cortical structures. Layer VI
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Figure 1.5: The cannonical connectivity of the principal cells of the neocortex. From Harris
and Mrsic-Flogel (2013). The figure has been redacted from this version to avoid copyright
infringement.
is the deepest layer, and both receives input and provides output to the thalamus.
The typical connectivity within the neocortex is an area of intense study, Fig. 1.5
shows a simplified summary, for a review see Harris and Mrsic-Flogel (2013).
Hippocampal and cerebellar tissue was also employed in a number of exper-
iments presented in this thesis. The hippocampus is a cortical structure strongly
implicated in memory and navigation. The hippocampus has a well characterised
structure (Fig. 1.6) comprising a number of ordered pathways (Strange et al., 2014).
These pathways are used for a wide range of investigations because the structure
facilitates a convenient stimulus evoked response and it was for this reason that hip-
pocampal tissue was employed here. Finally, cerebellar tissue was used in a number
of experiments. The cerebellum (Fig. 1.7) is a posterior structure, implicated in mo-
tor control. Cerebellar tissue was employed because one of its constituent cell types,
Purkinje cells, fire spontaneously (at a frequency of approximately 50 Hz (Raman
and Bean, 1999)) in acute slice (Apps and Garwicz, 2005; De Zeeuw et al., 2011).
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Figure 1.6: The hippocampal circuit, showing the well characterised pathways. From Dau-
mas et al. (2009). The figure has been redacted from this version to avoid copyright in-
fringement.
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Figure 1.7: The cerebellar circuit, showing the location of Purkinje cells that fire sponta-
neously in acute slice preparations. From Apps and Garwicz (2005). The figure has been
redacted from this version to avoid copyright infringement.
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Figure 1.8: The molecular structure of adenosine. From Ralevic and Burnstock (1998). The
figure has been redacted from this version to avoid copyright infringement.
1.2 The role of adenosine
The final study in the core of this thesis presents a characterisation of the spatiotem-
poral dynamics of extracellular adenosine concentration in response to electrographic
seizure activity in the neocortex. A brief summary of the current understanding of
the role of adenosine will be presented here, for more thorough reviews see Fredholm
et al. (2001) and Ralevic and Burnstock (1998).
Adenosine is a purine nucleoside (Fig. 1.8), it is an important signalling
molecule, implicated in both physiological and pathological processes. For example,
adenosine plays an important role in the regulation of sleep (Huang et al., 2011;
Blanco-Centurion et al., 2006; Bjorness and Greene, 2009; Schmitt et al., 2012; Sims
et al., 2013), is a powerful vasodilator and an important neuroprotectant implicated
in stroke, traumatic brain injury and epilepsy (Pasini et al., 2000; Dale et al., 2000;
Frenguelli et al., 2003; Hunter et al., 2003; Pearson et al., 2006; Dale and Frenguelli,
2009; Ross et al., 2014; Winn et al., 1980; During and Spencer, 1992; Van Gompel
et al., 2014).
Adenosine activates four types of G-protein coupled receptor: A1, A2A, A2B
and A3 (Ralevic and Burnstock, 1998; Fredholm et al., 2001), all composed of seven
putative transmembrane domains (the structure of the A1 receptor is shown in
Fig. 1.9). Activation of A1 and A3 receptors is largely inhibitory while that of A2
receptors is largely excitatory; A2A receptors are found in the central nervous system
and A2B are found in the peripheral nervous system (Wall and Dale, 2008). The
EC50 values for the four subtypes are 73 nM (Daly and Padgett, 1992); 150 nM
(Daly and Padgett, 1992); 5100 nM (Peakman and Hill, 1994) and 6500 nM (Zhou
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et al., 1992).
A1 receptors are particularly abundant in the central nervous system. They
are located both pre- and post-synaptically, on cell bodies and on axons. Activa-
tion of A1 receptors has an inhibitory effect on neurotransmission by decreasing the
probability of vesicle release and hyperpolarising neuronal membranes (Ralevic and
Burnstock, 1998). Adenosine is released during hypoxia and ischemia. The resulting
activation of A1 receptors reduces neuronal activity and, therefore, metabolic de-
mand and as such is neuroprotective. A1 receptors are also expressed on the heart,
activation of these receptors has negative chronotropic and inotropic effects, compli-
cating the use of an A1 receptor agonist therapeutically to treat excessive neuronal
activity such as occurs in epilepsy.
A2A receptors are found in a restricted number of tissues including the central
nervous system, particularly the striatum, and vascular smooth muscle. In the cen-
tral nervous system activation of A2A receptors largely facilitates neurotransmitter
release. However, striatal neurons express A2A receptors in close association with
dopamine D2 receptors, activation of these A2A receptors reduces the affinity of the
D2 receptors for dopamine. This has raised the possibility of using A2A receptor
antagonists to treat Parkinsons.
A2B receptors are widely expressed at low levels, requiring relatively high
concentrations of adenosine for activation. They appear to be implicated in inflam-
matory responses.
A3 receptors are also expressed widely and also appear to play a role in
inflammatory responses. Activation of hippocampal A3 receptors has also been
shown to desensitise A1 receptor mediated inhibition (Dunwiddie et al., 1997).
Changes in extracellular adenosine concentration are produced by a number
of mechanisms, for reviews see Latini and Pedata (2001) and Wall and Dale (2008).
Briefly, adenosine can be released from neurons through equilibritive nucleoside
transporters (ENTs) (Wall and Dale, 2013); adenosine can be produced by the
dephosphorylation of ATP released by exocytosis from astrocytes (Wall and Dale,
2013) and direct exocytosis of adenosine has been detected in the cerebellum (Klyuch
et al., 2012). A number of candidate mechanisms are shown in Fig. 1.10.
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Figure 1.9: The structure of the A1 receptor showing seven transmembrane domains,
thought to be composed of α-helices. From Ralevic and Burnstock (1998). The figure
has been redacted from this version to avoid copyright infringement.
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Figure 1.10: Possible mechanisms for activity-dependent adenosine release. (1) ATP released
by exocytosis and subsequently dephosphorylated to adenosine in the extracellular space.
(2) An intermediate signalling molecule is released by exocytosis and acts on another cell to
cause adenosine release. (3) Direct exocytotic release of vesicular adenosine. Additionally,
adenosine could be released through equilibritive nucleoside transporters. From Wall and
Dale (2008). The figure has been redacted from this version to avoid copyright infringement.
Adenosine is removed either by phosphorylation to AMP by adenosine ki-
nase (ADK) or deamination to inosine by adenosine deaminase (ADA) (Latini and
Pedata, 2001). Both ADK and ADA are primarily found intracellularly and act on
adenosine once it has entered a cell via ENTs, however, there is also evidence of
extracellular ADA (Latini and Pedata, 2001). A summary of some of the pathways
of production, metabolism and transport of adenosine are shown in Fig. 1.11.
1.3 Methods for recording neuronal activity
To study network activity in the nervous system a technique is required to measure
or infer neuronal activity. Many techniques have been developed, each striking a dif-
ferent balance in the compromise between spatial and temporal resolution; recording
duration; the area of the region of interest and the damage or ionic modification
caused in the tissue. In this section a number of commonly used techniques will
be briefly summarised, however, it should be noted that this is an intense area of
research and so the technology available is developing rapidly.
As already discussed, neurons are active electro-chemical systems. To in-
fer neuronal activity, the voltage changes that arise from neuronal activity can be
12
Figure 1.11: Pathways of adenosine production, metabolism and transport, with indica-
tions of the sites of action of various enzyme inhibitors. ADA: Adenosine deaminase;
AK: Adenosine kinase; AOPCP: α, β-methylene ADP; DCF: deoxycoformycin; EHNA:
erythro-9-(2-hydroxy-3-nonyl)adenosine; es: equilibrative-sensitive nucleoside transporters;
ei: equilibrative-insensitive nucleoside transporters; 5-IT: 5-iodotubercidin; NBMPR:
nitrobenzyl-thioiniosine; PDE: cAMP phosphodiesterase; SAH: S-adenosyl homocysteine.
From Latini and Pedata (2001). The figure has been redacted from this version to avoid
copyright infringement.
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measured directly, either from single neurons by patch clamp recording or by mea-
suring the averaged contribution from a population of neurons, such as with local
field potential (LFP), electrocorticogram (ECoG) or electroencephalogram (EEG)
recording. Alternatively neuronal activity can be measured using voltage or calcium
sensitive dyes, either loaded in to cells or expressed by the cells themselves. Finally,
activity can be inferred from changes in the intrinsic optical properties of brain
tissue at the network level, such as with in vitro intrinsic optical signal (IOS) imag-
ing, or by the effect of activity on the local perfusion, as with functional magnetic
resonance imaging (fMRI) or typical in vivo IOS imaging.
The intracellular voltage dynamics of single neurons can be recorded using
patch clamp recording techniques (Sakmann and Neher, 1984), using either whole
cell, cell attached (Perkins, 2006) or perforated patch (Linley, 2013) configurations.
These approaches give high resolution recordings specific to the neurons under in-
vestigation. However, the number of simultaneous recordings is limited, the highest
number to date is twelve (Anastassiou et al., 2011), this does not give a representa-
tive reflection of the activity of the ∼ 106 neurons in a slice of rat cortex.
The potential at any point in or around the brain is a weighted average
of contributions from the entire brain. This potential can be measured and its
time dependence can be used to make inferences about the underlying network
dynamics. When this potential is measured by electrodes on the scalp it is termed
the electroencephalogram (EEG), when it is measured by subdural electrodes on the
cortical surface it is termed the electrocorticogram (ECoG) and when measured from
within the brain, either in vivo or in vitro, the local field potential (LFP). Whilst
this technique does allow activity to be resolved spatially, the contribution at any
point includes contributions from all points. The contribution of each monopole
scales inversely with distance, spatial localisation is, therefore, limited. However,
advances in analysis approaches are improving the recoverable spatial resolution.
The advantage of these techniques, however, is that they produce a local spatial
average of neuronal activity. When coordinated network activity is of interest, such
as in the study of epilepsy, this averaging is highly desirable - the activity of a few
single neurons, such as would be obtained from patch clamp recordings, is not as
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representative. For a review of these recording modalities see Buzsaki et al. (2012).
Single cell resolution can also be achieved using dye based techniques. The
fluorescence characteristics of suitable dyes change in response to changes either in
intracellular voltage or intracellular calcium concentration. These changes can then
be used to infer neuronal activity. Dyes can either be loaded in to cells directly
or the cells can be modified to express the dyes themselves. Dye based techniques
allow single cell resolution recording from many more cells than is possible with
patch clamp recording. However, dyes bleach with a half life ∼ 800 s (Wenjun et al.,
2002; Takagaki et al., 2008) and so the recording duration is severely limited. These
approaches are, therefore, not suitable for the study of rare spontaneous events,
such as seizure onset. For reviews of these techniques see Kerr and Denk (2008) and
Knopfel (2012).
Other techniques infer the activity of neurons indirectly. Neuronal activity
has an associated metabolic demand and increased neuronal activity has an asso-
ciated increased metabolic demand. Such variations in metabolic demand can be
inferred from the blood oxygen level, this is termed the blood oxygen level dependent
(BOLD) signal. The BOLD signal is made up of three components: Immediately
after an increase in neuronal activity the ratio of oxy- to deoxy- haemoglobin tran-
siently decreases as a result of increased oxygen consumption. To compensate for
this the supply of oxygenated blood then increases. Finally, after the level of neu-
ronal activity has reduced, the blood flow also reduces. The BOLD signal can be
detected in a number of ways, for example, using magnetic resonance imaging (MRI)
and is the basis of functional MRI (fMRI), for a review see Heeger and Ress (2002).
It should be noted, however, that the neurovascular coupling that gives rise to the
BOLD signal may be altered in disease states and may vary with age so care is
needed when employing this technique (D’Esposito et al., 2003). The BOLD sig-
nal, in addition to changes in the oxidation state of cytochrome oxidase, can also
be detected spectroscopically and is often termed an intrinsic optical signal (IOS).
However, without a craniotomy or cranial window, the scalp and skull limit the sig-
nal, but this approach has shown significant promise for measurement in neonates
(Edwards et al., 1991; Cooper et al., 1999).
15
In addition to the BOLD and cytochrome oxidase dependent signals observed
in vivo there is an additional intrinsic optical signal (IOS) that persists in vitro
(Gouras, 1958; Aitken et al., 1999; Gurden et al., 2006). A number of mechanisms
contribute to this signal. There is a fast change in light scattering that is neuronal
in origin and closely tracks the dynamics of the underlying electrical activity (Cohen
et al., 1968; Stepnoski et al., 1991; Rector et al., 1997, 2005). However, because of
its small signal-to-noise ratio, averaging of many sweeps is required to detect this
signal in tissue; it is therefore unsuitable for the study of spontaneous activity. The
first response is followed by a slower, much larger, signal that results from a combi-
nation of glutamate dependent neuronal and glial swelling, changes in cytoplasmic
refractive index and possibly changes in the interactions between macromolecules
and organelles (Lipton, 1973; Holthoff and Witte, 1996; Andrew et al., 1999; Buch-
heim et al., 1999, 2005; Jarvis et al., 1999; Fayuk et al., 2002; Gurden et al., 2006;
Kitaura et al., 2009). This signal can be readily measured, however, the temporal
dynamics of the signal do not directly reflect the underlying network dynamics. This
signal is the subject of Chapter 3 and will be discussed more fully there.
1.4 Preparations used for the study of the nervous sys-
tem
A wide range of preparations have been developed for the study of the nervous
system. Each strikes a different balance between fidelity to the system ultimately of
interest, access for recording and the ability to control and manipulate the system
to implement experimental protocols.
Ultimately it is the in vivo human brain that is of interest, it can be studied
directly using non-invasive techniques such as fMRI and EEG and with more in-
vasive approaches, such as ECoG, when they are indicated for clinical reasons and
additional data can be obtained without significant modification to the surgical pro-
tocol. For example, depth electrodes may be implanted to determine the location
of seizure foci for evaluation for resection, (for examples see Truccolo et al. (2011);
Van Gompel et al. (2014); Chang et al. (2012)). However, experiments that require
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more invasive surgical procedures than clinically indicated or that require otherwise
unnecessary pharmacological manipulation are deemed unethical and so cannot be
carried out.
Pharmacological manipulation and invasive recording techniques can, how-
ever, be applied to ex vivo human brain tissue. Resection of the brain is indicated
for a number of neurological problems, for example, for the treatment of some cases
of pharmacologically refractory focal epilepsy. The tissue removed, after appropri-
ate clinical tests, is often made available for research purposes. This tissue often
provides exact insights in to disease processes, rather than only being a model of
them. However, the availability of such tissue is limited and clinical considerations
must always take precedence over maximising the quality of the samples for research.
Additionally, the tissue removed is almost always affected by a disease process and
so it is unlikely to be suitable for the study of physiological processes.
Although it is the human brain that is ultimately of interest, the brains of
other mammals are thought to provide a good model of human brain function and
are widely used for the study of the nervous system. As with human brain, the
brains of other mammals can be studied in vivo, however, although there are strict
ethical controls, where justified, more invasive in vivo surgical procedures can be
carried out. Furthermore these can be implemented in both healthy animals and
those affected by disease as well as in transgenic lines. The access for both recording
and manipulation is, however, still limited and so in vivo preparations are unsuitable
for some protocols. Equally, some protocols do not require in vivo measurement and
so it would be unethical to use such a preparation.
Typically experiments are either carried out in vivo, in tissue slices or in
cultured cells. However, an intermediate preparation is possible with the guinea
pig brain. The guinea pig brain can be removed and perfused through its circle of
Willis, allowing the intact brain to be viably maintained out of the skull, this is
termed the isolated brain. This preparation allows improved access and pharma-
cological manipulation while preserving the complete network connectivity. Access
for recording is, however, still more limited than in tissue slice or cell culture.
The acute tissue slice strikes a different balance between fidelity and ac-
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cess. The brain of an animal is rapidly removed and, whilst cold, cut in to slices
∼ 400 µm thick. The slices are then rewarmed and immersed in an oxygenated
artificial cerebrospinal fluid (aCSF) which maintains the viability of the tissue by
diffusion. The cutting process severs a large proportion of the network connections,
however, sections are cut that maximise connectivity within the slice and such slices
exhibit spontaneous activity, indicating a significant degree of connectivity. The
advantage of the acute tissue slice preparation is the degree of access to the tissue
that it facilitates, both for recording from the tissue and for pharmacological, ionic,
electrical and mechanical manipulation. Additionally, all experimentation is carried
out once the animal is dead and so the suffering caused is minimised. For these rea-
sons all experiments presented in this thesis that involved animal tissue employed
this preparation.
Typically acute tissue slices are only viable on the day of preparation, how-
ever, tissue from young animals can be cultured. Cultured slices are termed organ-
otypics and are well suited to the study of slow processes that require direct access
to the cells (Gahwiler et al., 1997). For example, cells in culture can be transfected
and the effect of expression of a resulting protein can be investigated, a process that
would not occur within the time scale of viability of an acute tissue slice. Unlike
in cultures of separate cells, some synaptic connections between cells are preserved,
allowing the study of synaptic transmission. However, the development of the cells
within an organotypic slice can differ from that which would occur in vivo so some
caution is required.
Finally, cellular processes and ion channel dynamics can be studied in cul-
tured cells, unlike in organotypic cultures, the cells do not form a network and so
synaptic transmission can not be studied using this preparation. However, cultured
cells are well suited to the study of ion channels and other proteins, such as con-
nexins, as mutant lines can be produced rapidly. Ion channel properties can also be
studied in relative isolation by reconstituting them in artificial membranes.
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1.5 Seizures
Clinically, an epileptic seizure is defined as an unprovoked transient occurrence of
signs or symptoms due to abnormal excessive or synchronous neuronal activity in
the brain (Fisher et al., 2005). The signs and symptoms of seizures vary considerably
depending on the location and extent of the affected brain area. Seizures are divided
in to two main classes: focal seizures, those that are localised to an area of the brain
and generalised seizures, those that involve the majority of the cortex. Some seizures
do not cause a loss of consciousness, but depending on the location of the seizure
activity, may cause motor signs or sensory, autonomic or psychic symptoms, these
are termed simple partial seizures (Alarcon et al., 2009). If a focal seizure affects
both hemispheres it can impair consciousness, this is then termed a complex partial
seizure. Generalised seizures cause a loss of consciousness in addition to one or
more of a number of other possible signs, most commonly (in approximately 60%
of patients) convulsions. Typically, limbs become rigid for a few seconds (tonic
phase) followed by repetitive contractions of all limbs at approximately 3 Hz, where
the limbs jerk in one direction followed by a slower movement back to the original
position before jerking again (clonic phase) (Alarcon et al., 2009).
The electrographic correlate of seizure symptoms is large amplitude rhythmic
activity with time dependent frequency components (an example LFP recording of
a seizure in vitro is shown in Fig 1.12). Traditionally this was interpreted as the
result of hyperexcitability and hypersynchronous neuronal activity. However, more
recent work has shown the dynamics of seizure onset, spread and termination to be
far more complex and are as yet not fully understood (Pinto et al., 2005; Jiruska
et al., 2010a; Zhang et al., 2011). The hallmark of seizure activity appears to be
hypersynchronous activity, however, recent studies have shown that there is actually
an increase in the heterogeneity of firing at seizure onset and that hypersynchron-
icty is a feature associated with, and potentially implicated in, seizure termination
(Truccolo et al., 2011; Jiruska et al., 2013). Furthermore, whilst seizures may re-
sult from an imbalance between excitation and inhibition in favour of excitability,
inhibition can promote their characteristic synchronisation. Inhibition can give rise
to synchronisation both by GABAergic depolarisation resulting from imbalance of
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Figure 1.12: The local field potential recorded during a typical burst of electrographic seizure
activity in the Mg2+ free seizure model in acute neocortical slice.
chloride (Pavlov et al., 2013) and by synchronous recovery from inhibition of a
larger population of principal neurons (Klaassen et al., 2006). The propagation of
seizures is also complex and involves all three known mechanisms of neuronal cou-
pling: chemical synapses, gap junctions and ephaptic coupling. Propagation can
even occur independently of both chemical synapses and gap junctions (Jefferys and
Haas, 1982; Zhang et al., 2014). During ictal events interacting networks appear to
coalesce and fragment (Kramer et al., 2010), similarly seizure may involve a micro
to macro seizure transition (Stead et al., 2010).
Understanding seizure dynamics is of fundamental scientific interest, but also
of significant practical importance. An understanding of seizure onset, particularly
identification of the features of pre-ictal states, would facilitate the implementation
of systems to predict seizures. Temporally targeted therapy could then be provided
to prevent the seizure occurring or a system could warn the patient of the impending
event so that they could take steps to avoid injury during the seizure. Greater
understanding of the mechanisms that cause seizure termination could be used to
inform the development of improved anti-epileptic therapies.
1.6 Epilepsy
Epilepsy is a disorder of the brain characterised by an enduring predisposition to
unprovoked seizures (Fisher et al., 2005). It is not a single condition, rather a term
for any disorder that gives rise to unprovoked seizures. Pragmatically, an individual
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is diagnosed with epilepsy if they have two or more unprovoked epileptic seizures
within a period of two years (Alarcon et al., 2009).
Epilepsy is broadly classified on the basis of its cause. Some types of epilepsy
are genetic, for example, Dravet’s syndrome is caused by a mutation in the sodium
channel αI subunit gene SCN1A (Depienne et al., 2009; Dravet, 2011; Marini et al.,
2011). Other types of epilepsy are termed symptomatic - the result of an insult to
the brain, for example, febrile infection related epilepsy syndrome (FIRES) - the
development of epilepsy by a school age child as the result of a period of status
epilepticus caused by a fever (Kramer et al., 2011; van Baalen et al., 2012; Serrano-
Castro et al., 2013). Finally, epilepsy can be idiopathic.
Although it is not completely understood, a number of processes have been
implicated in epileptogenesis. For example, granule cell dispersion, mossy fibre
sprouting, raised intracellular chloride potentials and astrogliosis and associated
ADK up regulation have all been observed (Pitkanen and Lukasiuk, 2011; Boison,
2008).
There are three approaches to the treatment of epilepsy: pharmacological,
surgical and electrical. Anti-epileptic drugs work via a variety of mechanisms, for
example, benzodiazepines work by enhancing inhibition by allosteric modulation of
GABAA receptors, gabapentin works by binding to the α2δ subunit of the voltage-
gated calcium channels and reduces synaptic release of glutamate. Resection can be
carried out to treat some cases of focal epilepsy. Finally, use of electrical stimulation
shows promise in treating epilepsy (Alarcon et al., 2009; Jiruska et al., 2010b).
Currently it is estimated that 30% of patients with epilepsy would still suffer from
seizures even with optimal treatment (Deacon, 2011), however, recent studies of the
mechanisms of pharmacological resistance have implicated P-glycoprotein (Loscher,
2005; Volk and Loscher, 2005; Brandt et al., 2006) and combined treatment with
both an anti-epileptic drug and a P-glycoprotein inhibitor has shown significant
promise (Potschka et al., 2002).
Epilepsy is a common disorder, affecting approximately 50 million people
worldwide (Scott et al., 2001), causing a significant detrimental effect on the quality
of life of affected individuals and also a significant financial cost. In the UK the
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incidence of epilepsy is approximately 51 per 100,000 of population per year, the
prevalence of epilepsy is around 1 in 103 people (1 in 242 for those under 18 years)
and approximately 600,000 people take anti-epileptic drugs (Deacon, 2011). In the
UK 1,150 people died of epilepsy related causes in 2009, the average number of years
of life lost per person was 30.2 (Deacon, 2011). In England, Wales and Scotland
69,700 people with epilepsy were claiming disability living allowance in 2009. This
cost ∼ £244 million per year (Deacon, 2011).
1.7 Models of epilepsy
Numerous models have been developed to replicate the features of epilepsy. These
range from in vivo models, through acute slice models and dissociated cells, to
cultures of transgenic cells and computational models. For example, lateral fluid
percussion is used in rats as a model of post-traumatic epilepsy. In contrast, cell
cultures are used to study the properties of ion channels arising from genes mutated
to reflect those causing genetic epilepsies. For thorough reviews of experimental and
computational models of epilepsy see Pitkanen et al. (2006) and Soltesz and Staley
(2008) respectively.
In this thesis the hypomagnesemic seizure model (Mody et al., 1987) was
employed in acute slice of the rat neocortex. This model produces spontaneous
seizures in neocortical tissue from wild type rats without any pretreatment in vivo.
Mg2+ ions block N-methyl-D-aspartate receptor channels, by removing this block
neocortical tissue becomes more excitable and spontaneous electrographic seizures
occur in the neocortex after approximately 20 minutes. This model exhibits the
spatio-temporal dynamics that were of interest here, while causing minimal suffering
to the animals and so was used for each of the projects presented here.
1.8 Thesis outline
This is a thesis ‘based on published work’ as per MOAC Doctoral Training Centre,
University of Warwick, regulations. It is comprised of three papers, Chapters 2, 3
and 4, that are either published, in review or in preparation. Chapter 2 presents
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a device for the perfusion of in vitro tissue with multiple solutions, providing an
entirely in vitro model of focal epilepsy. Chapter 3 presents a transformation to
convert the slow dynamics of intrinsic optical signals in vitro to the form of the
local field potential, facilitating the study of the spatio-temporal dynamics of focal
seizure activity in vitro. Chapter 4 presents the application of the transformation
derived in Chapter 3 to the study of the spatio-temporal dynamics of extracellular
adenosine release in response to electrographic seizure activity in vitro.
Finally the appendices of this thesis contain four additional papers. These
papers are not related to the core of this thesis but are projects to which I made a
significant contribution and so are included for completeness. These studies demon-
strate the potential for Field Asymmetric Ion Mobility Spectrometry (FAIMS) in
medical diagnosis. FAIMS is a highly sensitive tool for chemical detection, originally
applied to the detection of chemical warfare agents. FAIMS is able to detect a broad
range of chemicals at concentrations below one part per billion. As such, FAIMS was
thought to have significant potential in medical diagnosis, however, this had never
been explored due to the challenge of the analysis of FAIMS spectra from complex
biological mixtures. Our studies provide a proof of principle that biological mix-
tures can be distinguished using FAIMS (Appendix B) and then apply it to identify
inflammatory bowel diseases (Appendix C), patients at risk of high gastrointestinal
toxicity in response to radical pelvic radiotherapy (Appendix D) and patients with
colorectal cancer (Appendix E).
23
Bibliography
Aitken, P., Fayuk, D., Somjen, G. G., and Turner, D. Use of intrinsic optical signals
to monitor physiological changes in brain tissue slices. Methods, 18:91–103, 1999.
Alarcon, G., Nashef, L., Cross, H., Nightingale, J., and Richardson, S. Epilepsy.
Oxford University Press, 2009.
Anastassiou, C., Perin, R., Markram, H., and Koch, C. Ephaptic coupling of cortical
neurons. Nature Neuroscience, 14:217–224, 2011.
Andrew, R., Jarvis, C., and Obeidat, A. Potential sources of intrinsic optical signals
imaged in live brain slices. Methods, 18(2):185 – 196, 1999. ISSN 1046-2023.
Apps, R. and Garwicz, M. Anatomical and physiological foundations of cerebellar
information processing. Nature Reviews Neuroscience, 6:297–311, 2005.
Bean, B. The action potential in mammalian central neurons. Nature Reviews
Neuroscience, 8:451–465, 2007.
Bjorness, T. and Greene, R. Adenosine and sleep. Current Neuropharmacology, 7:
238–245, 2009.
Blanco-Centurion, C., Xu, M., Murillo-Rodriguez, E., Gerashchenko, D., Shiromani,
A., Salin-Pascual, R., Hof, P., and Shiromani, P. Adenosine and sleep homeostasis
in the basal forebrain. The Journal of Neuroscience, 26:8092–8100, 2006.
Boison, D. The adenosine kinase hypothesis of epileptogenesis. Progress in Neuro-
biology, 84:249–262, 2008.
Brandt, C., Bethmann, K., Gastens, A., and Loscher, W. The multidrug transporter
24
hypothesis of drug resistance in epilepsy: Proof-of-principle in a rat model of
temporal lobe epilepsy. Neurobiology of Disease, 24:202–211, 2006.
Briar, C., Lasserson, D., Gabriel, C., and Sharrack, B. Nervous System. Mosby,
2003.
Buchheim, K., Schuchmann, S., Siegmund, H., Gabriel, H., Heinemann, U., and
Meierkord, H. Intrinsic optical signal measurements reveal characteristic features
during different forms of spontaneous neuronal hyperactivity associated with ECS
shrinkage in vitro. Eur, J. Neurosci., 11:1877–1882, 1999.
Buchheim, K., Wessel, O., Siegmund, H., Schuchmann, S., and Meierkord, H. Pro-
cesses and components participating in the generation of intrinsic optical signal
changes in vitro. European Journal of Neuroscience, 22:125–132, 2005.
Buzsaki, G., Anastassiou, C., and Kocj, C. The origin of extracellular fields and
currents - EEG, ECog, LFP and spikes. Nature Reviews Neuroscience, 13:407–420,
2012.
Cajal, S. Comparative study of the sensory areas of the human cortex. 1899.
Chang, S., Kim, I., Marsh, M., Jang, D., Hwang, S., Van Gompel, J., Goerss, S.,
Kimble, C., Bennet, K., Garris, P., Blaha, C., and Lee, K. Wireless fast-scan
cyclic voltammetry to monitor adenosine in patients with essential tremor during
deep brain stimulation. Mayo Clinic Proceedings, 87:760–765, 2012.
Clarke, L. and Barres, B. Emerging roles of astrocytes in neural circuit development.
Nature Reviews Neuroscience, 14:311–321, 2013.
Cohen, L., Keynes, R., and B., H. Light scattering and birefringence changes during
nerve activity. Nature, 218:438 – 441, 1968.
Cooper, C., Cope, M., Springett, R., Amess, P., Penrice, J., Tyszczuk, L., Pun-
wani, S., Ordidge, R., Wyatt, J., and Delpy, D. Use of mitochondrial inhibitors
to demonstrate that cytochrome oxidase near-infrared spectroscopy can measure
mitochondrial dysfunction non-invasively in the brain. Journal of Cerebral Blood
Flow and Metabolism, 19:27–38, 1999.
25
Dale, N. and Frenguelli. Release of adenosine and ATP during ischemia and epilepsy.
Current Neuropharmacology, 7:160–179, 2009.
Dale, N., Pearson, T., and Frenguelli, B. Direct measurement of adenosine release
during hypoxia in the CA1 region of the rat hippocampal slice. Journal of Phys-
iology, 526:143–155, 2000.
Daly, J. and Padgett, W. Agonist activity of 2- and 5′-substituted adenosine analogs
and their N6-cycloalkyl derivatives at A1- and A2-adenosine receptors coupled to
adenylate cyclase. Biochem Pharmacol, 43:1089–1093, 1992.
Daumas, S., Ceccom, J., Halley, H., Frances, B., and Lassalle, J.-M. Activation of
metabotropic glutamate receptor type 2/3 supports the involvement of the hip-
pocampal mossy fiber pathway on contextual fear memory consolidation. Learning
and Memory, 16:504–507, 2009.
De Zeeuw, C., Hoebeek, F., Bosman, L., Schonewille, M., Witter, L., and Koekkoek,
K. Spatiotemporal firing patterns in the cerebellum. Nature Reviews Neuro-
science, 12:327–344, 2011.
Deacon, K. Epilepsy prevalence, incidence and other statistics. Technical report,
Joint Epilepsy Council, September 2011.
Depienne, C., Trouillard, O., Saint-Martin, C., Gourfinkel-An, I., Bouteiller, D.,
Carpentier, W., Keren, B., Abert, B., Gautier, A., Baulac, S., Arzimanoglou,
A., Cazeneuve, C., Nabbout, R., and LeGuern, E. Spectrum of SCN1A gene
mutations associated with Dravet syndrome: analysis of 333 patients. Journal of
Medical Genetics, 46:183–191, 2009.
D’Esposito, M., Deouell, L., and Gazzaley, A. ALterations in the bold fMRI signal
with ageing and disease: A challenge for neuroimaging. Nature Reviews Neuro-
science, 4:863–872, 2003.
Dravet, C. The core Dravet syndrome phenotype. Epilepsia, 52:3–9, 2011.
Dunwiddie, T., Diao, L., Kim, H., Jiang, J., and Jacobson, K. Activation of hip-
26
pocampal adenosine A3 receptors produces a desensitization of A1 receptor- me-
diated responses in rat hippocampus. Journal of Neuroscience, 17:607–614, 1997.
During, M. and Spencer, D. Adenosine: A potential mediator of seizure arrest and
postictal refractoriness. Annals of Neurology, 32:618–624, 1992.
Edwards, A., Brown, G., Cope, M., Wyatt, J., McCormick, D., Roth, S., Delpy,
D., and Reynolds, E. Quantification of concentration changes in neonatal human
cerebral oxidized cytochrome oxidase. Journal of Applied Physiology, 71:1907–
1913, 1991.
Fayuk, D., Aitken, P., Somjen, G., and Turner, D. Two different mechanisms under-
lie reversible, intrinsic optical signals in rat hippocampal slices. J. Neurophysiol.,
87:1924–1937, 2002.
Fisher, R., van Emde Boas, W., Blume, W., Elger, C., Genton, P., Lee, P., and
Engel, J. Epileptic seizures and epilepsy: Definitions proposed by the Interna-
tional League Against Epilepsy (ILAE) and the International Bureau for Epilepsy
(IBE). Epilepsia, 46:470–472, 2005.
Fredholm, B., Ijzerman, A., Jacobson, K., Klotz, K.-N., and Linden, J. Interna-
tional union of pharmacology. xxv. nomenclature and classification of adenosine
receptors. Pharmacological Reviews, 53:527–552, 2001.
Frenguelli, B., Lllaudet, E., and Dale, N. High-resolution real-time recording with
microelectrode biosensors reveals novel aspects of adenosine release during hy-
poxia in rat hippocampal slices. Journal of Neurochemistry, 86:1506–1515, 2003.
Gahwiler, B., Capogna, M., Debanne, D., McKinney, R., and Thompson, S. Organ-
otypic slice cultures: a technique has come of age. Trends in Neuroscience, 20:
471–477, 1997.
Gouras, P. Spreading depression of activity in amphibian retina. Am. J. Physiol.,
195:28–32, 1958.
Gurden, H., Uchida, N., and Mainen, Z. Sensory-evoked intrinsic optical signals
27
in the olfactory bulb are coupled to glutamate release and uptake. Neuron, 52:
335–345, 2006.
Harris, K. and Mrsic-Flogel, T. Cortical connectivity and sensory coding. Nature,
503:51–58, 2013.
Haydon, P. Glia: listening and talking to the synapse. Nature Reviews Neuroscience,
2:185–193, 2001.
Heeger, D. and Ress, D. What does fMRI tell us about neuronal activity? Nature
Reviews Neuroscience, 3:142–151, 2002.
Holthoff, K. and Witte, O. Intrinsic optical signals in rat neocortical slices measured
with near-infrared dark-field microscopy reveal changes in extracellular space. J.
Neurosci., 16:2740–2749, 1996.
Huang, Z., Urade, Y., and Hayaishi, O. The role of adenosine in the regulation of
sleep. Current Topics in Medicinal Chemistry, 11:1047–1057, 2011.
Hunter, C., Bennet, L., Power, G., Roelfsema, V., Blood, A., Quaedackers, J.,
George, S., Guan, J., and Gunn, A. Key neuroprotective role for endogenous A1
receptor activation during asphyxia in the fetal sheep. Stroke, 34:2240–2245, 2003.
Jarvis, C., Lilge, L., Vipond, G., and Andrew, R. Interpretation of intrinsic optical
signals and calcein fluorescence during acute excitotoxic insult in the hippocampal
slice. Neuroimage, 10:357–372, 1999.
Jefferys, J. and Haas, H. Synchronised bursting of CA1 hippocampal pyramidal
cells in the absence of synaptic transmission. Nature, 300:448–450, 1982.
Jiruska, P., Csicsvari, J., Powell, A., Fox, J., Chang, W.-C., Vreugdenhil, M., Xi-
aolia, L., Palus, M., Bujan, A., Dearden, R., and Jefferys, J. High-frequency
network activity, global increase in neuronal activity and synchrony expansion
precede epileptic seizures in vitro. Journal of Neuroscience, 30:5690–5701, 2010a.
Jiruska, P., Powell, A., Deans, J., and Jefferys, J. Effects of direct brain stimulation
depend on seizure dynamics. Epilepsia, 51:93–97, 2010b.
28
Jiruska, P., de Curtis, M., Jefferys, J., Schevon, C., Schiff, S., and Schindler, K.
Synchronization and desynchronization in epilepsy: controversies and hypotheses.
Journal of Physiology, 591:787–797, 2013.
Kandel, E., Schwartz, J., Jessell, T., Siegelbaum, S., and Hudspeth, A. Principles
of neural science. McGraw-Hill, 2013.
Kerr, J. and Denk, W. Imaging in vivo: watching the brain in action. Nature
Reviews Neuroscience, 9:195–205, 2008.
Kitaura, H., Tsujita, M., Huber, V., Kakita, A., Shibuki, K., Sakimura, K., Kwee,
I., and Nakada, T. Activity-dependent glial swelling is impaired in aquaporin-4
knockout mice. Neurosci. Res., 64:208–212, 2009.
Klaassen, A., Glykys, J., Maguire, J., Labarca, C., Mody, I., and Boulter, J. Seizures
and enhanced cortical GABAergic inhibition in two mouse models of human au-
tosomal dominant nocturnal frontal lobe epilepsy. Proceedings of the National
Academy of Sciences of the USA, 103:19152–19157, 2006.
Klyuch, B., Dale, N., and Wall, M. Deletion of ecto-5′-nucleotidase (CD73) reveals
direct action potential dependent adenosine release. Journal of Neuroscience, 32:
3842–3847, 2012.
Knopfel, T. Genetically encoded optical indicators for the analysis of neuronal
circuits. Nature Reviews Neurocience, 13:687–700, 2012.
Kramer, M., Eden, U., Kolaczyk, E., Zepeda, R., Eskandar, E., and Cash, S. Coa-
lescence and fragmentation of cortical networks during focal seizures. Journal of
Neuroscience, 30:10076–10085, 2010.
Kramer, U., Chi, C.-S., Lin, K.-L., Specchio, N., Sahin, M., Olson, H., Nabbout,
R., Kluger, G., Lin, J.-J., and van Baalen, A. Febrile infection related epilepsy
syndrome (FIRES): Pathogenesis, treatment, and outcome: A multicenter study
on 77 children. Epilepsia, 52:1956–1965, 2011.
Lamprecht, R. and LeDoux, J. Structural plasticity and memory. Nature Reviews
Neuroscience, 5:45–54, 2004.
29
Latini, S. and Pedata, F. Adenosine in the central nervous system: release mech-
anisms and extracellular concentrations. Journal of Neurochemistry, 79:463–484,
2001.
Linley, J. Perforated whole-cell patch-clamp recording. Methods in Molecular Biol-
ogy, 998:149–157, 2013.
Lipton, P. Effects of membrane depolarization on light scattering by cerebral cortical
slices. J. Physiol., 231:365–383, 1973.
Lisman, J., Raghavachari, S., and Tsien, R. The sequence of events that underlie
quantal transmission at central glutamatergic synapses. Nature Reviews Neuro-
science, 8:597–609, 2007.
Loscher, W. Drug resistance in brain diseases and the role of drug eﬄux transporters.
Nature Reviews Neuroscience, 6:591–602, 2005.
Marini, C., Scheffer, I., Nabbout, R., Suls, A., De Jonge, P., Zara, F., and Guerrini,
R. The genetics of Dravet syndrome. Epilepsia, 52:24–29, 2011.
Mody, I., Lambert, J., and Heinemann, U. Low extracellular magnesium induces
epileptiform activity and spreading depression in rat hippocampal slices. Journal
of Neurophysiology, 57:869–888, 1987.
Pasini, F., Guideri, F., Picano, E., Parenti, G., Petersen, C., and Varga, T., A.
abd Perri. Increase in plasma adenosine during brain ischemia in man: A study
during transient ischemic attacks, and stroke. Brain Research Bulletin, 51:327–
330, 2000.
Pavlov, I., Kaila, K., Kullmann, D., and Miles, R. Cortical inhibition, pH and cell
excitability in epilepsy: what are optimal targets for antiepileptic interventions?
Journal of Physiology, 591:765–774, 2013.
Peakman, M. and Hill, S. Adenosine A2B-receptor-mediated cyclic AMP accumula-
tion in primary rat astrocytes. British Journal Pharmacology, 111:191–198, 1994.
Pearson, T., Damian, K., Lynas, R., and Frenguelli, B. Sustained elevation of extra-
cellular adenosine and activation of A1 receptors underlie post-ischaemic inhibi-
30
tion of neuronal function in rat hippocampus in vitro. Journal of Neurochemistry,
97:1357–136, 2006.
Pereda, A. Electrical synapses and their functional interactions with chemical
synapses. Nature Reviews Neuroscience, 15:250–263, 2014.
Perkins, K. Cell-attached voltage-clamp and current-clamp recording and stimula-
tion techniques in brain slices. Journal of Neuroscience Methods, 154:1–18, 2006.
Pinto, D., Patrick, S., Huang, W., and Connors, B. Initiation, propagation, and
termination of epileptiform activity in rodent neocortex in vitro involve distinct
mechanisms. Journal of Neuroscience, 25:8131–8140, 2005.
Pitkanen, A. and Lukasiuk, K. Mechanisms of epileptogenesis and potential treat-
ment targets. Lancet Neurology, 10:173–186, 2011.
Pitkanen, A., Schwartzkroin, P., and Moshe, S. Models of seizures and epilepsy.
Elsevier Academic Press, 2006.
Potschka, H., Fedrowitz, M., and Loscher, W. P-glycoprotein-mediated eﬄux of
phenobarbital, lamotrigine, and felbamate at the blood-brain barrier: evidence
from microdialysis experiments in rats. Neuroscience Letters, 327:173–176, 2002.
Ralevic, V. and Burnstock, G. Receptors for purines and pyrimidines. Pharmaco-
logical reviews, 50:413–492, 1998.
Raman, I. and Bean, B. Ionic currents underlying spontaneous action potentials in
isolated cerebellar Purkinje neurons. The Journal of Neuroscience, 19:1663–1674,
1999.
Rector, D., Poe, G., Kristensen, M., and Harper, R. Light scattering changes follow
evoked potentials from hippocampal schaffer collateral stimulation. J. Neurophys-
iol., 78:1707 – 1713, 1997.
Rector, D., Carter, K., Volegov, P., and George, J. Spatio-temporal mapping of rat
whisker barrels with fast scattered light signals. NeuroImage, 26:619 – 627, 2005.
31
Ribrault, C., Sekimoto, K., and Triller, A. From the stochasticity of molecular pro-
cesses to the variability of synaptic transmission. Nature Reviews Neuroscience,
12:375–387, 2011.
Ross, A., Nguyen, M., Privman, E., and Venton, B. Mechanical stimulation evokes
rapid increases in adenosine concentration in the prefrontal cortex. Journal of
Neurochemistry, 130:50–60, 2014.
Sakmann, B. and Neher, E. Patch clamp techniques for studying ionic channels in
excitable membranes. Annual Review of Physiology, 46:455–472, 1984.
Schmitt, L., Sims, R., Dale, N., and Haydon, P. Wakefulness affects synaptic and
network activity by increasing extracellular astrocyte-derived adenosine. Journal
of Neuroscience, 32:4417–4425, 2012.
Scott, R., Lhatoo, S., and Sander, J. The treatment of epilepsy in developing
countries: where do we go from here? Bulletin of the World Health Organisation,
79:344–351, 2001.
Serrano-Castro, P., Quiroga-Subirana, P., Payan-Ortiz, M., and Fernandez-Perez, J.
The expanding spectrum of febrile infection-related epilepsy syndrome (FIRES).
Seizure, 22:153–155, 2013.
Sims, R., Wu, H., and Dale, N. Sleep-wake sensitive mechanisms of adenosine release
in the basal forebrain of rodents: An In Vitro Study. PLoS One, 8:e53814, 2013.
Sohl, G., Maxeiner, S., and Willecke, K. Expression and functions of neuronal gap
junctions. Nature Reviews Neuroscience, 6:191–200, 2005.
Soltesz, I. and Staley, K. Computational neuroscience in epilepsy. Elsevier Academic
Press, 2008.
Stead, M., Bower, M., Brinkman, B., Lee, K., Marsh, R., Meyer, F., Litt, B.,
Van Gompel, J., and Worrell, G. Microseizures and the spatiotemporral scales of
human partial epilepsy. Brain, 133:2789–2797, 2010.
32
Stepnoski, R., LaPorta, A., Raccuia-Behling, F., Blonder, G., Slusher, R., and
Kleinfeld, D. Noninvasive detection of changes in membrane potential in cultured
neurons by light scattering. Proc. Natl. Acad. Sci. USA, 88:9382 – 9386, 1991.
Strange, B., Witter, M., Lein, E., and Moser, E. Functional organization of the
hippocampal longitudinal axis. Nature Reviews Neuroscience, 15:655–669, 2014.
Takagaki, K., Lippert, M., Dann, B., Wagner, T., and Ohi, F. Normalization of
voltage-sensitive dye signal with functional activity measures. PLos ONE, 3:
e4041, 2008.
Truccolo, W., Donoghue, J., Hochberg, L., Eskandar, E., Madsen, J., Anderson,
W., Brown, E., Halgren, E., and Cash, S. Single-neuron dynamics in human focal
epilepsy. Nature Neuroscience, 14:635–641, 2011.
van Baalen, A., Husler, M., Plecko-Startinig, B., Strautmanis, J., Vlaho, S., Geb-
hardt, B., Rohr, A., Abicht, A., Kluger, G., Stephani, U., Probst, C., Vincent,
A., and Bien, C. Febrile infection-related epilepsy syndrome without detectable
autoantibodies and response to immunotherapy: a case series and discussion of
epileptogenesis in FIRES. Neuropediatrics, 43:209–216, 2012.
Van Gompel, J., Bower, M., Worrell, G., Stead, M., Chang, S.-Y., Goerss, S., Kim,
I., Bennet, K., Meyer, F., Marsh, W., Blaha, C., and Lee, K. Increased cortical
extracellular adenosine correlates with seizure termination. Epilepsia, 55:233–244,
2014.
Volk, H. and Loscher, W. Multidrug resistance in epilepsy: rats with drug-resistant
seizures exhibit enhanced brain expression of P-glycoprotein compared with rats
with drug-responsive seizures. Brain, 128:1358–1368, 2005.
Volterra, A. and Meldolesi, J. Astrocytes, from brain glue to communication ele-
ments: the revolution continues. Nature Reviews Neuroscience, 6:626–640, 2005.
Wall, M. and Dale, N. Activity-dependent release of adenosine: A critical re-
evaluation of mechanism. Current Neuropharmacology, 6:329–337, 2008.
33
Wall, M. and Dale, N. Neuronal transporter and astrocytic ATP exocytosis underlie
activity-dependent adenosine release in the hippocampus. Journal of Physiology,
591:3853–3871, 2013.
Wenjun, J., Zhang, R.-J., and Wu, J.-Y. Voltage-sensitive dye imaging of population
neuronal activity in cortical tissue. Journal of Neuroscience Methods, 115:13 –
27, 2002.
Winn, H., Welsh, J., Rubio, R., and Berne, R. Changes in brain adenosine during
bicuculine-induced seizures in rats. Circulation Research, 47:568–577, 1980.
Zhang, M., Ladas, T., Qiu, C., Shivacharan, R., Gonzalez-Reyes, L., and Durand, D.
Propagation of epileptiform activity can be independent of synaptic transmission,
gap junctions, or diffusion and is consistent with electrical field transmission.
Journal of Neuroscience, 34:1409–1419, 2014.
Zhang, Z., Valiante, T., and Carlen, P. Transition to seizure from ‘macro’ to ‘micro’
mysteries. Epilepsy Research, 97:290–299, 2011.
Zhou, Q., Li, C., Olah, M., Johnson, R., Stiles, G., and Civelli, O. Molecular
cloning and characterization of an adenosine receptor: The A3 adenosine receptor.
Proceedings of the National Academy of Sciences of the USA, 89:7432–7436, 1992.
34
Chapter 2
A chamber for the perfusion of
in vitro tissue with multiple
solutions
The acute neural tissue slice is a widely used preparation, providing a powerful
compromise between invasiveness, access and control. Tissue can readily be treated,
both locally and globally, pharmacologically or with changes in ionic conditions.
However, it is harder to manipulate the environment of regions of tissue on the
intermediate scale, that of areas comprising a significant proportion, but not the
whole, of a tissue slice. Manipulation of the perfusing aCSF on this scale could
be used, for example, as a model of focal epilepsy. An excitant solution could be
applied to part of a tissue slice, to induce electrographic seizure activity in that
region, while the remainder of the slice was perfused with a standard aCSF. The
propagation of the pathological activity from the activated region in to the otherwise
quiescent tissue could then be studied. A chamber was developed by Blake et al.
(2007) to enable the manipulation of the environment of extended regions of tissue.
However, the system developed by Blake et al. entirely encapsulated the tissue slice
except for a single edge. Micro-electrode recordings could, therefore, only be made
from that single edge.
We developed a chamber that allows the manipulation of the environment of
extended regions (> 5 mm2) of a tissue slice, whilst maintaining access to the tissue
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Figure 2.1: The chamber produced for Prof. Frenguelli, University of Warwick. For scale,
the chamber is mounted on a standard 26×75 mm microscope slide.
slice for micro-electrodes. This chapter contains the published paper describing this
work. Some preliminary development of the chamber was included in a submission
for an MSc, however, neither this chamber design, nor any of the data, analysis
or text presented here were included in the submission. I designed the chamber,
planned and carried out the experiments, carried out the data analysis and wrote
the paper. The design, manufacture and initial testing of the chamber was carried
out under the supervision of Dr James Covington, the planning and implementation
of the biological testing of the chamber was carried out under the supervision of
Dr Mark Wall.
After publication of this work, a commission was received from Prof. Bruno
Frenguelli, University of Warwick, for a similar device. As shown in our study, the
typical design of commercially available chambers results in turbulent flow across
tissue slices, resulting in areas of stagnant solution. Prof. Frenguelli required a
chamber that avoided this problem, to facilitate stable prolonged recordings for the
study of long term potentiation. For this purpose we produced a modified version
of the chamber we developed to generate laminar flow across tissue slices (Fig. 2.1).
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A chamber for the perfusion of in vitro tissue with
multiple solutions
Matthew G. Thomas1,2,3, James A. Covington2 and Mark J. Wall1
1 School of Life Sciences, 2 School of Engineering, 3 MOAC Doctoral Training
Centre, University of Warwick, CV4 7AL, United Kingdom
2.1 Abstract
There are currently no practical systems that allow extended regions (> 5 mm2) of
a tissue slice in vitro to be exposed, in isolation, to changes in ionic conditions or to
pharmacological manipulation. Previous work has only achieved this at the expense
of access to the tissue for recording electrodes. Here we present a chamber that allows
a tissue slice to be maintained in multiple solutions, at physiological temperatures,
and preserves the ability to record from the slice. We demonstrate the effectiveness
of the tissue bath with respect to minimising the mixing of the solutions, maintaining
the viability of the tissue and preserving the ability to simultaneously record from
the slice.
2.2 Introduction
The acute neural tissue slice is a valuable and widely used experimental preparation
(Huang et al., 2012). Tissue, in vitro, is typically maintained in a chamber where it
is perfused with an oxygenated solution (Croning and Haddad, 1998). The ability to
manipulate the tissue environment both focally and globally with changes to ionic
conditions or pharmacological manipulation, in addition to electrical stimulation
and electrophysiological recording, is a useful tool to elucidate tissue properties in
health and disease (Scott et al., 2013). Fluid manipulation on these scales is the
domain of microfluidics. The field of microfluidics potentially provides a powerful
set of tools for such manipulations and is therefore currently being adopted by
neuroscientists (Ahrar et al., 2013). A thorough review of microfluidic techniques
applied to brain tissue slices is given in Huang et al. (Huang et al., 2012). Recent
examples of the application of microfluidics in neuroscience applications include
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focal pharmacological manipulation on the micron scale, less invasively than with
conventional glass micropipettes (Mohammed et al., 2008; Queval et al., 2010; Tang
et al., 2011) and improved perfusion of tissue slices allowing thicker tissue slices to
be viably be maintained (Choi et al., 2007; Hill and Greenfield, 2011).
The global conditions of a tissue slice can be simply altered by changing the
solution supplied to the tissue bath. The environment of regions of tissue on the scale
of single cells can be modified using pressure ejection systems and micropipettes
(Smith and Cunningham, 1983; Salierno et al., 2007) as well as by microfluidic
approaches (Queval et al., 2010). However, the ability to expose an extended region
(> 5 mm2) within a tissue slice to a change in conditions is limited. Work by Blake
et al. (Blake et al., 2007) used laminar flow to successfully maintain adjacent regions
of tissue in different media. Their device did not, however, facilitate recording from
the tissue surface. Access for recording electrodes was only possible along a single
edge of the tissue. This was satisfactory for the medullary slices that were studied.
However, for many applications access for recording electrodes to the tissue surface
is essential (Rutecki et al., 1985; Mody et al., 1987).
An example of an application of a chamber capable of exposing an extended
region (> 5 mm2) within a tissue slice to a change in conditions is in the study of
the propagation of epileptiform activity across neural tissue. Epileptiform activity
is commonly induced in neural tissue by the modification of the perfusing medium
(Jefferys and Haas, 1982; Konnerth et al., 1984). A chamber that perfuses regions
of a tissue slice with different media would allow the study of the propagation of
epileptiform activity, in the region treated with excitant solution, into an adjacent
region, maintained in physiological medium. This provides a model for the study of
the generalisation of focal seizure activity.
Here we present a tissue bath that utilises laminar flow to maintain adjacent
regions of tissue in different media, whilst maintaining both the viability of the tissue
and the ability to record from its surface. Such targeting has application in a wide
range of network studies involving neural tissue, and also has applications in the
study of, for example, uterine and cardiac tissue. The chamber was manufactured
using microstereolithography (MSL), a rapid direct digital manufacturing technique.
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This allowed bespoke chambers to be manufactured in less than 12 hours.
2.3 Materials and methods
The requirements of the chamber were to:
1. Expose extended regions (> 5 mm2) within a tissue slice to different solutions,
minimising mixing at the interface between the solutions.
2. Allow access to the tissue surface for recording.
3. Perfuse both sides of the tissue to maintain its viability.
4. Maintain the tissue at a physiological temperature.
Design considerations
The chamber is composed of long, high surface area to volume ratio, inflow channels
prior to an accessible bath region (Figure 2.2A). The channels were designed to
minimise the Reynolds number of the perfusing medium flowing through them,
whilst allowing sufficient flow to maintain the viability of the tissue in the chamber.
The purpose of the reduced Reynolds number flow is to eliminate turbulence prior
to entry to the bath region. It was hypothesised (and tested, detailed below) that
longer in-flow channels would correspond to reduced mixing in the bath region. For
practicality, the size of the bath was limited to the area of a standard microscope
slide (75 mm x 25 mm). The length of the chamber’s channels was maximised,
given the overall size constraint and the size requirement of the bath region. This
gave channels 37.2 mm long. The channels were 4 mm high and, for a two channel
chamber, 8.15 mm wide. For a two channel chamber, water, at a flow rate of 5
ml/min, had a theoretical Reynolds number of 13.9 in the channels and 39.9 in the
bath, both in a laminar flow regime (Brody et al., 1996).
A structure was developed to support the tissue, vertically, in the centre of
the flow, allowing perfusion across both surfaces. Oxygen reaches tissue in recording
chambers by diffusion (Croning and Haddad, 1998). Perfusion of the tissue across
both surfaces increases the possible slice thickness that can be maintained hypoxia
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Figure 2.2: (A) A rendered CAD model of the chamber showing the bath region with mesh
tissue support and slice hold down with dividers. (B) Cross section showing dividers on
tissue support and hold down relative to tissue slice. (C) An image of the bath region of
a chamber built to target the entorhinal cortex region of a cortical slice with a different
solution to the rest of the cortex and hippocampus. Two microelectrodes (filled with a
2 mM solution of Brilliant blue R, to allow visualisation), a cortical slice, bath earth and
hypodermic needle (for outflow) are shown.
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free. Thicker slices provide a greater connected network for study. A similar com-
ponent was designed to hold the tissue in place from above. Both the slice support
and slice hold down were designed to fit in an accommodating slot in the bath region
of the chamber (Figure 2.2A). The horizontal bars connected the sides above the
level of the fluid and, therefore, did not obstruct the flow and thereby introduce
turbulence, which would increase mixing. The main structures of the support and
hold down were manufactured using MSL. A 10 Denier nylon mesh was stretched
across the support and 10 Denier nylon fibres were attached across the hold down.
The insertion of microelectrodes in to the chamber was expected to disrupt
the laminar flow and cause mixing of the perfusing solutions. To counteract this
effect dividers were included on the slice support and hold down. These aligned with
the divide between the channel inlets and thus reduced mixing in the chamber. The
dimensions of the dividers were such that they did not come into contact with the
tissue. The dividers reduced the perfusing flow to a small area of the tissue directly
beneath them, they, however, tapered to 200 µm in width above the tissue surface
to minimise this effect (Figure 2.2A and B). The maximum distance of any area of
tissue from flowing perfusing medium in a 350 µm slice was 300 µm, diffusion could
maintain tissue viability over this distance (Meme et al., 2009).
The bath region had a working area of 16.8 mm x 13.2 mm. This then tapered
symmetrically towards a hypodermic needle connected to a pump for out-flow. This
avoided the eddy currents that would be expected in corners. Behind this was a
region for an earth, allowing contact with the perfusing medium, but not affecting
the laminar flow.
The tissue bath was connected to in-flow tubing with 7 mm long sections of
3 mm diameter capillary tubes. These were inserted into collars on the chamber.
Chamber manufacture
The chamber consisted of a number of structures, manufactured by MSL, mounted
on a standard microscope slide (75 mm x 25 mm). MSL is an additive layer manufac-
turing process that employs a photocurable resin to produce solid three dimensional
structures. Two dimensional cross sections are sequentially projected into a tray
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of liquid resin to cure regions where a solid is required and build up a three di-
mensional structure. The parts were designed in a computer aided design package
(SolidWorks 2011). The parts were then converted into a set of two dimensional
cross sections at 25 m intervals using Envisiontec RP. The parts were manufactured
on a custom Envisiontec Perfactory Mini SLA system (Envisiontec, Gladbeck, Ger-
many) out of Envisiontec R11 (25 µm voxel depth) resin (Envisiontec, Gladbeck,
Germany). After manufacture the parts were washed with acetone and hardened
in an Envisiontec Otoflash (Envisiontec, Gladbeck Germany) (1000 flashes on each
side; flash frequency: 10 Hz; spectral distribution: 300 - 700 nm; power: 200 W).
This caused the polymerisation of any unreacted resin on the surface of the parts.
This was hypothesised (and tested, detailed below) to prevent contamination of the
perfusing medium with resin from the chamber.
The components were mounted on a microscope slide and 7 mm lengths of
glass capillary inserted into the chamber, to form the interface for inflow tubes.
These were secured with epoxy adhesive.
The nature of the manufacturing process meant that a chamber bespoke for
an experiment could be manufactured rapidly. The build time for each component
used here was 1 hour 42 minutes. Figure 2.2C shows the bath region of a chamber
produced to target the entorhinal cortex region of a sagittal slice of cortex, used
to investigate the origin of electrographic seizure activity. For such chambers the
in-flow rate to each region had to be corrected to generate equal flow speeds for the
different solutions, to prevent shear stress between the solutions in the chamber.
Chamber operation
Solutions were delivered (at the same flow rate) to the chamber through gas im-
permeable Tygon tubing by a double headed peristaltic pump (SciQ 400, Watson-
Marlow, Cornwall, UK). A system of four valves allowed the solution supplied to
each side to be changed without the introduction of air bubbles. Two syringes were
connected to T connectors immediately prior to the chamber. These were used to
remove air bubbles from the channels in the chamber when initially priming.
Solutions were maintained at 34 oC in a water bath to prevent de-gassing
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when heated prior to entry to the chamber.
To avoid the need for two heating systems (one for each solution), a simple
(and inexpensive) method of heating the two solutions was developed. A 125 ml
glass beaker (positioned within the faraday cage, close to the bath) containing wa-
ter was maintained at 40 oC. This was achieved by pumping (with a diaphragm
pump, 0.35 l/min, RS, Northants, UK) water from a bath at 60 oC, external to
the Faraday cage, through a tube coiled in the beaker and back to the bath. The
tubes containing the solutions were, at the end immediately prior to the bath, coiled
and immersed in the water. To test the temperature stability of the heating sys-
tem, the temperature in the bath region of the device was measured for periods
of one hour (n = 3) at 10 Hz, using a thermocouple connected to a TC-10 tem-
perature controller (npi electronic GmbH, Tamm, Germany) and recorded using a
CED Power 1401 mkII digitiser, controlled by Spike2 software (Cambridge Elec-
tronic Design, Cambridge, UK). This was compared to the temperature stability of
solution in a commercially available bath (RC-27, Warner Instruments, Hamden,
CT, USA) heated using a commercially available system. The solution was heated
by an HPT-2 heated perfusion tube (ALA Scientific Instruments Inc. Harmingdale,
NY, USA) and the temperature was controlled by a TC-10 temperature controller
(npi electronic GmbH, Tamm, Germany). The temperature was recorded for the
same periods and using the same methods for both systems, with a set temperature
of 32 oC. The mean temperature using the novel system (and the commercial sys-
tem) was 31.57 oC (29.46 oC). The standard deviation was 0.18 oC (0.12 oC) and
half of the maximum range was 0.47 oC (0.37 oC). The system we implemented was,
therefore, deemed acceptable for use.
A tissue slice was transferred on to the mesh support and the slice hold down
positioned on top to hold it in place (Figure 2.2A). Slices were positioned relative
to the divide between in-flow channels as necessary for each experiment.
For the out-flow, a hypodermic needle was held with its tip at the desired
level of the bath. This was connected, through a second peristaltic pump (323,
Watson-Marlow, Cornwall, UK), to a waste container.
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Solution mixing
The effectiveness of the chamber in minimising the mixing of two solutions was char-
acterised using a fluorescent dye. The chamber was supplied with a 50 µM solution
of fluorescein sodium salt (Sigma-Aldrich, Dorset, UK) in de-ionised water on one
side and de-ionised water on the other. The chamber was uniformly illuminated
with eight LEDs with peak emission at 458 nm (PLCC-4, RS, Northants, UK) in
an otherwise dark environment. An image of the chamber was captured with a
VMS-004D microscope (Veho, Hampshire, UK). Images were corrected for intensity
using a control region outside the chamber. The fluorescence profiles at cross sec-
tions 1 mm, 6 mm and 12 mm into the chamber, along the direction of flow, were
measured. Fluorescence was converted to concentration and the interface width
was measured, defined to be the distance over which the fluorescein concentration
changed from 25% to 75% of its maximum.
The effectiveness of the channels in suppressing inertial instability and there-
fore mixing was investigated. Four chambers were compared. These were manufac-
tured with inflow channels of lengths uniformly spanning the possible range, giving
channel lengths of 0 mm, 12.4 mm, 24.8 mm and 37.2 mm.
The effect on the width of the interface of the addition of microelectrodes and
supporting net to the bath region was investigated for a chamber with full length
(37.2 mm) channels. The effect of the addition of net with divider, in addition
to microelectrodes, tissue and supporting net to chambers with no inflow channels
(0 mm) and full length inflow channels (37.2 mm) was also compared.
Fluorescence profiles were measured six times for each chamber and addition.
The channel supplied with fluorescent solution was alternated and interleaved with
controls during which both channels were supplied with the same solution.
Solution exchange
The time for solution exchange in the chamber was measured using a fluorescent
dye. The bath was illuminated and imaged as for experiments to measure mixing.
The chamber was supplied on both sides with de-ionised water. This was then
changed to a 50 µM solution of fluorescein sodium salt (Sigma-Aldrich, Dorset, UK)
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in de-ionised water. The fluorescence intensity was converted to concentration and
the time taken for the concentration of fluorescent solution to change from 5% to
95% of its maximum was measured. The solution exchange time was measured for
a chamber with 4 mm high channels and a chamber with 2 mm high channels. For
comparison the exchange time in a commercial bath (RC-27, Warner Instruments,
Hamden, CT, USA) with solution depths of both 2 mm and 4 mm was also measured
using the same method. In all cases measurements were made (n = 3) both with
the chambers empty and when containing a tissue slice, and microelectrodes.
Contamination detection
Water was collected after passing though the system and tested for contamination
from the chamber. De-ionised water was passed though the chamber at 5 ml/min,
31−32 oC (as required of solutions for biological experiments) and collected. For
comparison, de-ionised water was passed though the tubing of the system, with
the chamber replaced with a Petri dish, and collected. A mixture of less than 100
parts per million (ppm), by volume, R11 resin monomer, cross-linker and associated
solvents, in de-ionised water, was also prepared. 100 µl of R11 resin monomer,
cross-linker and associated solvents was mixed with 10 ml of de-ionised water for
30 minutes in a glass bottle on an orbital shaker. R11 resin is orange (because of
the addition of photoinhibitors to aid layer thickness control) the majority was seen
to settle to the bottom of the bottle. 100 µl of the aqueous phase, that relevant to
contamination of water based solutions, was removed and mixed with 10 ml of de-
ionised water. This resulted in a solution of the water soluble components of R11 of
much less than 100 ppm. For each solution, a 2 ml aliquot was transferred to a 10 ml
sample bottle with a crimp lid, fitted with a septum. The samples were heated to
80 oC and exposed to a solid phase micro extraction (SPME) fibre (Supelco, Sigma
Aldrich, Dorset, UK) for 15 minutes. The SPME fibre was then inserted into a
Scion SQ 451 gas chromatography - mass spectrometry (GCMS) system (Bruker,
Bremen, Germany) and heated to 250 oC. The GCMS column oven was heated from
50 oC to 280 oC over 15 minutes. Mass spectra were recorded at 20 Hz over a mass
range of 35 - 400 u.
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Biological testing
Slice preparation
Parasagittal slices of cerebellar vermis or cortex (350 µm) were prepared from male
Wistar rats at postnatal days 18-21. In accordance with the UK Animals (Scientific
Procedures) Act 1986, rats were killed by cervical dislocation and decapitated. Ei-
ther the cerebellum or cerebrum was rapidly removed. Parasagittal slices were cut
on a Microm HM 650V microslicer (Carl Zeiss, Welwyn Garden City, UK) in cold
(2−4 oC) high Mg2+, low Ca2+ artificial cerebrospinal fluid (aCSF), composed of
(mM): 127 NaCl, 1.9 KCl, 8 MgCl2, 0.5 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 10 D-
glucose (pH 7.4 when bubbled with 95% O2 and 5% CO2). Slices were stored in
experimental aCSF (1.0 mM MgCl2, 2.0 mM CaCl2), bubbled with 95% O2 and
5% CO2. The slices were maintained in a Gibbs chamber at 34
oC for the first hour
after slicing and at room temperature for the remaining time before recording.
Electrophysiology
Individual tissue slices were transferred to the bath region of the chamber, main-
tained at 31−32 oC, and continuously perfused at 5 ml/min with aCSF bubbled
with 95% O2 and 5% CO2. Extracellular recordings were made with aCSF filled
electrodes, tip diameters 15 µm, placed on the surface of the tissue. The recordings
were made using WPI ISO-DAM amplifiers (WPI, Hertfordshire, UK), with band
pass filters: 10 Hz - 3 kHz and digitised on-line (10kHz) with a CED Power 1401
mkII digitiser, controlled by Spike2 software (Cambridge Electronic Design, Cam-
bridge, UK). Slices were maintained in the chamber for twenty minutes prior to the
start of recording.
Schaffer collateral stimulation
Schaffer collaterals were stimulated with a 50 µm diameter concentric bipolar stim-
ulating electrode (FHC, Bowdoin, ME, USA) from a Model 2100 isolated stimulator
(AM Systems, Sequim, WA, USA). The resulting field excitatory post synaptic po-
tentials (fEPSPs) in CA1 were recorded to test slice viability in the chamber. Slices
were maintained in the novel chamber for 3.5 hours prior to stimulation. A paired
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pulse protocol was implemented with a 50 ms interval between pulses, stimulating
with 5V for periods of 200 µs. The initial slope of the fEPSPs was measured and the
paired pulse ratio calculated. The evoked fEPSPs were compared with those from
slices that were maintained in a Gibbs chamber for 3 hours and then transferred to
the chamber for a 30 minute recovery period prior to stimulation. Slices that had
been maintained in the two environments were interleaved. The initial slopes and
the paired pulse facilitation ratios of the evoked fEPSPs were compared to published
results from other work (Sui et al., 2005; Manahan-Vaughan and Schwegler, 2011).
Cerebellar recording
Purkinje cells exhibit spontaneous action potentials, at a frequency of approximately
50 Hz, in the absence of synaptic input (Raman and Bean, 1999) and thus are active
in in vitro cerebellar slices. This spontaneous activity was used as a functional
measure of the effectiveness of the bath. Microelectrodes were placed on the surface
of the Purkinje cell layer, one on each side of the chamber, such that spontaneous
firing of Purkinje cells was recorded. Initially both sides of the bath were perfused
with aCSF (5 minutes). Following this, one side of the bath was perfused with
the sodium channel blocker, tetrodotoxin (TTX, 1 µM, Ascent, Cambridge, UK)
to terminate the spontaneous firing on that side of the bath. The other side was
still perfused with aCSF. If the chamber functioned successfully, the spontaneous
firing would be terminated on the side perfused with TTX but continue on the other
side. After a further 5 minutes, 1 µM TTX was applied to both sides of the bath to
confirm that firing on both sides could be abolished. In total nine experiments were
performed, the side of the chamber to which TTX was first applied was alternated.
For three of the experiments the distance between the recording microelectrode on
the side opposite to that initially supplied with TTX and the divide was minimised.
This biologically tested the effectiveness of the solution separation. In all three cases
the microelectrode was less than 2 mm from the divide and in one case less than
1.5 mm from the divide.
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Epileptiform activity recording
Epileptiform activity was elicited in slices of cortex by perfusion with an excitant
solution (experimental aCSF with 0 mM Mg2+, 5 mM K+, (Mody et al., 1987)).
Slices were positioned such that approximately half of the cortex was on each side
of the divide. The hippocampus did not cross the central divide of the bath. Mi-
croelectrodes were placed, one on each side of the bath, over layer five of the cortex.
After transfer to the bath and placement of the microelectrodes the slices were left
to recover for twenty minutes before recording. Initially both sides of the bath were
perfused with aCSF for 5 minutes. Following this, one side of the bath was perfused
with excitant solution, and the other with aCSF, for 30 minutes. If the chamber was
functioning successfully it was expected that this would elicit epileptiform activity
on the side of the tissue exposed to excitant but not on the other side (perfused with
aCSF). Subsequently both sides of the bath were perfused with aCSF for 30 minutes
to terminate any seizure activity. Both sides of the tissue were then perfused with
excitant solution for 30 minutes. This was expected to elicit epileptiform activity
on both sides of the tissue and thus confirm that they were viable and that the
microelectrodes were correctly placed. Synchronicity of activity on both sides of the
divide during this final period would demonstrate the viability of the region of the
tissue under the divider.
2.4 Results
Solution mixing
The effectiveness of the inflow channels in reducing turbulence and mixing in the
chamber was tested (as detailed above). The images of the bath region of the
chamber with 0 mm channels (Figure 2.3A) showed significant mixing arising from
inertial instability. In contrast, images of the bath region of the chamber with
37.2 mm channels showed a straight, narrow, interface (Figure 2.3C). Profiles of
cross sections of the bath regions of the two chambers (Figures 2.3B and 2.3D
respectively) show a poorly defined interface in the case of the chamber with 0 mm
channels and a well defined, consistently positioned, interface in the case of the
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Figure 2.3: Dye characterisation of solution
interface width. (A) Image of bath region of
chamber with 0 mm channels supplied with a
fluorescent solution to left and water to the
right. Significant mixing can be seen aris-
ing from inertial instability. (B) Concentra-
tion profile at cross sections 1 mm, 6 mm
and 12 mm along flow direction into empty
bath region of chamber with 0 mm channels
as shown in (A). (C) Image of bath region of
chamber with 37.2 mm channels supplied with
a fluorescent solution to left and water to the
right. The separation of the distinct solutions
is seen to be well maintained. (D) Concen-
tration profile at cross sections 1 mm, 6 mm
and 12 mm along flow direction into empty
bath region of chamber with 37.2 mm chan-
nels as shown in (C). (E) Dependence of in-
terface width on input channel length. Mea-
sured along cross sections 1 mm, 6 mm and
12 mm along flow direction into chamber re-
gion. Mean of n = 6, bars show the standard
error. (F) Width of interface 12 mm along
flow direction in chamber with 37.2 mm or
0 mm channels, with listed additions. Mean
of n = 6, bars show the standard error.
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chamber with 37.2 mm channels (the maximum length possible given the other
design constraints). A greater than 90% change in concentration occurred over less
than 0.5 mm in the bath region of the full device. The interface width decreased
with increasing channel length, as did the variation in interface width (Figure 2.3E).
The interface width (25% to 75% change in concentration) was 3.7 ± 0.6 mm in the
centre of the bath region of the chamber with 0 mm channels and 0.4 ± 0.1 mm in
the chamber with 37.2 mm channels (n = 6 for both). The visible effects of inertial
instability in the chamber with 0 mm channels, its apparent absence in the chamber
with 37.2 mm channels, and the decrease in interface width with channel length all
support the conclusion that the high surface area to volume ratio inflow channels
acted to suppress inertial instability and, therefore, mixing.
The effect on the interface width of the introduction of microelectrodes and
a supporting net to the chamber was measured. The presence of the microelectrodes
or net in the images limited analysis to the profile at the cross section at 12 mm.
As expected, the addition of both microelectrodes and a supporting net caused an
increase in interface width, to 2.7 ± 0.8 mm and 3.4 ± 0.6 mm respectively (n = 6 for
both) (Figure 2.3F). The replacement of the supporting net and hold down with ones
with a divider effectively compensated for this effect. The interface width 12 mm
into the bath region of a chamber with 37.2 mm channels, containing a support
and hold down with dividers, a tissue slice and two microelectrodes, was 1.1 ± 0.2
mm. The dividers were, however, insufficient to prevent mixing independent of
inflow channels. The interface width in a chamber with 0 mm channels, containing
a support and hold down with dividers, a tissue slice and two microelectrodes was
4 ± 0.8 mm.
Solution exchange
After the change in solution supplied to the chamber, the fluorescence intensity
increased uniformly across the bath region of the chamber (Figure 2.4A). In con-
trast, there was mixing in the commercially available bath that resulted in stagnant
regions, free from fluorescent solution, more than 20 s after the fluorescent solu-
tion reached the in-flow of the bath (Figure 2.4A). The increase in concentration of
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Figure 2.4: Dye characterisation of solution change. (A) Sequence of images during the
change from water to a fluorescent solution taken at the indicated times. On the left are
images of the bath region of the novel chamber, showing a uniform increase in fluorescence
intensity, free from turbulence. On the right are images of a commercial tissue bath (detailed
in the text) showing mixing of the two solutions with a stagnant region of water persisting,
unmixed with fluorescent solution. (B) Concentration profile during change from water
to fluorescent dye for the region occupied by a tissue slice in the novel chamber. (C)
Comparison of times for change from 5% to 95% of the maximum fluorescein concentration
for both the novel chamber and the commercially available bath. The contents of the bath
and the depth of solution is indicated for each case. Mean of n = 3, bars show the standard
error.
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fluorescent solution in the bath region of the chamber increased sigmoidally (Fig-
ure 2.4B) with a characteristic time scale less than or equal to that of the commercial
bath under the same conditions (Figure 2.4C). There was mixing of the two solu-
tions in both the novel chamber and the commercially available bath. In the novel
chamber, however, the mixing occurred in the in-flow channels, prior to the bath
region. In both the novel chamber and the commercial bath the exchange time was
significantly longer with a solution depth of 4 mm than with a solution depth of
2 mm. When containing a tissue slice and two microelectrodes the time for ex-
change with 4 mm deep solution for the novel chamber (and the commercial bath)
was 68.9 ± 7.5 s (69.0 ± 2.9 s) and with a solution depth of 2 mm 26.6 ± 2.3 s
(36.0 ± 1.5 s).
Whilst mixing did occur between solutions supplied consecutively to the same
side of the chamber, the time for exchange from 5% to 95% concentration was no
worse than that for a commercially available bath. Mixing was isolated to the in-
flow channels prior to the region containing the tissue slice. This reduced areas of
stagnant solution in contact with the slice.
Contamination detection
There were no differences, above measurement noise, between the GCMS results
from the solution that had passed through the chamber and the control solution
that only passed through the associated tubing (Figure 2.5A). The solution of R11
resin monomer, cross-linker and associated solvents ( 100 ppm by volume) re-
sulted in GC peaks consistently over 50 times greater than the measurement noise.
The upper limit on contamination was, therefore, 2 parts per million by volume.
Given the concentration of the R11 solution was an upper bound, the actual level
of contamination was, however, much less than this. MSL, using R11 resin, pro-
vides a rapid technique for the productions of chambers bespoke for experiments.
The resulting parts have been shown not to contaminate water based solutions, at
physiological temperatures, that pass through them. MSL using R11 resin could,
therefore, be an effective manufacturing technique for many types of chamber with
biological applications.
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Figure 2.5: Results of tests for contamination of slices in the chamber from components of
the R11 resin used for its manufacture. (A) Top: Result of gas chromatography of a control
solution of less than 100 ppm of the water soluble components of R11 resin monomer,
cross-linker and associated solvents. Bottom: Result of gas chromatography of water after
being passed through the chamber at 30 - 31 oC, showing no detectable contamination with
any components of R11 resin. (B) Example recordings from hippocampal slices using a
paired pulse stimulation protocol (50 ms interval) illustrating the viability of slices after an
extended period in the novel chamber. Top: Example fEPSPs from a slice maintained in the
novel chamber for 3.5 hours. Bottom: Example fEPSPs from a slice maintained in a Gibbs
chamber for 3 hours before being transferred to the novel chamber for a 30 minute recovery
period before stimulation. (C) Comparison of the initial slope of the first fEPSP evoked
in slices maintained in the novel chamber and in a Gibbs chamber, showing no significant
difference. Mean of n = 6, bars show the standard error. (D) Comparison of the paired pulse
facilitation ratio from the initial slope of the fEPSPs evoked in slices maintained in the novel
chamber and in a Gibbs chamber, showing no significant difference. Mean of n = 6, bars
show the standard error. Recordings were made from interleaved slices either maintained in
the bath or in a Gibbs chamber and fEPSPs were evoked with the same stimulus strength.
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Schaffer collateral stimulation
The fEPSPs evoked in hippocampal slices maintained in the novel chamber were
indistinguishable from those evoked in slices maintained in a Gibbs chamber (Fig-
ure 2.5B and 2.5C). The mean initial slope of the first fEPSP evoked in slices main-
tained in the novel chamber (and the Gibbs chamber) was -0.078 ± 0.012 mV/ms
(-0.078 ± 0.014 mV/ms) and the paired pulse facilitation ratio (for a 50 ms interval)
was 2.14 ± 0.13 (2.15 ± 0.10). These results are consistent with published results
from other work (Sui et al. 2005; Manahan-Vaughan and Schwegler 2011). Slices
maintained in the chamber for over 3.5 hours exhibited stimulus evoked responses in-
distinguishable from those evoked in slices maintained in standard chambers. There
was, therefore, no evidence of any adverse effects either from contamination of the
perfusing solution with components of the R11 resin (consistent with the results
from tests with GCMS) or from a difference in perfusion.
Cerebellum recording
The effectiveness of the chamber was tested using extracellular recordings from
Purkinje cells. All slices (n = 9) exhibited spontaneous activity, demonstrating
slice viability in the chamber. In all cases application of 1 µM TTX to one side
terminated the activity on that side (n > 3 for each side of the chamber) but had no
effect on the opposite side, including those cases (n = 3) when the microelectrode
on the side opposite to that initially perfused with TTX was less than 2 mm from
the divide. The ongoing activity was shown to be sensitive to TTX with subsequent
application to that side (Figure 2.6). This demonstrated the effectiveness of the
chamber in maintaining the solution separation under typical recording conditions
with a slice present in the chamber.
Recording of epileptiform activity
The effectiveness of the chamber was further tested by eliciting epileptiform activity
in slices of cortex. Extracellular recordings (n = 12) were made while implementing
the perfusion protocol described above. This protocol was implemented with the side
initially exposed to excitant being either the anatomically anterior region (n = 6)
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Figure 2.6: Example of an individual cerebellar slice recording demonstrating the effective-
ness of the chamber. (A) Schematic of cerebellar slice showing microelectrode placement
relative to the interface. Arrows indicate perfusion with distinct solutions. (B) Extracellular
recordings of spontaneous Purkinje cell action potential firing on a compressed time base.
Microelectrode placement as in (A). Application of 1 µM TTX (grey bars) at five minutes
causes cessation of firing on perfused side while not affecting the opposite side. Application
of TTX to both sides caused a complete loss of activity. (C) Expanded portion of panel
(B) from (*) illustrating multi-unit firing on both sides of the tissue. (D) Expanded portion
of panel (B) from (**) illustrating continued multi-unit firing on one side although activity
has been blocked on the other side of the tissue.
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Figure 2.7: Example recording of induced epileptiform activity, demonstrating the effec-
tiveness of the chamber both with respect to targeted perfusion and the maintenance of
tissue viability. (A) Schematic of cortical slice showing microelectrode placement relative to
the interface. Arrows indicate perfusion with distinct solutions. (B) Extracellular voltage
recording on a compressed time base. Microelectrode placement as in (A). Application of
excitant solution is indicated by grey bars. Initially excitant was applied to one side, which
became active, while the other side remained quiescent. Application of excitant to both
sides induced activity on both sides. (C) Expanded portion of panel (B) from (*) showing a
burst of epileptiform activity on one side of the slice while the other side remained quiescent.
(D) Expanded portion of panel (B) from (**) showing a burst of population spikes on both
sides of the tissue. The synchronicity of the burst, and the population spikes with in it,
demonstrates the viability of the centre of the tissue between the dividers, which connects
them.
or the anatomically posterior region (n = 6). In all cases epileptiform activity
was recorded on the side perfused with excitant but not on the side perfused with
experimental aCSF. Activity was recorded on both sides when both were perfused
with excitant (Figure 2.7). This demonstrated the effectiveness of the chamber
in generating isolated activity in a tissue slice. As both anatomical regions were
recorded as the first side perfused with excitant in isolation, the activity was not
a result of the side exposed being more excitable. The slices were alternated in
orientation such that half of each set of six recordings was made with excitant
first perfusing on each side of the chamber. This eliminated the possibility of an
asymmetry in the perfusion. In all cases the epileptiform activity recorded when
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both sides were perfused with excitant was synchronised. Bursts of seizure activity,
and the population spikes within them, were temporally correlated (Figure 2.7C).
This demonstrated the viability of the tissue between the central dividers. This
was required for transmission and, therefore, correlation between the activity in
the two regions of tissue. Synchronisation was exhibited at the end of 95 minutes
of recording. Including the time for microelectrode placement and that allowed
for slice recovery, this demonstrated the chamber maintained the viability of entire
slices for periods in excess of two hours.
This form of protocol has application in the study of seizure propagation
from pathological to physiological regions of tissue. This is exhibited in secondary
generalisation of seizure activity in vivo and is of significant research interest.
2.5 Discussion
A chamber has been produced that allows extended regions of a tissue slice in
vitro to be exposed, in isolation, to changes in conditions or drugs. The device
facilitates the study of the propagation of epileptiform activity between regions of
tissue in different ionic environments. The chamber could also be used to carry
out experiments with a simultaneous control in coronal slices, with each side of a
slice being maintained in different conditions. This would reduce bias as the regions
being compared would be from the same position in the brain and when being tested
would have been maintained for the same amount of time since dissection.
The effectiveness of the chamber has been shown to be preserved with the
introduction of microelectrodes to the chamber, to record from the slice. This simul-
taneous solution targeting and access for microelectrodes has not previously been
achieved. The chamber was manufactured from R11 resin using MSL. This is an
additive manufacturing technique allowing chambers bespoke for experiments to be
produced rapidly. It has been shown that chambers manufactured from R11 using
MSL do not contaminate water based solutions that pass through them at physi-
ological temperatures. The chamber has been shown to maintain the viability of
tissue slices for periods in excess of 3.5 hours, perfusing them across all surfaces and
maintaining them at a physiological temperature. The design employed generalises
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to varied geometries bespoke for experiments. In future work chambers with greater
numbers of channels will be developed.
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Chapter 3
High-resolution recording of
neural activity by
transforming Intrinsic Optical
Signals
The intrinsic optical properties of brain tissue are known to be activity dependent.
Measurement of these intrinsic optical signals (IOSs) is commonly used as a non-
invasive method to infer neuronal activity. Their use as a proxy for neuronal activity
has many advantages; they require no mechanical, chemical or genetic interference
with the tissue and are not limited by recording rate or duration. The temporal
dynamics of the IOS are, however, slow and so do not directly correspond to the
underlying network dynamics.
We characterised the intrinsic optical signal (IOS) that persists in vitro and
derived a transformation that converts the slow temporal dynamics of the IOS to a
form that accurately reflects the underlying network dynamics, thereby mitigating
the primary disadvantage of the use of IOSs as a method to record neuronal dy-
namics, allowing their advantages to be fully exploited. This chapter contains the
submitted paper describing this work. The results of some preliminary experiments
characterising the in vitro IOS were included in a submission for an MSc, however,
none of the data, analysis or text presented here was included in the submission. I
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planned and carried out the experiments, carried out the data analysis and wrote
the paper under the supervision of Dr James Covington, Dr Magnus Richardson,
Prof. Matthew Turner and Dr Mark Wall.
The full paper has been redacted from this version to avoid copyright in-
fringement.
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Chapter 4
Characterisation of the
spatio-temporal dynamics of the
extracellular concentration of
adenosine in the neocortex in
response to electrographic
seizure activity
Adenosine is a potent neuromodulator known to be released in response to seizure
activity. The temporal dynamics of this release have previously been investigated,
however, the spatial dynamics have not been readily accessible because of the lack
of a suitable recording tool for the associated network activity. The transforma-
tion presented in Chapter 3 has now rendered this regime accessible. This chapter
contains a paper in preparation describing work characterising the spatio-temporal
dynamics of adenosine release in response to seizure activity. I planned and carried
out the experiments, carried out the data analysis and wrote the paper under the
supervision of Dr Magnus Richardson and Dr Mark Wall.
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Characterisation of the spatio-temporal dynamics of the
extracellular concentration of adenosine in the
neocortex in response to electrographic seizure activity
4.1 Abstract
Adenosine is a potent neuromodulator, providing important negative feedback in
response to cortical network activity. Adenosine is critical for seizure termination
and has significant potential in the treatment of epilepsy. The spatio-temporal dy-
namics of endogenous adenosine peri-ictally are, however, not well characterised.
A number of real-time measurement techniques sensitive to adenosine are available,
however, they all have significant cross-sensitivities to other compounds that exhibit
transient variation in response to seizure activity. Here, we simultaneously employ
two independent techniques to measure extracellular adenosine, along with optical
recording of seizure activity and a modelling approach, to elucidate these dynamics
and their underlying mechanisms.
Key words: adenosine, electrographic seizure activity, biosensor, fast scan cyclic
voltammetry, intrinsic optical signal
4.2 Introduction
Adenosine plays an important role in many physiological processes, such as loco-
motion and sleep, and can be neuroprotective during pathological events, such as
hypoxia and ischaemia (Barraco et al., 1993; Florio et al., 1997; Nagel et al., 2003;
Ralevic and Burnstock, 1998; Fredholm et al., 2001; Latini and Pedata, 2001).
A basal tone of adenosine is present in brain tissue (Fredholm et al., 2001;
Latini and Pedata, 2001; Kerr et al., 2013) which is augmented by release in response
to neuronal activity, metabolic stress and other insults(Ralevic and Burnstock, 1998;
Fredholm et al., 2001; Latini and Pedata, 2001). The origins of extracellular adeno-
sine are not completely understood, but could include breakdown of previously re-
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leased ATP and direct release through equilibritive transport (Latini and Pedata,
2001; Wall and Dale, 2008). Adenosine can activate four types of G-protein coupled
receptors: A1, A2A, A2B, and A3 (Fredholm et al., 2001; Ralevic and Burnstock,
1998). Activation of A1 and A3 receptors has a mostly inhibitory effect while that
of A2 receptors is largely excitatory. Adenosine is removed to AMP by adenosine
kinase (ADK) and to inosine by adenosine deaminase (ADA) (Latini and Pedata,
2001).
Adenosine plays a particularly important role in epilepsy, providing negative
feedback in response to seizure activity and it is strongly implicated in seizure ter-
mination (During and Spencer, 1992; Ilie et al., 2012; Van Gompel et al., 2014).
Changes in adenosine metabolism may also be involved in epileptogenesis (Fedele
et al., 2005; Boison, 2006, 2007) and the mechanism of action of the ketogenic diet
(Masino et al., 2011). The inhibitory and neuroprotective effects of adenosine make
it a promising candidate for therapeutic use (Huber et al., 2001; Boison, 2006), how-
ever, the spatio-temporal dynamics of endogenous adenosine release in response to
seizure activity remains poorly characterised.
A number of studies of adenosine release in response to seizure activity
have been carried out (for example see (Winn et al., 1980; During and Spencer,
1992; Etherington et al., 2009; Van Gompel et al., 2014; Wall and Richardson,
2015)). These studies have, however, yielded inconsistent results, Van Gompel et
al. (Van Gompel et al., 2014) found adenosine release to be associated with seizure
termination, with the peak in extracellular adenosine release occurring up to 26.8 ±
16.5 s after seizure termination. Wall and Richardson (Wall and Richardson, 2015),
however, found that extracellular adenosine could not be directly detected as it was
metabolised to inosine so rapidly. These studies have, however, been limited in two
ways. Firstly in their spatial resolution, microelectrodes can be used to provide high
temporal resolution measurement of analyte concentration, the spatial localisation
of the associated seizure activity has, however, been limited. Secondly, the methods
of detection have not been specific to adenosine, actually measuring, for example,
the sum of adenosine, inosine and hypoxanthine. To elucidate the negative feedback
suppressing seizure activity it is important to measure adenosine specifically as the
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other compounds do not significantly activate A1 receptors.
A number of methods have been used to measure local extracellular adeno-
sine concentration. It can be inferred from its effect on synaptic transmission (for
example see (Fredholm et al., 1984; Yoon and Rothman, 1991; Kerr et al., 2013).
However, peri-ictally there are at least two sources of synaptic depression, that
caused by transient adenosine release and that resulting from vesicular depletion.
Pharmacological approaches could be used to separate the two, but this would be
slow compared to the temporal dynamics of the two processes. It is, therefore, not
practical to use this approach to infer adenosine dynamics periictally. Microdialysis
(During and Spencer, 1992) can be used to measure adenosine concentration, how-
ever, its spatial and temporal resolution are both poor. Freeze blow techniques have
also been used to measure adenosine concentration (Winn et al., 1980), however, this
only allows measurement at a single time point and does not distinguish between in-
tra and extra-cellular adenosine. Two further, microelectrode based, techniques can
provide higher spatio-temporal resolution of adenosine concentration: fixed poten-
tial amperometry (FPA) and fast scan cyclic voltammetry (FSCV). Both, however,
suffer from cross-sensitivity to other compounds.
FPA uses an enzyme coated microelectrode, held at a constant potential, to
detect adenosine (Fig. 4.1a) (Dale et al., 2005). The enzymes break down adenosine,
through inosine and hypoxanthine, to urate and hydrogen peroxide. The hydrogen
peroxide is then detected amperometrically by the platinum microelectrode polarised
to 500 mV (Llaudet et al., 2003; Dale et al., 2005). A permselective layer over the
enzymes prevents direct oxidation of other analytes such as ascorbate, 5HT and
dopamine. Enzymatic specificity means that the response is highly specific to the
purines adenosine, inosine and hypoxanthine. The sensors are, however, not specific
to adenosine. As inosine and hypoxanthine are steps in the enzymatic cascade,
presence of these compounds endogenously also results in an amperometric signal.
Measurement with an inosine FPA biosensor (a sensor identical to an adenosine
biosensor without adenosine deaminase) gives a signal corresponding to the local
inosine and hypoxanthine. Subtraction of the signal from an inosine sensor from that
of an adenosine sensor could give a signal specific to adenosine, however, the purine
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concentration in the neocortex has been shown to be heterogeneous on the scale of
the minimum separation of two FPA biosensors and so this method is ineffective
(Kerr et al., 2013; Wall and Richardson, 2015).
FSCV detects adenosine by oxidising it directly (Swamy and Venton, 2007;
Chang et al., 2012; Van Gompel et al., 2014; Nguyen et al., 2014). A triangular
waveform is applied to a microelectrode and the resulting current is measured. The
applied voltage results in the oxidation and reduction of many compounds, including
adenosine. The current at the voltages of the characteristic oxidation peaks of
adenosine in the voltammagram gives a measure of the local adenosine concentration
(Swamy and Venton, 2007). The voltages at which the adenosine oxidation peaks
occur are relatively specific to adenosine, however, other analytes that are likely
to exhibit transient dynamics in response to ictal activity also give rise to finite
currents at these voltages. Furthermore, it is possible that FSCV may modify the
local adenosine tone and available stock by directly causing adenosine release. It is
known that electrical stimulation can elicit adenosine release (Klyuch et al., 2011;
Chang et al., 2012). Whilst the effect of the FSCV waveform would be constant on
the time-scale of ictal events it may modify transient adenosine release by chronically
depleting the available stock.
Both FPA and FSCV provide high spatio-temporal information about ex-
tracellular adenosine concentration, albeit both with cross-sensitivity to other com-
pounds. The cross-sensitivities of the two techniques are, however, different. In
combination they provide a more specific measure of adenosine than can be ob-
tained with either technique in isolation.
Adenosine provides critical negative feedback during seizure activity, how-
ever, the spatio-temporal dynamics of peri-ictal adenosine release are poorly char-
acterised. Here we use a transformed form of the intrinsic optical signal (Thomas
et al., 2015) to determine the spatio-temporal dynamics of seizure activity in acute
neural tissue slice and perform simultaneous FPA and FSCV to resolve the associ-
ated adenosine dynamics and thereby characterise the spatio-temporal dynamics of
adenosine release associated seizure activity.
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4.3 Materials and Methods
Slice preparation
Parasagittal slices of cortex (400 µm) were prepared from male Sprague-Dawley
rats at postnatal days 18−21. In accordance with the United Kingdom Animals
(Scientific Procedures) Act 1986, rats were killed by cervical dislocation and decapi-
tated. The cerebrum was rapidly removed. Parasagittal slices were cut on a Microm
HM 650V micro-slicer (Carl Zeiss, Welwyn Garden City, United Kingdom) in cold
(2−4oC) high Mg2+, low Ca2+ artificial cerebrospinal fluid (aCSF) composed of (in
mM): 127 NaCl, 1.9 KCl, 8 MgCl2, 0.5 CaCl2, 1.2 KH2PO4, 26 NaHCO3, 10 D-
glucose (pH 7.4 when bubbled with 95% O2 − 5% CO2). Slices were stored in aCSF
(1.0 mM MgCl2, 2.0 mM CaCl2) in a Gibbs chamber at 34
oC for at least one hour
before recording. The number of slices used for each experiment was determined
empirically from the results of preliminary tests. All experiments were approved by
the University of Warwick Animal Welfare and Ethical Review Body.
Recording from slices
Slices were transferred to a bespoke recording chamber after Thomas et al. (2013)
that supported the tissue in the aCSF flow, allowing it to be perfused on both sides.
Slices were perfused with aCSF at a constant flow rate of 4 ml/min at 35 ± 0.5 oC.
All tubing was gas tight (Tygon) and solutions were vigorously bubbled with 95%
O2 − 5% CO2. Slices were allowed to recover in the chamber for 40 minutes before
recording.
Induction of network activity
Population spikes were induced by application of 40 µM bicuculline methiodide
(Sigma Aldrich, Gillingham, UK). Electrographic seizure activity was induced by a
gradual change from standard aCSF to Mg2+ free aCSF (Mody et al., 1987). What
is believed to be mixed state activity was induced by rapidly changing from normal
aCSF to Mg2+ free aCSF. Spreading depression was induced by rapidly changing
from normal aCSF to Mg2+ free aCSF with 3.8 mM KCl.
Local Field Potential recording
Extracellular recordings were made with aCSF filled electrodes, tip diameters 15
µm, placed on the surface of the tissue. The recordings were made using A-M
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systems amplifiers with bandpass filter 10 Hz to 3 kHz and digitised online (10 kHz)
with a CED Power1401 mk II digitiser controlled by Spike2 software (Cambridge
Electronic Design, Cambridge, UK).
Fixed potential amperometry
Adenosine FPA biosensors (Fig. 4.1a) were obtained from Sarissa Biomedical (Coven-
try, UK). These consisted of a 50 µm diameter, 500 µm long, Pt wire coated with
a matrix containing ADA, nucleoside phosphorylase, and xanthine oxidase (respon-
sive to adenosine, inosine and hypoxanthine), then further coated with a permselec-
tive layer to prevent direct oxidation of other analytes such as ascorbate, 5HT and
dopamine (Llaudet et al., 2003). Null sensors, also from Sarrisa Biomedical, identi-
cal to the adenosine biosensors except lacking the enzymes, were used in preliminary
experiments to control for nonspecific electro-active interferents. No responses were
detected on the null sensors and so they were not used for later experiments. The
biosensors were inserted through the tissue. Biosensor signals were acquired at 1
kHz with a Micro CED (Mark 2) interface using Spike (version 6.1) software (Cam-
bridge Electronics Design). When not simultaneously recording with FSCV the FPA
signal was low pass filtered at 100 Hz, thereby simultaneously detecting the LFP
associated with electrographic seizure activity. When simultaneously recording with
FSCV a low pass filter of 1 Hz was used. Preliminary experiments showed adeno-
sine transients to be sufficiently slow for this filtering not to affect the transients
recorded, whilst also suppressing the aretfacts resulting from the FSCV waveform.
The times of the FSCV artefacts was recorded and they were removed from record-
ings retrospectively, but by suppressing them live, the biosensor responses could be
used to monitor experiments in real-time. After each experiment, the biosensors
were calibrated with 10 µM adenosine.
Local field potential recording from biosensor
The LFP was extracted from FPA recordings (where a 100 Hz low pass filter was
employed) by Fourier transforming the recording, separating the low (<1 Hz) and
high (>1 Hz) frequency components and Fourier transforming the result to give the
adenosine transients and the LFP respectively.
Fast Scan Cyclic Voltammetry
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FSCV was carried out by applying a triangular waveform to a 7 µm diameter, 500
µm long, carbon fibre micro-electrode (CFME, Fig. 4.1d, purchased from Sarissa
Biomedical, Coventry, UK) inserted in to the tissue. The waveform was applied
using a CED Power1401 mk II digitizer and consisted of a baseline of -0.4 V with
a triangular waveform at 10 Hz rising to 1.6 V and returning to baseline in 10
ms (Fig. 4.1e). The voltage across a 4.6 kΩ resistor in series with the CFME was
measured using an A-M systems amplifier with bandpass filter 0.1 Hz to 20 kHz
and was digitised online (20 kHz) with a CED Power1401 mk II digitiser controlled
by Spike2 software (Cambridge Electronic Design, Cambridge, UK). The current
corresponding to the applied voltage waveform was calculated using Ohm’s law.
The current at the voltages associated with adenosine oxidation (Swamy and Venton,
2007) were identified and converted to a time series retrospectively.
Intrinsic optical signal imaging
Network activity was inferred from the intrinsic optical signal (IOS) recorded from
the tissue (Thomas et al., 2015). The tissue was illuminated by three L-7113VGC-E
LEDs (Kingbright, New Taipei City, Taiwan). The LEDs were connected in parallel
to each other and in series to a 100 Ω resistor. An HY3003 DC power supply
(Digimess, Derby, UK) was used to supply 6.2 V, giving a total current through
the LEDs of 30 mA. The peak in the emission spectrum of the LEDs was 520
nm, this maximised the signal-to-noise ratio of the recording given the wavelength
dependence of the camera’s sensitivity and the wavelength dependence of the signal
amplitude (Thomas et al., 2015). The incident light intensity was optimised to
give a typical baseline reflected intensity 70 % of that which would saturate the
camera sensor, this prevented inhomogeneities in the reflected intensity resulting in
regions saturating the camera sensor whilst maximising the signal to noise ratio.
The LEDs were positioned around the slice to avoid shadows resulting from the
microelectrodes. The LEDs were angled to illuminate the slice at approximately
25o to normal. The reflected light was recorded using a Hitachi KP-M1A camera
(Scientifica, Bedford, UK). Recordings were made at 25 frames per second (fps) at a
resolution of 640 x 480 pixels. The recordings were saved as uncompressed avi files
on external hard drives. The time base of the optical recording was synchronised
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Figure 4.1: Methods for the measurement of adenosine: Fixed Potential Amperometry
(FPA) and Fast Scan Cyclic Voltammetry (FSCV). (a) Schematic of FPA biosensor. (b)
Example calibration of an FPA biosensor. (c) Example response of an FPA biosensor to
10 µM adenosine and 10 µM inosine, showing the cross sensitvity of the biosensors. (d)
Schematic of a carbon fibre microelectrode (CFME) used for FSCV. (e) Applied voltage
waveform. (f) Example current measured in response to application of voltage shown in
(e). (g) Voltammagrams of aCSF (black) and aCSF and 10 µM adenosine (red). (h)
Background subtracted voltammagram of 10 µM adenosine. (i) Example calibration of
FSCV to adenosine. (j-l) Example cross sensitivities of FSCV: subtracted voltammagrams
of potassium chloride (j), inosine (k) and dopamine (l).
to the others (LFP, FPA, FSCV) by a TTL pulse to both the digitiser and the
illuminating LEDs at the beginning and end of recordings. The recorded IOS was
transformed to the tIOS (Thomas et al., 2015) which then accurately reflected the
spatial and temporal dynamics of the underlying network activity (Fig. 4.2).
Pharmacological manipulation
All drugs were made up as 10−100 mM stock solutions, stored frozen, and then
thawed and diluted with aCSF on the day of use. Adenosine was purchased from
Sigma (Poole, UK). Erythro-9-(2- hydroxy-3-nonyl)adenine (EHNA, an adenosine
deaminase inhibitor), Nitrobenzylthioinosine (NBMPR, an ENT1 inhibitor) and
Dipyridamole (an inhibitor of ENT1 and ENT2) were purchased from Tocris-Cookson
(Bristol, UK).
Analysis and modelling
Data analysis and modelling were both carried out using Matlab R2011b (Math-
Works, Natick, USA) using custom scripts.
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Figure 4.2: Recovery of an LFP like time-series from the IOS recorded. (a) train of fEPSPs
(20 at 10 Hz) (b) population spikes (c) electrographic seizure activity and (d) spreading
depression. For all types of activity, the top row shows the change in reflected intensity. The
second row shows the associated LFP. The third row shows the result of the transformation
to the tIOS. The tIOS accurately reflects the dynamics of the LFP, with the exception of
spreading depression, which produces a characteristic tIOS waveform.
4.4 Results
The macroscopic structure of the neocortex allows the spatio-temporal dynamics of
extracellular adenosine to be readily separated into two components. The structure
of the neocortex is approximately translationally invariant perpendicular to the
normal to the nearest point on the pial surface. Long range connections in these
directions are, however, less frequent and so the level of neuronal activity can vary
significantly as a function of these directions. Normal to the pial surface, although
continuous tissue, the neocortex has a layered structure, each layer having a distinct
cellular composition. The degree of connection between cells lying close to the same
normal is, however, high and so variation in the level of neuronal activation is
relatively small.
The spatial dynamics of purines were, therefore, separated into the direction
of the local surface normal, along which the cellular composition of the tissue varied
significantly, but the degree of activation could be considered uniform, and the
directions perpendicular to the surface normal along which the composition of the
tissue did not vary significantly but the degree of activation did (Fig. 4.3a). For the
400 µm tissue slices used in this study, the degree of neuronal activation was also
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Figure 4.3: Separation of spatial components. (a) Example micrograph of a tissue slice with
superimposed grid reflecting the organisation of the tissue. A cartesian coordinate system
(x-y-z) and a natural coordinate system (l-d-w) are indicated. (b) A schematic of the tissue
slice shown in (a) transformed on to a rectilinear grid. (c) Projection of tissue slice, normal
to that shown in (b).
considered to be invariant along the short dimension perpendicular to the surface
normal (w, Fig. 4.3c).
With an appropriate Jacobian, the structure of the neocortex can be trans-
formed on to a rectilinear grid (Fig. 4.3b) with only structural variation along one
direction, only activation variation along the other and no variation in either acti-
vation or structure along the third.
We assume extracellular purine (PE) dynamics to be governed by diffusion,
removal (BP ) and release (RP ), where the release is dependent on the current local
level of activation (EP (l, t)), the available stock of purine (PS) and the nature of
the local tissue (DP (d)). Given the above assumptions this gives:
∂PE(l, d, w, t)
∂t
= D′∇2(PE(l, d, w, t))−BP (PE(l, d, w, t))+RP (E(l, t), PS(l, d, t), DP (d)).
(4.1)
Where D′ is a diffusion constant, assumed to be equal for adenosine, inosine and
hypoxanthine, modified to account for the tortuosity of the tissue. We assume a
similar equation applies for the dynamics of extracellullar adenosine (AE , with BA,
RA, AS and DA). Here we seek to test this model and constrain the parameters
and functional forms.
Layer dependence of purine release
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To investigate the layer dependence of purine release, three FPA biosensors were
inserted in to somatosensory cortex, one in layer I, one in layer II/III and one in
layer V; all along the same normal to the pial surface. Network activity was then
induced in the tissue and was recorded optically. The optical recording was used to
ensure that the active region completely encompassed the biosensors and that they
were not close to the boundary of the active region.
Two types of response were detected, a monophasic rise in purine concen-
tration associated with network activity induced by gradually reducing the Mg2+
concentration of the perfusing aCSF, thought to be electrographic seizure activity,
and a biphasic rise in purine concentration associated with network activity induced
by a rapid change from standard aCSF to Mg2+ free aCSF, thought to be mixed
state activity.
The network activity induced by a gradual reduction in Mg2+ concentration
caused a transient monophasic rise in purine concentration on all three biosen-
sors (n=7, Fig. 4.4a). The temporal dynamics and peak amplitudes of the purine
transients in layers II/III and V were not significantly different: layer II/III peak:
1.0 ± 0.1 µM; layer II/III time to maximum: 41 ± 1 s; layer V peak: 1.3 ± 0.2 µM;
layer V time to maximum: 39 ± 4 s. The dynamics of the transients in layer I
were, however, different to those in layers II/III and V. The transients in layer I
were smaller in amplitude than those in layers II/III and V (P<0.01); layer I peak:
0.3 ± 0.1 µM and the time to maximum was greater in layer I than in layers II/III
and V (P<0.01), time to maximum in layer I: 90 ± 10 s.
The network activity induced by a rapid reduction in Mg2+ concentration
caused a transient biphasic rise in purine concentration on all three biosensors (n=7,
Fig. 4.4b). The initial downward deflection on the biosensor recordings was followed
by an initial rise and plateau phase followed by a second rising phase and subsequent
decay. Neither the peak amplitudes nor the time to maximum were significantly
different across all three biosensors: layer I peak: 3.6 ± 1.0 µM; layer I time to
maximum: 126 ± 14 s; layer II/III peak: 7.6 ± 2.0 µM; layer II/III time to maxi-
mum: 110 ± 26 s; layer V peak: 6.7 ± 2.0 µM; layer V time to maximum: 110 ± 25
s.
75
Figure 4.4: Layer dependence of monophasic (a) and bisphasic (b) purine release as measured
with FPA biosensors. The top panels show example traces from the biosensors and the
associated intrinsic optical signals. The bottom panels show summary data (n=7 for both
types of response), bars indicate result of a paired sample t-test < 1%.
For all other experiments a gradual change to Mg2+ free aCSF was employed
to induce network activity, as this was thought to cause electrographic seizure ac-
tivity.
Model of layer dependent release
Layer I has different boundary conditions to layers II/III and V. Tissue within the
slice preparation in layers II/III and V has a zero purine concentration boundary
condition along the two cut surfaces. Layer I of a tissue slice also has a zero purine
concentration boundary condition across the pial surface. We modelled the system
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to investigate whether this difference in boundary conditions explains the difference
in purine dynamics in layer I.
Given the measurements were made from locations distant from the edges of
the active region, as confirmed optically, purine flux along direction l (Fig. 4.3a,b)
could be ignored. This therefore resulted in a two dimensional reaction-diffusion
equation. Assuming breakdown of hypoxanthine to be much slower than its loss
from the slice by diffusion (Klyuch et al., 2011), breakdown can be ignored, leaving:
∂PE(d,w, t)
∂t
= D′∇2(PE(d,w, t)) +RP (d,w, t). (4.2)
The case where purine release is a delta function at all position within the tissue at
t = 0 was solved analytically, giving:
PE(w, d, t) =
∞∑
n=1
∞∑
m=1
4Ω
nmpi2
(1−cos(npi))(1−cos(mpi
2
))·sin(npi
α
w) sin(
mpi
β
d)e
−D′(n2pi2
α2
+m
2pi2
β2
)t
(4.3)
where α is the thickness of the tissue, β is the depth of the neocortex (Layers I
- V) and Ω is the adenosine concentration in the tissue immediately after release.
This result was then used to validate a numerical scheme to solve the reaction
diffusion system (Fig. 4.5). The numerical result accurately matched the analytic
one (Fig. 4.5c) and so was used to solve the system with more complex release
dynamics.
Considering a burst of electrographic seizure activity to be made up of spikes
occurring at a constant, high, firing rate, with the duration of the burst much smaller
than the re-stock time constant, it is reasonable to approximate the discrete release
of a resource depletion model (Klyuch et al., 2011) with a decaying exponential.
We therefore solved Eq. 4.2 with exponential release dynamics and compared the
resulting purine concentration dynamics at a point adjacent to the pial surface,
representative of the dynamics in layer I, to those at a point in the middle of the
active region, representative of the dynamics in layer V (Fig. 4.6a).
With spatially uniform release of purine, the peak in purine concentration in
layer I was smaller than that in layer V (Fig. 4.6 b,c), as was observed experimentally.
The time of the peak was, however, earlier in layer I than in layer V (Fig. 4.6d),
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Figure 4.5: Validation of numerical PDE solution scheme. (a) Schematic of test geometry.
(b) Analytic solution of diffusion equation at the four locations shown in (a). (c) Comparison
of numeric and analytic solutions at the four regions shown in (a) showing good agreement
between the two solutions.
which was inconsistent with the experimental results. We therefore modelled the
system without purine release in the region adjacent to the pial surface, considering
a range of sizes of this region (Fig. 4.6a,e). In this system the time to peak was
greater in layer I than in layer V (Fig. 4.6 b,g), as observed experimentally, and
again the peak in layer I was smaller than that in layer V (Fig. 4.6h). However,
experimentally there was a positive correlation between the ratio of release of purine
in layer I to layer V and the lag to the peak (Fig. 4.6e). The model without release in
layer I did not exhibit this property, instead showing a negative correlation between
relative release and lag to peak as the duration of release was varied (Fig. 4.6f).
Diffusion correction
Tissue slices allow access and control not possible in vivo. However, a consequence
of slicing the tissue and maintaining it in aCSF is a significant modification to the
boundary conditions of the tissue. The cut surfaces of slices are exposed to a rapidly
replaced solution not containing any purines. This is effectively a zero concentration
boundary condition across all of the tissue, this does not reflect the in vivo conditions
and leads to a significant modification to decay dynamics.
The loss of purines from the tissue by diffusion can, however, be corrected
for. Assuming the release of purine to be slowly varying with depth (d) on the
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Figure 4.6: Model of release as a function of depth into neocortex. (a) Schematic of system,
indicating a non-releasing layer I. (b) Time courses of purine concentration for location 1
(blue) and 2 (black) in (a). (c) Relative peak in purine concentration as a function of depth
into the neocortex for a releasing layer I. (d) Lag to peak in purine concentration as a function
of depth in the neocortex for a releasing layer I. (e) Relative peak in purine concentration
plotted against the lag to the maximum for a range of depths of layer I, all points along
the line equidistant from both cut surfaces are shown (colours), and experimental results
and linear fit (black). Relative peak in purine concentration plotted against the lag to the
maximum for a 300 µm layer I. A number of durations of release are shown at a number of
distances from the pial surface. (g) Relative peak in purine concentration as a function of
depth into the neocortex for a 300 µm layer I. (h) Lag to peak in purine concentration as a
function of depth in the neocortex for a 300 µm layer I.
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length scale of the thickness of the slice, considering a point within a large releasing
region, away from both the dorsal and ventral edges (Fig. 4.7a) and ignoring removal
of purine by the biosensor, the concentration of purine can be considered to be
invariant in the plane of the slice (directions d and l). The temporal dynamics of
purine concentration can, therefore, be considered as a one dimensional reaction
diffusion problem.
The biosensor inserted through the tissue (Fig. 4.7b) then measures the in-
tegral of the extracellular purine concentration (PE) as a function of w:
MP (t) = γ
∫ α
0
PE(w, t)dw. (4.4)
The one dimensional reaction diffusion equation for purine concentration is assumed
to be:
∂PE(w, t)
∂t
= D′
∂2PE
∂w2
+RP (w, t)−BP (PE(w, t)). (4.5)
Where D′ is a diffusion constant, assumed to be equal for adenosine, inosine and
hypoxanthine, modified to account for the tortuosity of the tissue; RP (w, t) is the
rate of release of purine and BP is the rate of breakdown of purine.
The functions of interest in Eq. 4.5 are RP (w, t) and BP (P (w, t)), while what
is measured experimentally is MP (t)(Eq. 4.4). We seek to identify an operation to
determine RP (w, t) and BP (PE(w, t)) given M(t).
Integrating Eq. 4.5 gives:
∂
∂t
∫ α
0
PE(w, t)dw =
∫ α
0
D′
∂2PE(w, t)
∂w2
dw+
∫ α
0
RP (w, t)dw−
∫ α
0
BP (PE(w, t))dw.
(4.6)
Slice thickness (α) is small, so the release of purine is considered to be in-
variant along this direction. Substituting for the expression for M(t) in to Eq. 4.6
gives:
80
∂∂t
(
1
γ
MP (t)
)
= D′
[
∂PE(w, t)
∂w
]
+ αRP (w, t)−
∫ α
0
BP (PE(w, t))dw. (4.7)
If we then assume that BP (PE(w, t)) is proportional to PE(w, t) with a constant of
proportionality of 1τP :
∂PE(w, t)
∂t
= D′
∂2PE
∂w2
+RP (w, t)− PE(w, t)
τP
. (4.8)
Substituting for the resulting expression for MP (t) this gives:
1
γ
MP (t) = D
′
[
∂PE(w, t)
∂w
]
+ αRP (w, t)− MP (t)
γτP
. (4.9)
Combining Eqs. 4.5 and 4.9 to eliminate RP (w, t) yields:
∂PE(w, t)
∂t
=
1
αγ
∂MP (t)
∂t
+
1
αγτ
MP (t)+D
′∂2PE(w, t)
∂w2
−PE(w, t)
τP
−D
′
α
[
∂PE(w, t)
∂w
]α
0
.
(4.10)
Assuming PE(w, t = 0) = 0, a numerical integration scheme can then be used with
Eq. 4.10 to determine PE(w, t) from MP (t).
Substituting Eq. 4.10 in to Eq. 4.8 then gives an expression for RP (w, t).
Assuming that the breakdown of hypoxanthine is much slower than loss of purines
from the slice by diffusion (Klyuch et al., 2011), τP can be assumed to be infinite
and RP (t) can be recovered from M(t):
R(t) =
1
αγ
∂MP (t)
∂t
+
MP (t)
αγτP
− D
′
α
[
∂PE(w, t)
∂w
]α
0
. (4.11)
The same argument can be used to recover adenosine dynamics from MA(t),
however, τA in that case is finite and so needs to be determined.
Purine release
To characterise purine release in response to electrographic seizure activity, an FPA
biosensor was inserted into layer II/III of somatosensory cortex and electrographic
seizure activity was induced (n=15). The activity was recorded optically and the
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active region was thereby confirmed to encompass the location of the biosensor and
extend significantly beyond it (Fig. 4.7a). The approach to correction for diffusion
derived above could, therefore, be applied to the measured purine concentration.
Figure 4.7c shows an example LFP trace extracted from a biosensor record-
ing, exhibiting bursts of electrographic seizure activity. The associated biosensor
measurement (Fig. 4.7d) shows typical transient increases in purine concentration
with each burst of seizure activity. Applying the procedure derived in the previous
section the form of the release was derived (Fig. 4.7e), showing isolated bursts of
release.
A resource depletion model for purine release (Klyuch et al., 2011) was com-
pared to the derived release dynamics. Spike times were extracted from the LFP
and used as input to the model in which a proportion, f , of available purine stock
was released with each spike, with a re-stock of form:
dPS(t)
dt
=
P0 − PS(t)
τS
− fPS(t− )
∑
δ(t− tk) (4.12)
where PS is the available purine stock, P0 is the maximum level of the store, τS
is the re-stock time constant, tk are the spike times and  is small and positive.
This model reflected some of the temporal dynamics of the purine release, however,
the measured release was significantly delayed compared to the model prediction
(Fig. 4.7f,g). This comparison is, however, complicated by the transient downward
deflection observed on biosensor recordings at seizure onset (Fig. 4.7f). The cause
of this downward deflection is unknown, but is routinely observed (Lopatar et al.,
2011; Wall and Richardson, 2015) and may be the result of the change in ionic
environment around the sensor due to the sustained action potential firing.
Spatial spread
Having measured the layer dependence of purine dynamics, we then considered the
dynamics along the layers (direction l, Fig. 4.3a). We inserted FPA biosensors in to
layer V of the neocortex and induced electrographic seizure activity, recording the
spatial dynamics of the activity optically.
We measured no transient rise in purine concentration associated with bursts
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Figure 4.7: Measurement of purine release in response to electrographic seizure activity
and correction for loss through diffusion. (a) Illustration of biosensor placement relative to
active region (red) and the boundaries of the tissue slice. (b) Schematic, normal to (a), of
biosensor placement. The releasing region is indicated in red, with loss of purine from the
slice indicated by the arrows. (c) Example LFP recording showing electrographic seizure
activity. (d) FPA recording associated with the LFP recording shown in (c). (e) Purine
release associated with (c) recovered from (d). (f) and (g) Recovered purine release (black)
and model of release driven by LFP (red). The measured purine release is significantly
delayed relative to the model.
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of activity unless the active region encompassed the biosensor (Fig. 4.8).
We investigated whether this is consistent with release local to the active
region and spread beyond this the result of diffusion only. The layer dependence
of release was not significant between layers II/III and V. Considering a point at
the centre of this band, purine flux in direction d could be ignored. As with the
model of layer dependent release, we assumed the breakdown of hypoxanthine to
be slow compared to the loss of purine from the slice by diffusion. This yielded the
reaction-diffusion equation:
∂PE(l, w, t)
∂t
= D′∇2(PE(l, w, t)) +RP (l, w, t). (4.13)
Solving this equation using the numerical scheme discussed above showed that, in a
tissue slice, spread of purine from a releasing region in to adjacent tissue is limited
(Fig. 4.9). Peak purine concentration was 10 % of its maximum 170 µm from the
boundary of the active region in to the quiescent region, consistent with experimental
results.
Simultaneous FPA and FSCV
Having characterised the spatio-temporal dynamics of total purine, we carried out si-
multaneous FPA and FSCV to resolve the dynamics of adenosine specifically (n=7).
We inserted an FPA biosensor in to layer II/III of somatosensory cortex and a car-
bon fibre microelectrode (CFME) for FSCV was inserted in to layer V, along the
same normal to the local pial surface as the FPA biosensor. Electrographic seizure
activity was then induced in the tissue. Optical measurements were simultaneously
carried out to ensure that the active region completely encompassed and extended
significantly beyond the location of the biosensor and the CFME.
Both the FPA and FSCV showed transients in response to bursts of elec-
trographic seizure activity (Fig. 4.10a). The onset of the transients recorded using
FSCV was, however, more rapid than those recorded using FPA and the FSCV tran-
sients were also more rapid to rise and to decay. Application of EHNA, an adenosine
deaminase (ADA) antagonist, caused both an increase in baseline and an increase
in duration of transients measured using FSCV (Fig. 4.10b). EHNA suppressed the
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Figure 4.8: Purine release is local to region of electrographic seizure activity. (a) Left:
Micrograph of tissue slice indicating location of LFP microelectrode and FPA biosensor,
the scale bar corresponds to 700 µm. Right: False colour map showing spatial spread of
activity across the slice as a function of time with the associated LFP recording (bottom)
and biosensor measurement (top). (b) Left: micrograph of tissue slice indicating the location
of three FPA biosensors. Right: tIOS for regions of interest across the tissue slice (black)
and biosensor measurements (red).
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Figure 4.9: Modelling of the spatial spread of purine by diffusion in a tissue slice. (a)
Schematic of system modelled. (b) Peak in purine concentration as a function of position
(black) shows little penetration of purine beyond releasing region (red). (c) Lag to peak in
purine concentration. (d) Time courses of purine concentration at locations adjacent to a
boundary. (e) Normalised time courses of purine concentration at locations adjacent to a
boundary.
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Figure 4.10: Comparison of simultaneous FPA and FSCV measurements. (a) Simultaneous
FPA and FSCV measurements during a period of bursts of electrographic seizure activity.
The black bar inidcates the application of EHNA. (b) Overlay of adenosine transients from
FSCV from control period (black) and with EHNA (red) showing an increase in transient
width with application of EHNA. (c) Plot of normalised transients measured with FPA
(blue) and FSCV (green) with a stock release model (Eq. 4.12, red).
responses of the FPA biosensors as they are dependent on ADA to detect adenosine
(Wall and Dale, 2007).
The transients recorded using FPA and FSCV were compared to a resource
depletion model driven by the LFP associated with the transients. The model fit
the FSCV recordings much more closely than those of the FPA (Fig. 4.10c).
FSCV across layers
The layer dependence of adenosine transients was investigated by simultaneously
carrying out FSCV in layers I and V of somatosensory cortex, along the same local
normal to the pial surface (n=5). Electrographic seizure activity was induced and
monitored optically to ensure that the active region included and extended well
beyond the region measured from.
Adenosine transients were detected in both layers I and V in response to
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bursts of electrographic seizure activity (Fig. 4.11a). The transients were smaller in
amplitude in layer I than in layer V (P<0.05): layer I peak amplitude: 3.4 ± 0.5 µM;
layer peak: 15.6 ± 3.7 µM (Fig. 4.11b). The transients were not significantly differ-
ent in duration (layer I FWHM: 46 ± 16 s; layer V: 69 ± 5 µM).
Application of EHNA or the equilibritive nucleoside transporter (ENT) in-
hibitors dipyridamole and NBMQR did not have a significant effect on the amplitude
of adenosine transients in layer I. Inhibition of the ENTs did, however, cause an in-
crease in the duration of the adenosine transients (P<0.05, Fig. 4.11c).
Inhibition of the ENTs caused a reduction in the peak amplitude in layer V
(P<0.05) and both EHNA and ENT inhibition caused an increase in the duration of
the transients (P<0.05). Thus ENTs appear to play a role in the release of adenosine
during seizures and adenosine deaminase and ENTs play a role in adenosine removal.
4.5 Discussion
In this study we have begun to characterise the transient adenosine dynamics asso-
ciated with electrographic seizure activity. By making chronic optical measurements
we have been able to directly relate the spatial extent of network activity to adeno-
sine release. As suggested by previous work (Wall and Richardson, 2015) we found
that adenosine release is localised to the active area. However, contrary to previ-
ous studies (Van Gompel et al., 2014; Wall and Richardson, 2015) we found that
adenosine release appears to commence with onset of seizure activity and persists ex-
tracellularly as adenosine for the duration of the seizure, only decaying after seizure
termination. The release in layer I is significantly smaller than in other layers and
may also be slower; this difference is not explained by the difference in boundary con-
ditions. In the quasi two-dimensional system studied here, extracellular adenosine
transients were not detected beyond the region of tissue exhibiting electrographic
seizure activity.
Acute tissue slice is a preparation widely used for the study of network ac-
tivity and its modulation. With such preparations there is, however, a significant
modification to the boundary conditions occurring in vivo. A large proportion of
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Figure 4.11: Layer dependence of adenosine release measured with FSCV. (a) Adenosine
transients in response to electrographic seizure activity in layer I (blue) and layer II/III
(black). (b) Comparison of release peaks (left) and the full width at half maximum of
adenosine transients in layers I and II/III. (c) Effect of treatment with EHNA and ENT
inhibitors on adenosine transients in layer I. (d) Effect of treatment with EHNA and ENT
inhibitors on adenosine transients in layer II/III.
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transiently released compounds are lost from the cut surfaces of the slice exposed
to aCSF. Here we have derived an approach to correct for this loss to determine the
actual release dynamics from just a measurement of the integral of the compound
concentration across the thickness of the slice, as is measured using FPA or FSCV.
The dynamics of purine release in response to electrographic seizure activity
has been characterised in previous work (Winn et al., 1980; During and Spencer,
1992; Dale and Frenguelli, 2009; Lopatar et al., 2011; Van Gompel et al., 2014; Wall
and Richardson, 2015) . However, it is adenosine specifically that activates receptors
causing negative feedback to control network activity. By simultaneously using
two techniques for the measurement of extracellular adenosine, with different cross
sensitivities, we have obtained data to achieve greater specificity to adenosine. We
hope to develop a complete model consistent with both results for purine dynamics
from FPA and for those largely specific to adenosine from FSCV. By constraining
the model using the results from the two independent techniques we hope to achieve
high specificity to adenosine, and thereby characterisation of a large component of
the negative feedback system that suppresses seizure activity.
FPA and FSCV suggest different adenosine dynamics
In a previous study, Wall and Richardson (2015) used simultaneous measurements
with adenosine and inosine FPA biosensors to resolve adenosine specifically. Adeno-
sine biosensors respond to adenosine, inosine and hypoxanthine while inosine biosen-
sors only respond to inosine and hypoxanthine. By subtracting the scaled recordings
from the inosine biosensor from that of the adenosine biosensor the result was specif-
ically extracellular adenosine. The application of this procedure to the transients
associated with electrographic seizure activity showed no adenosine to be present.
The transients measured on the adenosine and inosine biosensors exhibited the same
dynamics, strongly suggesting that the compounds detected were metabolites of
adenosine. This indicated that the breakdown of adenosine to inosine is extremely
rapid. Further, they showed that the breakdown of inosine into hypoxanthine was
a slower process.
These results would suggest that no adenosine transients would be detected
with FSCV. However, we detected substantial transients at the oxidation voltage
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of adenosine in response to electrographic seizure activity. The duration of these
transients was increased by the application of EHNA, strongly suggesting they were
adenosine. The onset of the transients was synchronous with the onset of seizure
activity, the duration of the rising phase was the same as that of the seizure activity,
with a decay over a similar time period.
The experimental preparation in our two studies were identical other than
for the methods of adenosine detection. We hypothesise that the difference in the
detection of adenosine is a result of a difference in the degree of tissue damage
caused by insertion of the microelectrodes used for the two types of measurement.
The microelectrodes used for the FPA were based on 50 µm diameter Pt wire, the
enzyme matrix then further increased the diameter. The CFMEs used for the FSCV
were 7 µm in diameter. The microelectrodes used for FPA therefore had a cross-
sectional area over 50 times that of the CFMEs used for FSCV. We hypothesise that
the damage to the tissue caused by the FPA microelectrodes ruptured significantly
more cells, releasing formerly intracellular ADA in to the space around the electrode.
This would then convert adenosine adjacent to the FPA biosensor to inosine before
detection. We hypothesise that the CFMEs used for FSCV caused far less damage,
that adenosine was released in to the extracellular space and was only broken down
in to inosine once it entered cells through the ENTs, a slow process, allowing the
detection of extracellular adenosine before it was broken down. The very rapid
breakdown to inosine presented in Wall and Richardson would, therefore, be an
artefact specific to the location of the biosensor. The FSCV measurement would be
a more accurate reflection of adenosine dynamics, suggesting a significantly longer
presence of extracellular adenosine.
This hypothesis can be tested by repeating the experiments presented in Wall
and Richardson (2015) using FPA biosensors based on a 7 µm carbon fibres. This
would use the same method of detection, whilst reducing the tissue damage to a
level comparable to that caused by the CFMEs used for FSCV.
Adenosine release starts with seizure onset not termination
Gompel et al. (Van Gompel et al., 2014) made measurements of adenosine transients
in response to seizure activity using FPA and FSCV in pigs in vivo and using FSCV
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in humans in vivo. They found that adenosine release started just prior to seizure
termination, peaking after the end of seizure events. Our measurements suggest
that adenosine release starts synchronously with seizure onset, peaking at seizure
termination and subsequently decaying. Our in vitro preparation had the advantage
of allowing accurate monitoring of the region of tissue involved in seizure events.
We could therefore be confident that transients were the result of activity in the
tissue adjacent to the microelectrodes. Gompel et al. used electrocorticography
to monitor seizure activity in their preparations. This approach does not allow as
accurate spatial localisation of activity. The delay between seizure onset and the
adenosine transients they detected may have been the result of the active region
not including the location of the FPA and FSCV microelectrodes, the adenosine
they detected having diffused from the active region, hence being delayed. The
geometry and boundary conditions of their preparation mean that adenosine would
diffuse over far greater distances than we observed in our quasi two-dimensional
preparation. In further work, our model constrained using our preparation will be
applied to three dimensions and the resulting length scales of diffusion investigated.
Adenosine transients in layer I are significantly smaller and slower than
those in other layers
The transients measured using both FPA and FSCV in response to electrographic
seizure activity were smaller in layer I than in other layers. We eliminated the
possibility that this is the result of the difference in boundary conditions. The
duration of the transients recorded using FPA was significantly greater in layer I
than those in other layers. The same difference was not seen using FSCV, however,
the signal to noise ratio of the small transients recorded in layer I was such that the
FWHM could not be accurately determined from the FSCV recordings.
We propose two hypothesise for the observed differences in dynamics. Firstly,
the ratio of glia to neurons in layer I is greater than that in the other layers (Shipp,
2007). The exchange dynamics of adenosine between the extracellular matrix and
glia maybe slower than those with neurons. This may then explain the slower dy-
namics in layer I. This, however, seems unlikely to explain the observed positive
correlation between the relative lag to peak and peak amplitude in layer I relative
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to other layers. The second hypothesis is that an interposed transmitter is released
in response to electrographic seizure activity and that adenosine is then released in
response to the second transmitter (Wall and Dale, 2008). If this interposed trans-
mitter was not released in layer I, only reaching it by diffusion, and caused adenosine
release with a non-linear dependence, this may explain the observed dynamics.
ENTs appear to be involved in adenosine release
Application of ENT inhibitors significantly reduced the amplitude of the transients
in response to electrographic seizure activity. We hypothesise that a significant
component of the adenosine released in response to electrographic seizure activity
is released through the ENTs. This component is then suppressed by inhibiting the
ENTs. This component of release could be investigated further by measuring the
effect of ENT inhibitors on adenosine release in response to seizures induced with
calcium free aCSF (Jefferys and Haas, 1982), a regime in which there would be no
contribution from exocytosis.
ADA plays an important role in regulating adenosine tone and is involved
in the breakdown of transiently released adenosine
Inhibition of ADA resulted in a significant increase in extracellular adenosine concen-
tration between bursts of seizure activity, suggesting, that ADA plays a significant
role in regulating adenosine tone. In future work the effect of the inhibition of ADA
in quiescent tissue will be investigated. Inhibition of ADA also increased the FWHM
of adenosine transients in response to electrographic seizure activity.
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Chapter 5
Conclusions
Understanding the brain in both health and disease is of fundamental scientific in-
terest and of great practical importance. The acute neural tissue slice is a widely
used experimental preparation, facilitating treatments and measurements not prac-
tical in vivo while preserving a largely connected network representative of the true
in vivo structure. In this thesis two methods that further the ability to study the
acute neural tissue slice have been presented, followed by an application of one of
the methods to the study of seizure evoked adenosine release.
In Chapter 2 a novel chamber was presented and characterised that allows
extended areas of acute tissue slice to be exposed, in isolation, to changes in ionic
conditions or pharmacological manipulation whilst preserving the ability to record
from the entire surface of the tissue. Such spatial targeting had previously only
been achieved at the expense of access to the tissue for recording. The chamber
facilitates an entirely in vitro model of focal seizure activity.
Changes in the intrinsic optical properties of brain tissue correlated with
neuronal activity are known to occur both in vivo and in vitro. These changes are
used as the basis of non-invasive approaches to the recording of neuronal activity.
The use of IOSs as a proxy for neuronal activity has many advantages; they require
no mechanical, chemical or genetic interference with the tissue and are not limited
by recording rate or duration. The temporal dynamics of the IOS are, however, slow
and so do not directly correspond to the underlying network dynamics. In Chapter 3
we characterised the intrinsic optical signal (IOS) that persists in vitro and derived
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a transformation that converts the slow temporal dynamics of the IOS to a form
that accurately reflects the underlying network dynamics, thereby mitigating the
primary disadvantage of the use of IOSs as a method to record neuronal dynamics,
allowing their advantages to be fully exploited.
Adenosine is a potent neuromodulator that plays an important role both in
physiological processes and in neuroprotection during pathological events. Adeno-
sine largely provides negative feedback in response to neuronal activity and it is,
therefore, of fundamental interest in epilepsy. Adenosine is known to be released in
response to seizure activity and is implicated in seizure termination. Dis-regulation
of adenosine may be involved in epileptogenesis and there are promising applications
of adenosine therapeutically. In Chapter 4 we characterised the spatio-temporal dy-
namics of adenosine in response to seizure activity in vitro. The temporal dynamics
of adenosine release in response to seizure activity had previously been investigated,
however, the spatial dynamics had not been readily accessible because of the lack
of a suitable recording tool for the network activity, able to record over sufficiently
large areas of tissue for sufficiently long periods. Recording of the IOS in combina-
tion with the transformation presented in Chapter 3 rendered this regime accessible
and so facilitated the study. In this work we identified two qualitatively different
forms for adenosine release, observed a significant difference in adenosine release
between layers of the neocortex, resolved the spatial spread of adenosine relative to
the associated network activity and determined that a component of seizure evoked
adenosine release is dependent on equilibritive nucleoside transporters (ENTs).
Finally, in the appendices of this thesis, four studies are presented that in-
vestigate the potential for Field Asymmetric Ion Mobility Spectrometry (FAIMS) in
medical diagnosis. FAIMS is a highly sensitive tool for chemical detection, originally
applied to the detection of chemical warfare agents. FAIMS was thought to have
significant potential in medical diagnosis, however, this had never been explored
due to the challenge of the analysis of FAIMS spectra from complex biological mix-
tures. Appendix B presents a first proof of principle of the effectiveness of FAIMS
at discriminating between complex biological mixtures. Following this we go on
to present proof of principle of the potential of FAIMS in medical diagnosis (Ap-
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pendix C), obtaining prognostic information (Appendix D) and as a screening tool
(Appendix E). The approach presented here for the analysis of FAIMS spectra is
almost certainly not optimal, however, the proof of principle will hopefully stimulate
further development.
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Appendix A
FAIMS analysis introduction
Abstract
Field Asymmetric Ion Mobility Spectrometry (FAIMS) is a highly sensitive tool for
chemical detection, originally applied to the detection of chemical warfare agents.
FAIMS is able to detect a broad range of chemicals at concentrations below one part
per billion. As such, FAIMS was thought to have significant potential in medical
diagnosis, however, this had never been explored due to the challenge of the anal-
ysis of FAIMS spectra from complex biological mixtures. In the following section
an analysis approach is presented that allows the FAIMS spectra of complex bio-
logical mixtures to be distinguished. In the following appendices the approach is
then applied to identify inflammatory bowel diseases, patients at risk of high gas-
trointestinal toxicity in response to radical pelvic radiotherapy and patients with
colorectal cancer.
A.1 Ion mobility spectrometry
Ion mobility spectrometry (IMS) discriminates between ions on the basis of their
transport properties when moving through a medium under the influence of an
electric field. Conventional IMS refers to methods dependent on transport properties
that can be measured using a constant electric field. Differential IMS refers to
methods that rely on transport properties that are dependent on the applied electric
field (Shvartsburg, 2009).
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When exposed to an electric field in a medium, ions rapidly accelerate to a
terminal (drift) velocity, v. The drift velocity is proportional to the applied electric
field, E: v = KE, where K is the ion mobility. The mobility of an ion depends on
its physical characteristics, mobility can therefore be used to distinguish ions.
In a conventional IMS system molecules are ionised and then driven through
a medium filled drift tube by a constant electric field. The ions can be separated on
the basis of the time taken for them to traverse the drift tube.
Differential IMS depends on the fact that ion mobility usually varies as a
function of the applied electric field. Ions are then separated on the basis of dif-
ferences in this voltage dependence by exposing them to a time dependent electric
field.
A.2 Principles of FAIMS
Field asymmetric ion mobility spectrometry (FAIMS) is a type of differential ion
mobility spectrometry. Molecules are ionised and then carried between two parallel
plates towards a detector by a carrier gas. A time dependent electric field, E(t), with
an asymmetric waveform is applied to the plates, such that the ions experience an
electric field perpendicular to the direction of carrier gas flow. If an ion touches one
of the plates it is likely to be neutralised. If an ion traverses the space between the
two plates (the filter gap) without touching either plate it is detected (Fig. A.1).
The applied electric field consists of an asymmetric waveform, f(t), with
variable dispersion field amplitude, 0 ≤ S ≤ 1, and a compensation voltage, C:
E(t) = Sf(t) + C. The moments of f(t) are defined as:
〈fn〉 ≡ 1
T
∫ T
0
fn(t)dt (A.1)
where T is the period of the waveform. The waveform is constructed such that
〈f〉 = 0, but so at least some odd moments are non-zero.
If ion mobility were independent of electric field all ions would traverse the
filter gap (other than as a result of diffusion) and be detected when the compensation
voltage was set to zero. The field dependence of the ion mobility results, however,
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Figure A.1: Schematic of a FAIMS system. From Owlstone Inc., Cambridge. The figure
has been redacted from this version to avoid copyright infringement.
in a net drift of ions parallel to the applied electric field. Ions are only detected
when the compensation voltage corrects for this drift, resulting in ions traversing
the filter gap without coming in to contact with either plate.
The output from a FAIMS system consists of two matrices, one corresponding
to positive ions and one corresponding to negative ions. The matrices consist of ion
counts at different combinations of compensation voltage and dispersion field, for
example see Fig. A.2.
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Figure A.2: An example positive ion FAIMS spectrum of air contaminated with a single
dopant (acetone). The residual ion peak (RIP) corresponds to hydronium ions (O− in the
case of the negative ion matrix) produced from the beta decay of 63Ni, to ionise the analytes.
A.3 Clinical potential for FAIMS
Recent advances have led to the development of microchip based FAIMS systems
(Shvartsburg et al., 2009; Wilks et al., 2012). This has resulted in devices that
have high sensitivity (< 0.1 parts per billion (ppb) for many low molecular weight
compounds (Shvartsburg et al., 2009)) whilst also being compact (Fig. A.3) and
robust, with low power consumption and no moving parts (Boyle, 2006).
These properties make microchip based FAIMS systems ideal for a number
of detection and screening applications. These devices have been widely adopted
by defence and security agencies for the detection of explosive and chemical detec-
tion (Boyle, 2006). FAIMS is also thought to have significant potential in clinical
diagnosis and screening (Arasardnam et al., 2011). The challenges associated with
the analysis of the FAIMS spectra of complex biological mixtures are, however, far
greater than those associated with, for example, the detection of chemical warfare
agents contaminating air. As a result, the exploitation of FAIMS for clinical appli-
cations has been slow.
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Figure A.3: The Owlstone Lonestar, a self contained FAIMS system. From Owlstone Inc.,
Cambridge. The figure has been redacted from this version to avoid copyright infringement.
A.4 The challenge of identifying clinically relevant in-
formation in FAIMS spectra of complex biological
mixtures
Algorithmic detection of the contamination of air with a single dopant, such as
a chemical warfare agent, is readily implemented. Analysis of uncontaminated air
shows a single peak. This is the residual ion peak (RIP) corresponding to hydronium
ions in the case of the positive ion matrix and O− ions in the case of the negative ion
matrix. These ions are produced by the beta decay of 63Ni to ionise analytes. When
a contaminant is added to the air an additional peak is detected. Figure A.4 shows
the FAIMS spectra and representative cross-sections for air (top) and for air with a
single contaminant, such as the neurotoxin sarin (bottom). Automatic detection of
such contamination is simply implemented by imposing thresholds at the locations
that correspond to contaminants of interest.
Unlike the FAIMS spectra of air and a single dopant, the FAIMS spectra
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of complex mixtures consist of multiple overlapping peaks, for example Figure A.5
shows the positive ion FAIMS spectra of the headspace of urine from a healthy
individual and that from an individual with colorectal cancer (CRC). It was un-
known whether such spectra contained diagnostic information. They would almost
certainly show variability not related to disease state, and even if they did contain
diagnostic information, it may not simply be as the presence or absence of a specific
peak. It would, however, be valuable to explore the the possibility of using FAIMS
to screen for CRC, because if it were possible the analysis of urine using FAIMS
would be a significant improvement on the currently available screening tools (these
potential advantages are discussed in Appendix E.
The methods used to detect contamination of air with chemical warfare
agents were clearly unsuitable for the investigation of the possibility of discriminat-
ing between the FAIMS spectra of similar biological samples. The direct application
of unsupervised machine learning techniques, such as principal component analysis,
proved unsuccessful. Approaches for supervised machine learning could not be di-
rectly applied because the number of elements in the FAIMS spectra (∼51 000) was
far greater than the number of patients in the trials (∼100). Any training set was
likely to contain dimensions on which the groups could be discriminated correctly,
however, this was likely to be a result of noise. The application of the resulting
classification criterion to a test set was likely to yield re-classification no better than
that expected from random re-classification.
A.5 Analysis approach
To allow the effective application of supervised machine learning techniques, an
approach to reduce the number of elements associated with each patient was re-
quired. Both theoretical and empirical analyses have shown that the profiles of
FAIMS spectra at constant dispersion fields are made up of a number of localised
peaks (Fig. A.6A (Krylov et al., 2007; Buryakov, 2005). The nature of this structure
suggested that a basis set of similar functions may be a more natural choice and
may make diagnostic information easier to identify.
A wavelet, ψ, is a function consisting of an isolated oscillation, such as that
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Figure A.4: An example positive ion FAIMS spectrum of air (top left) showing the residual
ion peak (RIP) and an example cross-section at constant dispersion field (top right) and an
example positive ion FAIMS spectrum of air contaminated with a single dopant (acetone,
bottom left) and an example cross-section at constant dispersion field (bottom right).
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Figure A.5: An example positive ion FAIMS spectrum of the headspace of urine from a
healthy individual (top left) and an example cross-section at constant dispersion field (top
right) and an example positive ion FAIMS spectrum of the headspace of urine from an
individual with colorectal cancer (bottom left) and an example cross-section at constant
dispersion field (bottom right).
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Figure A.6: (A) An example cross section through a FAIMS peak at constant dispersion
field. (B) An example wavelet.
shown in Fig. A.6B that has zero mean and L2 norm one. By translating and dilating
ψ (Eqn. A.2), a basis set can be generated. A basis set of this form seemed natural
for FAIMS data.
ψa,b(x) =| a |−1/2 ψ
(
x− b
a
)
(A.2)
An intuition driven approach based on wavelet transforming the FAIMS spec-
tra was implemented as follows. To test the validity of the approach, for each data
set the process was applied to a randomly selected training set and the resulting
classification matrix was tested on the remaining data and compared to the true
classification:
1. Firstly, the rows of the positive and negative ion count matrices were concate-
nated to form a one dimensional vector corresponding to each matrix. These
vectors were then concatenated. This gave a single vector containing every
element from the two output matrices. This re-arrangement was obviously
invertible and so preserved the information content in the spectra whilst pro-
ducing a one dimensional vector to which a wavelet transform could be carried
out.
2. The vector was then wavelet transformed using a multi-level discrete wavelet
transform using a Daubechies D4 wavelet. This was also an invertible opera-
tion and so the information content of the original spectra was still preserved at
this stage. However, intuition suggested that the information content relating
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to the ion peaks would now be compressed on to fewer dimensions.
3. Dimensions in the transform space suitable for discrimination were then iden-
tified. Thresholds were set for the between class scatter: (σµ)
2/(Σσ)2 and the
within class scatter: (Σσ)2. In both cases the thresholds were used as a lower
bounds. Large between class scatter was clearly desirable in a dimension used
for discrimination - the form used for this compensating for the within class
scatter. The second threshold, the minimum imposed on the within class scat-
ter was required to prevent dimensions with small values and correspondingly
narrow distributions giving anomalously large values for the between class
scatter. Dimensions meeting the criteria for both thresholds were included in
an output vector.
4. The number of dimensions identified for discrimination was compared to a
final threshold of approximately 200. If the number of dimensions identi-
fied exceeded this threshold, the data was not reclassified and the result was
counted as incorrect. This avoided the computational demand associated with
applying Fisher Discriminant Analysis to a large number of dimensions. The
threshold was larger than the number of patients in any of the trials and so
a preclassified machine learning technique applied to this many variables was
not likely to identify a classification matrix that would yield accurate reclas-
sification. Assuming that the reclassification would have been incorrect was
only likely to modify the result that would otherwise have been the ∼ 50%
expected for random reclassification.
5. Fisher Discriminant Analysis (FDA) (Fisher, 1936) was applied to the out-
put vectors. FDA is a linear, preclassified, machine learning technique. The
approach identifies a projection matrix that maximises the separation of the
groups.
The dimensions identified for discrimination from the training set were also
selected for each sample in the test set. The projection matrix identified by
the FDA was then applied to these vectors corresponding to each sample and
the result was compared to the true classification. The fraction of success-
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ful reclassifications of test sets was then compared with that expected from
random reclassification.
A.6 Testing of analysis process
The effectiveness of the analysis process was investigated by applying it to the
data set discussed in Appendix B. Briefly, urine samples were obtained from eight
patients who underwent partial bowel cleansing prior to flexible sigmoidoscopy and
from eight patients who underwent total bowel cleansing prior to colonoscopy. The
urine samples were heated and the resulting headspaces were characterised using
FAIMS.
For each group, seven randomly selected samples were used as the training
set and the remaining sample from each group was reclassified. This process was
repeated ten times for each combination of the input parameters, the within class
scatter threshold and the between class scatter threshold. The percentage reclassi-
fication for each set of these parameters was then calculated. Fig. A.7A shows the
result of this process. A robust region in parameter space was identified that yielded
reclassification significantly better than that expected from random reclassification.
A 100 element region, spanning 10% of the parameter range in each dimension
yielded a mean correct reclassification of 84.2 ± 1.2 %.
To confirm the validity of this result, the same process was applied after the
data had been randomised such that each of the two new groups consisted of four
patients from each treatment group. Fig. A.7B shows the result of this process.
No robust region in the parameter space was found where the reclassification was
significantly better than that expected from random reclassification. Equally, the
distribution of reclassification success did not extend beyond 70 %, unlike for the
correctly grouped data for which it extended to 100 %.
These results indicate that the proposed analysis process can identify features
specific to a group and accurately reclassify spectra on the basis of these features,
and does not give spurious results, overestimating the success of the reclassification.
The wavelet transform step was included in the analysis process on the basis
of intuition. Its effect on the process was investigated empirically using the same
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Figure A.7: Comparison of reclassification success for the original data sets and for the data
relabelled to give two equivalent groups. (A) Result of the application of the analysis process
to the original data as a function of the input parameters, showing a robust region where
successful reclassification significantly exceeded that expected from random reclassification.
(B) Result of the application of the analysis process, as a function of the input parameters, to
the data relabelled such that each new group contained half of each of the original members
of each group (no spectrum was duplicated in each new group), showing significantly fewer
correct reclassifications than that from reclassification of the correctly labelled data.
data as discussed above and in Appendix B. The analysis process was applied to the
data both with the wavelet transform step included and with it omitted. The process
without the wavelet transform step did not identify a significant robust region that
yielded successful reclassification and the distribution of reclassification success was
truncated at lower success fractions than for the complete process (Fig A.8.
This suggests that the wavelet transform acts as expected to compress the
information content of the FAIMS spectra and that this is a beneficial step in the
process presented here.
A.7 Pilot studies
The application of this analysis process to the FAIMS spectra of these samples (dis-
cussed fully in Appendix B) demonstrated that the health of the gut affects the
composition of urine, that at least some of these differences can be detected with
FAIMS of the headspace of the urine and that the spectra can be separated better
than would be expected by random reclassification using the analysis process pre-
sented here. This proof of principle was a significant step towards exploiting the
advantages of FAIMS in clinical diagnosis. The separation of the specific groups,
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Figure A.8: The wavelet transform step increases accurate reclassification. (A) Correct re-
classification of the test sets as a function of the input parameters for the analysis process
including the wavelet transform step, showing a robust region where successful reclassifica-
tion significantly exceeds that expected from random reclassification. (B) Correct reclassi-
fication of the test sets as a function of the input parameters without the wavelet transform
step showing significantly less accurate reclassification when the wavelet transform step is
not included in the analysis.
however, had no clinical value, the difference between the groups was the inter-
vention. To investigate the application of FAIMS to clinically relevant problems a
further three pilot studies were carried out. The first investigated the possibility
of diagnosing inflammatory bowel disease from urine samples; the second investi-
gated the possibility of extracting prognostic information from faecal samples from
patients due to undergo radical pelvic radiotherapy and the third investigated the
possibility of screening for colorectal cancer from urine samples. These studies are
presented in the following appendices.
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Appendix B
Evaluation of gut bacterial
populations using an electronic
e-nose and field asymmetric ion
mobility spectrometry: further
insights into fermentonomics
This Appendix contains a paper presenting an initial proof of principle of the effec-
tiveness of Field Asymmetric Ion Mobility Spectrometry (FAIMS) at discriminating
between complex biological mixtures, specifically urine samples from patients after
partial and total bowel cleansing prior to flexible sigmoidoscopy and colonoscopy re-
spectively. I developed the analysis procedure for the FAIMS spectra, wrote the code
to implement it and applied it to the data. The trial was designed and otherwise
implemented by the other authors.
The full paper has been redacted from this version to avoid copyright in-
fringement.
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Appendix C
A novel tool for noninvasive
diagnosis and tracking of
patients with inflammatory
bowel disease
This Appendix contains a paper presenting a proof of principle of the effectiveness of
FAIMS at analysing urine samples to discriminate between disease states, specifically
ulcerative colitis and Crohn’s disease both in remission and flare. I developed the
analysis procedure for the FAIMS spectra, wrote the code to implement it and
applied it to the data. The trial was designed and otherwise implemented by the
other authors.
The full paper has been redacted from this version to avoid copyright in-
fringement.
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Appendix D
The detection of patients at risk
of gastrointestinal toxicity
during pelvic radiotherapy by
electronic nose and FAIMS: A
pilot study
This Appendix contains a paper investigating the possibility of using FAIMS to
analyse urine samples to provide prognostic information, specifically the reaction
to radical pelvic radiotherapy. I developed the analysis procedure for the FAIMS
spectra, wrote the code to implement it and applied it to the data. The trial was
designed and otherwise implemented by the other authors.
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Abstract:   It   is   well   known   that   the   electronic   nose   can   be   used   to   identify   differences  
between   human   health   and   disease   for   a   range   of   disorders.  We   present   a   pilot   study   to  
investigate  if  the  electronic  nose  and  a  newer  technology,  FAIMS  (Field  Asymmetric  Ion  
Mobility  Spectrometry),  can  be  used  to  identify  and  help  inform  the  treatment  pathway  for  
patients  receiving  pelvic  radiotherapy,  which  frequently  causes  gastrointestinal  side-­effects,  
severe  in  some.  From  a  larger  group,  23  radiotherapy  patients  were  selected  where  half  had  
the  highest  levels  of  toxicity  and  the  others  the  lowest.  Stool  samples  were  obtained  before  
and   four  weeks   after   radiotherapy   and   the   volatiles   and   gases   emitted   analysed   by   both  
methods;;  these  chemicals  are  products  of  fermentation  caused  by  gut  microflora.  Principal  
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component  analysis  of  the  electronic  nose  data  and  wavelet  transform  followed  by  Fisher  
discriminant   analysis   of   FAIMS   data   indicated   that   it   was   possible   to   separate   patients    
after  treatment  by  their  toxicity  levels.  More  interestingly,  differences  were  also  identified  
in   their   pre-­treatment   samples.   We   believe   these   patterns   arise   from   differences   in   gut  
microflora  where  some  combinations  of  bacteria  result  to  give  this  olfactory  signature.  
In  the  future  our  approach  may  result  in  a  technique  WKDWZLOOKHOSLGHQWLI\SDWLHQWVDW³KLJK
risk´  even  before  radiation  treatment  is  started.  
Keywords:  electronic  nose;;  FAIMS;;  fermentome;;  gastrointestinal   toxicity;;  gut  permeability;;  
pelvic  radiotherapy  
  
1.  Introduction  
The   electronic   nose   (e-­nose)   was   first   conceived   in   the   early   1980s   [1]   and   has   undergone  
continuous  refinement  ever  since.  Developed  as  a  means  of  replicating  the  biological  olfactory  system,  
it  does  not   identify  specific  chemicals  within  a  complex  mixture   (as  possible  with,   for  example,  gas  
chromatography  and/or  mass  spectrometry²GCMS),  but  analyses  the  sample  as  a  whole  to  create  an  
³ROIDFWRU\VLJQDWXUH´6XFKLQVWUXPHQWVKDYHEHHQDSSOLHGZLGHO\LQFRPPHUFHDQGUHVHDUFKLQFOXGLQJ
for  food  and  beverage  quality,  perfumes  and  process  control  [2,3].  Of  increasing  importance  has  been  
the  application  of  this  technology  to  the  medical  domain.  The  possibility  of  using  the  electronic  nose  
for  the  identification  and  monitoring  of  disease  has  shown  considerable  promise.  The  detection  of  gas  
phase  bio-­markers  from  human  biological  output,  be  it  breath,  sweat,  blood,  urine  or  faecal  matter,  has  
been  shown  to  identify  a  disease  state.  E-­nose  technology  is  close  to  real-­time,  can  be  operated  without  
special  gases,  at  room  temperature  and  pressure,  is  non-­invasive  and  could  be  produced  at  a  financially  
acceptable   cost   for   the   medical   profession.   The   range   of   diseases   that   e-­nose   technology   has   been  
applied   to   is   considerable,   ranging   from   lung   cancer,   brain   cancer   and   melanoma   to   inflammatory  
bowel  disease  and  even  schizophrenia  [4±9].  
A   more   recent   technological   development   is   that   of   field-­asymmetric   ion   mobility   spectrometry  
(FAIMS)  for  monitoring  complex  odours.  As  with  the  electronic  nose,  FAIMS  can  be  used  for  the  
real-­time   analysis  of   complex  chemical   components,   looking  at   the   total   chemical   composition  of   a  
sample.  Such  instruments  use  differences  in  the  mobility  of  ionised  molecules  in  high  electric  fields  to  
SURYLGH D ³PRELOLW\ VLJQDWXUH´ RI D FRPSOH[ VDPSOH 7his   mobility   signature   is   in   many   ways  
comparable  to  the  olfactory  signature  created  by  the  array  of  chemical  sensors  in  the  e-­nose.  FAIMS  
instruments  have  found  widespread  use  within  the  security  sector  [10],  as  they  can  detect  large  volatile  
molecules  at  extremely  low  concentration  (e.g.,  explosives),  but  it  has  not  as  yet  been  used  extensively  
within  the  medical  field.  
One  medical  area  yet   to   receive  attention  by  either  e-­nose  or  FAIMS  technology   is   that  of  pelvic  
cancer   patients,   undergoing   radiotherapy.   The   pelvis   is   a   confined   area   bounded   by   bone   and   thick  
muscle,  leaving  only  a  fairly  small  central  cavity.  This  is  packed  (from  front  to  back)  with  the  bladder,  
ovaries,   uterus/cervix,   the   rectum,   sigmoid   colon   (the   lower   part   of   the   large   bowel)   and   a   variable  
number  of  small  bowel  loops.  As  a  result,  pelvic  irradiation  for  a  tumour  affecting  an  organ  inevitably  
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injures   the  others.  Almost   all  patients   experience  changes   in  bowel  habits  during   their   five   to   seven  
week   course   of   radiotherapy.   Up   to   90%   of   patients   report   abnormal   gastrointestinal   symptoms   of  
YDU\LQJVHYHULW\ WHUPHG³SHOYLF UDGLDWLRQGLVHDVH´ >,12].  A  wealth  of  data  now  supports   the  view  
that   acute   radiotherapy-­induced   damage   is   characterised   by   inflammatory   processes.   Maximum  
damage   to   the  gastrointestinal  mucosa  occurs  about   two  weeks   into   treatment   [13].  However,  whilst  
acute  mucosal  damage  may   then   improve,   the  prevalence  of  moderate  or   severe  chronic  side  effects  
can  be  as  high  as  50%  [13,14].  Despite  increasingly  sophisticated  radiotherapy  planning  and  delivery,  
those  patients  who  are  at  most  risk  of  severe  late  problems  cannot  be  predicted  using  normal  medical  
measures.   There   is   evidence   that   this   high   level   of   susceptibility   may   be   due   to   differences   in   the  
composition   and   treatment-­induced   change   of   their   gut   bacterial   populations   [15,16].   Directly  
measuring  the  composition  of   these  populations   is   incredibly  difficult  due   to   their   location  and  huge  
variation   in  bacterial   types,  but  we  believe   information   in   regard   to   its  overall  composition  could  be  
attained  by  looking  at  the  gaseous  emissions  of  bacteria  within  faecal  samples.  Thus,  in  an  attempt  to  
HYDOXDWH LI LW LV SRVVLEOH WR LGHQWLI\ WKHVH ³KLJK-­ULVN´ SDWLHQWVZH KDYH XQGHUWDNHQ D SLORW VWXG\ WR
evaluate   if   either   a   traditional   e-­nose   or   a   FAIMS   instrument   can   identify   differences   in   faecal   gas  
emissions.  Here  we  have  taken  samples  before  and  after  treatment  from  patients  who  have  had  a  high  
toxicity   and   low   toxicity   response   after   treatment   to   investigate   if   there   is   a   difference   in   these   gas  
emissions.  If  feasible,  it  may  be  possible  in  the  future  to  warn  the  clinician  of  patients  that  are  likely  to  
become   seriously   ill,   thereby   indicating   who   requires   closer   monitoring   and/or   possibly   to   be  
considered   for   an   alternative   treatment   pathway.   Such   a   patient-­tailored   approach   offers   a   potential  
route  towards  minimising  morbidity  associated  with  this  treatment.    
2.  Material  and  Methods    
To  undertake  this  study  an  in-­house  traditional  electronic  nose  and  a  commercial  FAIMS  instrument  
has  been  used  to  analyse  faecal  samples  from  pelvic  radiation  patients.    
2.1.  Electronic  Nose  
Electronic   noses   are   instruments   that   attempt   to   replicate   the   biological   olfactory   system,   by  
investigating  gas  phase  samples  as  a  whole,  instead  of  identifying  specific  chemicals  within  a  complex  
gas  mixture.  In  an  electronic  nose,  the  air  above  the  sample  (or  headspace)  is  drawn  into  the  electronic  
nose   and   is   passed   across   an   array   of   chemical   sensors.   The   size   of   the   array   varies,   but  most   are  
between   six   and   32   sensors.   Each   sensor   of   the   array   is   broadly   tuned   to   a   chemical   group,   with  
overlapping  sensitivity,  but   importantly,   is  different   in  some  way  from  the  rest  of   the  array.  As  each  
sensor   is  dissimilar,   the   interaction  between   the  sensor  and  the  complex  sample   is  unique  within   the  
array.  Thus,  an  olfactory  signature  of   this  complex  odour  can  be  created.  In  most  applications,  some  
form  of  pattern  recognition  algorithm  is  applied  to  learn  this  olfactory  signature  and,  when  presented  
with  the  same  profile,  is  able  to  recognize  the  odour.    
The  electronic  nose  used  in  this  study  is  an  in-­house  instrument  developed  at  Warwick  University.  
It  contains  an  array  of  six  metal  oxide  based  sensors  (high  temperature  resistive  sensors),  as  well  as  six  
electrochemical   sensors,   a   pellister   (catalytic   sensor),   and   an   NDIR   sensor   (optical,   to   monitor  
CO2).  A   list   of   sensors   and  manufacturers   is   given   in  Table   1.   These   different   sensor   technologies  
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were   chosen   for   two   reasons.  First,   it   provides  considerable  diversity   to   the   information   that   can  be  
gathered  from  the  array.  Second,  the  sensors  were  selected  to  be  broadly  tuned  to  gases  and  vapours  
that  we  believe  may  be  important  products  in  the  normal  metabolic  activity  of  the  gut.    
Table   1.   Sensors   deployed   within   the   electronic   nose,   with   descriptions.   Number   is  
brackets  is  sensor  number  within  the  instrument.    
Metal  Oxide  Sensors  
(Figaro  Jpn)  
Electrochemical  Sensors  
(Alphasense/Sensors  Direct,  UK)  
Others  
(Alphasense,  UK)  
TGS813²Low  pressure  gas  (1)   NO2-­A1²Nitrogen  dioxide  (8)   IRC-­A1²Carbon  dioxide  (7)  
TGS821²Hydrogen  (2)   NO-­A1²Nitrous  oxide  (9)   CH-­A3²Flammable  gases  (13)  
TGS822²Organic  solvents  (3)   H2S-­A1²Hydrogen  sulphide  (10)     
TGS824²Ammonia  (4)   CO-­A1²Carbon  monoxide  (11)     
TGS825²Hydrogen  sulphide  (5)   SO2-­A1²Sulphur  dioxide  (12)     
TGS880²Volatile  vapours  (6)   S+H2²Hydrogen  (14)     
Due  to  the  different  types  of  sensors  deployed  within  the  instrument,  it  is  useful  to  transduce  each  of  
the  sensor  outputs  into  a  common  form²in  this  case  voltage.  The  six  metal-­oxide  sensors  were  driven  
with   a   constant   current   source   (100   µA)   and   the   voltage   across   the   sensor   then   amplified   and  
monitored.   The   electrochemical   sensors   were   attained   with   transmitter   boards,   containing   a  
potentiostat  and  drive  circuit  to  give  a  4±20  mA  output.  This  current  was  converted  to  a  0±10  V  signal  
(note  that  the  boards  and  sensors  were  calibrated  for  the  gas  concentration  operating  ranges  defined  by  
the  manufacturer).  The  NDIR  was  also  supplied  with  a   transmitter  board,  giving  a  4±20  mA  output,  
which  again  was  converted  to  0±10  V.  Finally,  for  the  pellister  a  bridge  circuit  was  manufactured  with  
a  differential  output  stage.  Here  the  offset  was  trimmed  to  be  zero  in  laboratory  air  and  the  differential  
output  stage  gain  set  to  20.  The  output  voltage  of  all  these  sensors  was  measured  using  two  National  
Instruments   (USA)   USB-­6009   boards.   The   electronic   nose   was   also   fitted   with   a   temperature   and  
humidity  sensor   (Sensirion  SHT-­15,  Staefa,  Switzerland)   to  monitor   the   input  sample.   In  addition   to  
the   sensors,   the   electronic   nose   was   fitted   with   a   pump   with   flow   sensors,   chamber   temperature  
control,   valves   and  dedicated   software   interface   (written   in  LabVIEW  8.6,  National   Instruments,  
Woburn,  MA,  USA).  
2.2.  FAIMS  Instrumentation  
For  this  study  a  commercial  FAIMS  instrument  was  used,  specifically  a  Lonestar  (Owlstone,  UK).  
FAIMS   is   a   fairly   recent   technological   development   whereby   separation   occurs   due   to   ionised  
molecules  having  different  mobilities  in  high  and  low  electric  fields.  Such  instruments  have  a  number  
of   advantages,   for   example,   they   can   use   scrubbed   air   as   the   carrier   gas,   operate   at   room   pressure    
(or  above),  and  so  no  vacuum  pump  is  required.    
In  a  FAIMS  instrument  the  gas  phase  chemical  input  is  first  ionised  (in  our  case  using  a  Ni-­63  source).  
These  ionised  molecules  then  enter  an  oscillating  high  electric  field,  whereby  molecules  zig-­zag  between  
two  plates  to  which  this  electric  field  is  applied.  This  waveform  is  ³asymmetric´,  thus  a  high  positive  
voltage  is  applied  for  a  short  period  of  time  and  a  low  negative  voltage  is  applied  for  a  longer  period.  
However,   the   integral  of   the  voltage  over  a   time  period   is  zero.  The  waveform   is   stepped   through  a  
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series  of  magnitudes  and  is  called  the  ³dispersion  field´  (DF).  Below  200  V/cm  the  ions,  on  average,  
simply  move  back  and  forth  between  the  plates  but  do  not  drift   preferentially   towards  either  one.  
At   higher   voltages   in   contrast,   for   example   5,000   V/cm   or   more,   some   ions   within   the   complex  
mixture,  on  average  move  more   in   the  direction  of  one  plate.   If  an   ion  contacts   the  plate   it   loses   its  
charge  and  is  not  detected  as  it  exits  the  plates.  Thus  a  balancing  voltage  (known  as  the  ³Compensation  
Voltage´   or   ³CV´)   is   applied,   which   counteracts   this   drift.   This   compensation   voltage   can   be   set  
whereby  only  the  drift  from  a  specific  ion  is  compensated  for  and  will  be  detected.  Thus  by  sweeping  
through   a   range   of   dispersion   fields   and   compensation   voltages   a   complex  mixture   of   gases   can   be  
separated   by   their   differences   in   mobility   in   high   and   low   electric   fields   [17].   Figure   1   gives   an  
example  of  the  applied  waveform  for  FAIMS  and  the  separation  of  ions  by  the  field  plates.  
Figure  1.  (a)  Asymmetric  waveform  applied  in  FAIMS  and  (b)  ions  being  separated  by  an  
asymmetric  waveform.    
  
(a)                                 (b)  
2.3.  Patients  
Patients   were   recruited   from   a   larger   cohort   undergoing   long   course   (radical)   radiotherapy   with  
different  end  points  and  will  be  reported  independently.  Two  groups  were  selected  and  stool  samples  
from   these   patients   were   used   for   this   study.   The   only   criterion   for   inclusion   was   the   degree   of  
gastrointestinal  disturbance  between  baseline  and  after  four  weeks  of  radiotherapy.  This  was  measured  
by   the   IBDQ-­B   score   (described   below).   The   first   group   selected   (group   1)  were   patients  who   had  
minimal  toxicity  as  indicated  by  the  least  fall  in  the  score;;  patients  in  the  second  group  (group  2)  were  
those  who  experienced  the  greatest  fall  in  the  score.  Scientific  and  ethical  approval  was  obtained  from  
local   Research   Ethics   and   Scientific   Committees   of   the   Royal   Marsden   NHS   Foundation   Trust,  
London.   Written   informed   consent   was   obtained   from   all   patients   who   participated   in   the   study.  
Previous   studies   examining   the   potential   for   identifying   patients   at   risk   of   developing   severe  
gastrointestinal   toxicity   during   long   course   pelvic   radiotherapy   treatment   have   employed   similar  
methodologies  and  patient  numbers  [15].    
2.4.  Samples  
All  data  and  samples  were  collected  prospectively.  Faecal  samples  (between  10  and  50  mL)  were  
collected  within  12  h  of   evacuation  and   immediately   stored  at  í20  °C.  Gastrointestinal   toxicity  was  
recorded  using  the  validated  IBDQ-­B,  which  has  been  developed  for  use  in  monitoring  disease  activity  
LQ 8OFHUDWLYH &ROLWLV DQG &URKQ¶V 'LVHDVH >8,19].   The   IBDQ-­B   is   the   bowel   specific   part   of   the  
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questionnaire,  which   is  a  10  question  subset  of   the  IBDQ.  A  maximum  of  seven  points  per  question  
can  be  attained  indicating  no  bowel  toxicity  (totaling  a  maximum  score  of  70)  and  a  minimum  score  of  
1  point  per  question  (minimum  score  of  10  points  showing  most  severe  symptoms).  A  decline  in  score  
therefore  represents  increasing  severity  or  frequency  of  symptoms.  A  decrease  of  more  than  six  points  
has  been  shown  to  be  clinically  significant   in  a  variety  of  settings   [20,21].  Stool  samples  and  IBDQ  
questionnaires  were  collected  from  all  patients  immediately  before  the  start  of  radiotherapy  (indicated  
as  the  baseline  measurement)  and  after  four  weeks  of  treatment.  
2.4.  Analysis  Methodology  
Stool  samples  were  thawed  overnight  to  room  temperature  and  then  heated  to  40  ±  0.1  °C  in  a  
dri-­blockTM  heater  for  1  h  before  the  experiment.  Ten  mL  of  sample  was  aliquoted  to  a  25  mL  sterilin  
bottle  and  5  mL  of  deionized  water  added  and  manually  shaken  to  homogenize  the  sample.  Here,  each  
sample  was  divided  into  two  aliquots,  one  for  e-­nose,  the  other  for  FAIMS.  Due  to  limited  volume  of  
sample,  in  some  cases  there  was  only  enough  sample  for  one  aliquot.  In  these  cases  FAIMS  analysis  
was  prioritized  over  e-­nose.  The  sterilin  bottle  lids  were  also  modified  to  take  pipe  fittings  for  3  mm  
PTFE  tubing.    
For  e-­nose  experiments,  laboratory  air  was  used  as  the  carrier  gas  with  a  measured  humidity  of  
20  ±  2%  r.h.  (relative  humidity).  Before  each  experiment,  laboratory  air  was  pumped  through  the  
e-­nose  at  a  flow  rate  of  500  mL/min  for  450  s  to  create  a  stable  baseline.  The  stool  sample  line  was  
then  switched  in  and  the  headspace  from  the  stool  sample  was   passed  into  the  instrument  (also  at  
500  mL/min  for  450  s),  with  a  further  450  s  of  laboratory  air  to  allow  the  sensors  to  recover  back  to  
their  original  baseline.  Each   sample  was  analysed   in  a   random  sequence  and   run   twice.  The   sample  
humidity  was  measured  for  all  experiments  at  49  ±  5%  r.h.  with  a  random  distribution  between  groups.  
Figure  2.  Typical  output  of  the  (a)  Electronic  Nose  and  (b)  Owlstone  FAIMS  instrument.  
  
(a)  
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Figure  2.  Cont.  
  
(b)  
For  the  FAIMS  instrument,  a  similar  approach  was  taken,  though  here,  clean  scrubbed  compressed  
air   was   used   as   the   carrier.   The   flow   rate   over   the   sample   was   2   L/min,   with   the   dispersion   field  
scanned  between  0  and  90%  in  51  steps  and  the  compensation  voltage  from  í6  V  to  6  V  in  512  steps.  
Each  analysis  took  typically  180  s  and  each  sample  was  analysed  twice.  Figure  2  shows  both  a  typical  
e-­nose  response  (without  legend  for  simplicity)  and  a  FAIMS  response  to  a  stool  sample.  
E-­nose   feature   extraction  was   performed   using  Multisens  Analyzer   (JLM   Innovations,   Tübingen,  
Germany).   E-­nose   analysis   used   the   change   in   voltage   (delta   V)   as   the   input   feature   for   analysis.  
Before  exploratory  analysis  was  performed,  the  data  was  pre-­processed  with  a  standardization  routine,  
built  into  the  Multisens  software.  Here  the  mean  value  of  all  the  features  was  subtracted  from  all  the  
features.  Additionally,   the   features  were   then  divided  by   the   standard  deviation  of   the   features.  This  
was   done   for   two   reasons,   the   first   process   allows   only   the   differences   between   features   to   be  
evaluated,  thus  the  absolute  feature  value  (normally  associated  with  intensity)  was  not  considered.  The  
second  process  ensures  that  each  feature  will  receive  equal  weighting  in  the  exploratory  analysis.  This  
method  has  been  applied  due  to  the  very  different  sensor  technologies  used  within  the  electronic  nose.  
This  data  was  then  analysed  by  two  different  methods,  Principal  Component  Analysis  (PCA)  and  by  
Linear  Discriminant  Analysis  (LDA).  For  PCA,  the  samples  were  analysed  as  a  single  group  and  then  
post-­categorized,  whereas   for   LDA   the   samples  were   pre-­categorised   according   to   clinical   outcome  
(low  and  high  toxicity).  Principal  component  analysis  is  a  method  to  convert  multiple  sensor  responses  
from   a   group   of   observations   (here   patients)   into   a   smaller   number   of   artificial   variables   called  
principal   components,   where   the   total   number   of   principal   components   is   less   that   the   number   of  
sensors.  This   transformation  produces  results  whereby  the  first  principal  component  accounts  for   the  
largest  variability  in  the  data  as  possible.  The  succeeding  principal  components,  in  order,  have  the  next  
highest   variability   and   so   on.   These   additional   components   are   constrained   in   that   they   must   be  
orthogonal   to   (i.e.,   uncorrelated   to)   the   proceeding   components.   Thus,   the   results   produced   by   this  
transformation   are   unclassified,   but   also   show   if   the   different   observations   produce   the   most  
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differences   in   the   sensor   responses.   LDA   is   in   some   ways   similar   to   PCA,   but   in   this   case,   LDA  
attempts   to   find   the   optimum   combination   of   sensors   that   best   separates   the   differences   between  
sample  groups.  So  unlike  PCA,  which  analyses  samples  based  on  the  maximum  difference,  LDA  looks  
for  similarities  within  groups  of  samples.    
FAIMS  data  was  processed   in  Matlab  (Mathworks  Inc.,  Natick,  MA,  USA).  As  stated  earlier,   for  
each  FAIMS  measurement,  the  dispersion  field  was  scanned  between  0  to  90%  and  the  compensation  
voltage  between  í6  V  and  6  V.  This  produces  26,112  data  points  (as  shown  in  Figure  1).  In  addition,  
both  positive  and  negative  ion  counts  were  measured  separately.  Thus,  the  total  number  of  data  points  
was   52,254.   To   pre-­process   this   data,   a   wavelet   transform   was   applied   (Daubechies   D4).  Wavelet  
transforms  are  a  method  used  most  commonly  as  a  way  of  conditioning  a  signal  into  a  more  reduced  
form,   before   data   compression.   In   simple   terms,   it   projects   the   data   on   to   a   basis   set   of   short  
waveforms   (or   wave-­lets).   Where   the   projections   are   large,   this   gives   frequency   and   location  
information  of  this  part  of  the  original  signal.  Such  techniques  are  incredibly  good  at  separating  signal  
information  from  noise.  This  is  a  natural  method  of  pre-­processing  as  the  FAIMS  output  is  a  series  of  
overlapping   peaks,   where   one   peak   arises   from   molecules   with   a   specific   mobility.   The   wavelet  
transform  gives  information  about  this  molecule,  but  also  aids  in  discovering  any  additional  molecules  
with  similar,  but  not   identical  mobilities,  by  looking  for  differences   in   the  frequency  components  on  
the  signal.  Figure  3,  gives  a  section  of  the  data  after  a  wavelet  transform  had  been  applied.  This  was  
for  a  low  toxicity  patient,  before  treatment.  
Figure  3.  Wavelet  transform  of  a  low  toxicity  patient  for  elements  1  to  5,000.  
  
For  analysis  both  the  positive  and  negative  ion  count  matrices  from  each  sample  were  concatenated  
into  a  single  1D  array  52,224  elements  in  length  and  then  the  wavelet  transform  applied.  This  produced  
a  new  1D  array,  again  52,224  elements  in  size.  Due  to  the  large  size  of  the  dataset,  it  was  required  to  
identify   elements   that   are   suitable/useful   in   discriminating   the   different   samples.   To   achieve   this,  
thresholds  were   set   for   the  within   group   (i.e.,   low   toxicity/high   toxicity,   pre   and  post   treatment,  
thus  four  groupsVFDWWHUȈıi)2  DQGWKHEHWZHHQJURXSVFDWWHUıȝ)2Ȉıi)2,  to  identify  dimensions  for  
VHOHFWLRQıi WKHVWDQGDUGGHYLDWLRQRI WKHGLPHQVLRQ LQTXHVWLRQZLWKLQ WKHJURXS LDQGıȝ  was   the  
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standard  deviation  of  the  means  of  the  dimension  under  test  between  classes).  The  exponents  change  
the  form  to  reflect  that  employed  in  Fisher  Discriminant  Analysis  (FDA).  FDA  is  almost  identical  to  
LDA,  except  that  it  does  not  make  some  of  the  assumptions  used  in  LDA  (such  as  normal  distributed  
classes).   It   was   discovered   that   this   gave   better   discrimination   for   the   methods   and   data   captured    
by  FAIMS.  
This  approach  gave  a   two  dimensional   input  parameter   space   to  control   the  separation  algorithm.  
This  space  was  explored  as  follows.  For  each  point  in  the  input  space  20  test  sets  (each  containing  
one   high   toxicity   response   and   one   low)   was   re-­classified.   These   test   sets   were   not   used   in   the  
identification  of  dimensions  or  the  implementation  of  the  FDA.  This  exploration  identified  regions  in  
the  parameter  space  where  re-­classification  exceeded  the  65.8%  that  would  be  expected  for  random  
re-­classification   (two   standard  deviations   from   the  mean),   and   for  which   the   success  of   re-­classification  
was  robust  to  perturbation  in  the  parameters  while  changing  the  number  of  dimensions  identified.    
3.  Results  and  Discussion  
In   total,   23   patients   were   investigated,   11   in   the   low   toxicity   group   and   12   in   the   high   toxicity  
group.   The   sample   number,   age,   male/female   ratio,   radiotherapy   dose   and   symptom   burden  
(IBDQ-­B  score)  analyzed  by  e-­nose  and  FAIMS  is  shown  in  Table  2.  The  patients  were  of  a  similar  
age   in   both   groups   and   had   a   similar   dose   of   radiotherapy,   including   fractionation   and   duration   of  
treatment   (data   not   shown).   By   selection,   the   fall   in   the   IBDQ-­B   score   was   only   slight   in   the   low  
toxicity  group,  but  was  marked  and  significant  in  the  high  toxicity.  Numbers  of  samples  per  instrument  
differs  slightly  due  to  available  volume  of  biological  matter.  Figure  4  shows  the  average  e-­nose  sensor  
responses   to   the   four   groups   from   Table   2   (Figure   4(a)²raw   values   and   Figure   4(b)²normalized  
before  averaged).  Here,  only  one  set  of  data  was  used  for  these  figures,  even  though  the  samples  were  
run  twice.  This  was  done  as  we  have  previously  noticed  sample  depletion  with  running  samples  using  a  
dynamic  sampling  approach,  thus  the  sensors  are  exposed  to  different  gas  profiles  between  tests.    
Table   2.   Baseline   demographic   characteristics   and   treatment   features:   Groups   1   (low  
toxicity)  and  2  (High  toxicity).  
Feature   Electronic  Nose  Analysis   FAIMS  Analysis  
Least  Toxicity:  
Number  of  patients  
(Male:Female)  
Mean  Age  (s.d.):  
Mean  Radiotherapy  dose  
Mean  IBDQ  Scores  (s.d.)  
Pre-­treatment  
N  =  11  
(9:2)  
71.9  (4.8)  
61.8  
67.4  (2.6)  
Post-­treatment  
N  =  8  
(7:1)  
70.9  (5.1)  
63.3  
67.5  (2.7)  
Pre-­treatment  
N  =  11  
(9:2)  
71.9  (4.8)  
61.8  
67.4  (2.6)  
Post-­treatment  
N  =  10  
(8:2)  
71.3  (4.5)  
61.0  
67.3  (2.7)  
High  Toxicity:  
Number  of  patients  
(Male:Female)  
Mean  Age  (s.d.):  
Mean  Radiotherapy  dose  
Mean  IBDQ  Scores  (s.d.)  
Pre-­treatment  
N  =  12  
(9:3)  
69.8  (11.3)  
60.4  
68.8  (1.7)  
Post-­treatment  
N  =  11  
(8:3)  
69.1  (11.1)  
59.5  
48.5  (7.4)  
Pre-­treatment  
N  =  12  
(9:3)  
69.8  (11.3)  
60.4  
68.8  (1.7)  
Post-­treatment  
N  =  10  
(8:2)  
71.8  (7.3)  
61  
49.8  (6.2)  
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Figure  4.  (a)  Averaged  e-­nose  sensor  responses  for  different  sample  groups  (axis  is  change  
in  output  voltage)  and  (b)  Normalized  responses.  
  
(a)  
  
(b)  
Samples  after  radiotherapy  were  analysed  first,  as  the  differences  between  these  groups  were  likely  
to   be   greatest.   Figure   5(a)   shows   the   PCA   of   the   two   groups   after   treatment;;   there   was   a   clear  
separation  between  the  low  and  high  toxicity  groups.  Figure  5(b)  shows  the  loadings  of  this  analysis,  
indicating  that  a  large  number  of  sensors  contributed  to  the  variability.  LDA  was  also  performed   that  
again  showed  clear  separation  between  the  two  groups  (hence  the  results  not  shown  here).  
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Figure  5.  (a)  PCA  results  from  e-­nose  data  and  (b)  loadings  for  samples  taken  four  weeks  
after  treatment  referenced  to  Table  1.  
  
(a)  
  
(b)  
Analysis  of  the  pre-­treatment  samples  by  PCA  Figure  6(a)  and  by  loadings  Figure  6(b)  indicated  a  
difference  between  those  who  ultimately  went  on  to  have  high  or  low  toxicity.  The  differences,  though  
statistically  significant,  were  less  striking.  
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Figure   6.   (a)   PCA   results   from   e-­nose   data   and   (b)   loadings   for   samples   taken   before  
treatment;;  categorized  on  their  post-­treatment  toxicity  referenced  to  Table  1.  
  
(a)  
  
(b)  
Finally,  LDA  was  undertaken  for  all  four  groups.  Though  LDA  could  clearly  separate  high  and  low  
toxicity,  pre  and  post  treatment,  it  could  not  separate  all  four  groups  when  analyzed  together,  as  shown  
in  Figure  7.  What  it  does  suggest  is  that  there  is  a  significant  difference  between  those  susceptible  to  
radiation  damage  to  those  who  are  less  so.    
Although  the  sample  numbers  were  small,  a  KNN  (K-­nearest  neighbour)  algorithm  was  applied  to  
the  electronic  nose  data  to  evaluate  if  it  was  possible  to  classify  each  sample  correctly.  Using  n  í  1  as  
the  training  set  (where  n  is  the  number  of  samples),  it  was  possible  to  correctly  classify  22  out  of  
23  samples  correctly  (pre-­treatment).  When  10  samples  were  moved  at  random  from  the  reference  set  
to  the  test  set,  it  was  still  able  to  correctly  classify  80%  of  the  samples  consistently.  
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Figure  7.  (a)  LDA  of  all  four  groups  using  the  e-­nose  and  (b)  loading  plot  associated  with  
LDA  referenced  to  Table  1.  
  
(a)  
  
(b)  
FAIMS   analysis   was   done   first   from   post   radiotherapy   samples   as   greater   differences   were  
expected,  then  on  the  pre-­treatment  samples  and  finally  as  all  samples  together.  It  was  discovered  that  
FDA  could  separate  the  different  groups  in  all  three  cases.  Figure  8(a)  shows  the  FDA  result  from  the  
FAIMS  data   from  all   the   samples.  Thresholds  of   0.16   on   the   between   class   scatter   and   0.12   on   the  
within  class  scatter  were  imposed  for  the  selection  of  dimensions.  This  identified  23  dimensions  which  
were   used   for   the   FDA.   Taking   one   sample   out   (n  í   1)   and   re-­performing   the   FDA,   the   accuracy    
of   reclassification   was   in   excess   of   90%   for   both   groups.   Figure   8(b)   shows   the   components   of    
the   projection   vector   identified   and   indicate   that   a   large   number   contribute   significantly   to    
the  classification.    
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Figure  8.  (a)  FDA  of  FAIMS  data  to  all  four  groups  and  (b)  loading  plot  associated  with  
FDA  using  dimensions  created  in  the  analysis  described  earlier.  
  
(a)  
  
(b)  
3.1.  Discussion  
Pelvic  radiotherapy  is  a  highly  invasive  procedure  that  frequently  causes  gastrointestinal  side-­effects  as  
a  result  of   tissue  damage.  Currently  there  is  no  reliable  means  of   identifying  those  patients  who  will  
have  a  severe  reaction.  Our  results  indicate  that  the  difference  in  odour  profiles  distinguishes  patients  
severely  affected  from  those  with  milder  symptoms,  using  the  patients  themselves  as  the  control  group  
for  this  pilot  study.  Furthermore,  this  difference  may  be  measured  before  treatment.  As  shown  in  the  
loading  plot  Figures  5(b)  and  6(b)  volatiles  and  gases  obtained  from  stools  collected  before  and  after  
radiotherapy   activate   different   sets   of   sensors,   a   clear   indication   of   a   change   in   the   gas   chemical  
profile.  The  gaseous  outputs  reflect  the  pattern  of  chemicals  released  by  the  fermentation  of  undigested  
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fibre   by   resident   gut  microbes,   principally  within   the   colon.   The   change   observed,  we   hypothesise,  
results  from  radiation  which  perturbs  the  balance  between  the  many  species  that  together  make  up  the  
gut  microflora.  Of  note   is   that   the  LDA  plot  of   the   toxicity  groups  Figure  7(a)   is  unable   to  separate   the  
before  and  after  treatment  for  either  toxicity  group,  but  clearly  distinguishes  those  patients  who  will  be  
severely  affected   from   those   less  so.  More   interesting,   the   loading  plot  Figure  7(b)  shows   that   these  
groups  are  separated  by  gases/vapours  that  could  be  associated  with  the  fermentation  process,  specifically  
hydrogen,  methane/combustible,  carbon  dioxide,  nitrogen  dioxide  and  volatile  organic  compounds.  
Our  pilot  data  do  not  allow  us  to  comment  upon  how  radiation  affects  microbial  behaviour,  either  
by  direct  action  or  indirectly  through  resultant  mucosal  inflammation.  We  are  also  unable  to  comment  
if  the  altered  microbial  balance  is  a  passive  reflection  of  mucosal  inflammation  or  whether  it  actively  
ZRUVHQVLW1HYHUWKHOHVVRXUUHVXOWVVXJJHVWZHQRZKDYHWKHSRWHQWLDOWRLGHQWLI\SDWLHQWV³DWULVN´RI
severe  radiation-­induced  gastrointestinal  damage  before  starting  such  treatment.  
Our  speculation  on  the  role  of  microbes  is  plausible  aQGKDVDSUHFHGHQWLQ&URKQ¶VGLVHDVHDJXW
disease   characterized   by   inflammation²some   patients   affected   mildly   but   others   severely.   Using  
electronic  noses  we  have   identified  that   the  patterns  of  volatiles  and  gases  emitted  from  the  urine  of  
such  patients  has  a  different  pattern  to  that  in  health,  signifying  a  difference  in  the  respective  resident  
PLFURELDOIORUDIXUWKHUPRUHWKHSDWWHUQFKDQJHVDJDLQZKHQ&URKQ¶VDFWLYLW\IODUHVup  [22].  An  interesting  
and  very  relevant  recent  finding  is  that  the  spectruPRIPLFURELDOSURILOHLVUHGXFHGLQ&URKQ¶VGLVHDVH
Hence   there   is   growing   interest   in   the   possibility   that   altered   gut  microbes  may   be  more   intimately  
linked  with  the  disease  than  was  at  first  thought.  
Studying  the  microbial  flora  is  difficult  as  many  species  cannot  (as  yet)  be  cultured;;  hence  complex  
molecular  methods   are   required,  which   currently   remains   at   the   research   level.  Studying   instead   the  
volatiles   from   gut   fermentation   provides   a   more   accessible   insight   into   microbial   behaviour.   Gas  
chromatography   (GC)-­mass   spectrometry   (MS)   can   identify   individual   volatiles   but   is   complex   and  
H[SHQVLYH H[DPLQLQJ WKH RYHUDOO SDWWHUQ RI WKH ³IHUPHQWDWLRQ VLJQDWXUH´ LQVWHDG XVLQJ HOHFWURQLF
noses  or  FAIMS,  is  more  accessible.  
Using  the  electronic  nose  WRUHFRJQL]HRGRXUSDWWHUQVZHZHUHDEOHWRVHSDUDWHWKH³KLJKULVN´JURXS
from   those   at   lower   risk.  We  achieved   the   same  separation  with  FAIMS,  proof  of  principle   that   the  
investigation  of  movement  patterns  of  the  volatiles  can  be  used  in  such  medical  investigations.  
FAIMS  is  an  interesting  technology  for  future  development.  It  has  the  advantages  of  high  sensitivity  
(compared  with  traditional  electronic  nose  instruments),  can  operate  at  room  temperature  and  does  not  
require   special   gases   (as   with   GC   or   GC-­MS).   Its   high   sensitivity   is   however   also   a   limitation   as  
contamination  reduces  performance.  Its  other  limitation  is  the  very  large  datasets  it  generates,  which  in  
our   study   was   50,000   data   points   per   sample.   However,   our   technique   of   wavelet   transformation  
combined  with  FDA  allows  us  to  handle  such  large  data.  FAIMS  is  still  in  its  infancy  but  the  technique  
is   powerful;;   it   therefore   seems   likely   that   as   research   continues   the   instruments   will   improve   and  
evaluation  of  large  datasets  will  allow  full  comparison  with  traditional  electronic  nose  instrumentation.    
4.  Conclusions    
Radiotherapy  as  a  treatment  for  cancer  has  attained  a  high  level  of  success,  but  can  have  major  
side-­effects.  For  those  patients  receiving  pelvic  radiotherapy  there  is  a  marked  variability  in  the  level  
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of  gastro-­intestinal   toxicity   they  may  suffer.  To   inform   treatment  pathway,   it  would  be  beneficial   to  
identify   those   patients   who   will   have   the   most   significant   reaction   and   then   alter   their   treatment  
accordingly²a  patient  tailored  approach.  In  this  pilot  study,  we  have  taken  stool  samples  from  patients  
before  and  four  weeks  after  receiving  radiotherapy.  Of  these  patients  a  subset  of  23  patients,  who  had  
the   most   significant   reaction   and   those   with   the   minimum   reaction,   were   analysed   by   an   in-­house  
electronic  nose  and  a  FAIMS  instrument.  In  this  instance  patients  acted  as  their  own  control,  as  the  aim  
of  our  study  was  to  determine  and  track  any  changes  (gases/volatiles)  which  could  be  detected.  Using  
PCA  for  e-­nose  data  and  a  wavelet  transform  followed  by  FDA  for  FAIMS  data,  the  results  indicated  
that   it   was   possible   to   detect   differences   in   odour   profile   of   stool   samples   after   treatment.   More  
interestingly,  these  patients  can  be  separated  using  these  analysis  techniques  before  radiotherapy.  This  
suggests  that  there  are  substantial  differences  in  stool  composition  between  these  two  groups,  prior  to  
radiotherapy,  indicating  a  difference  in  indigenous  bacterial  micro-­flora  between  patients.  Future  work  
will   look   at   increasing   the   size   of   the   sample   groups,   analysing   patients   between   the   two   extremes,  
undertaking  GCMS   (which   is   particularly   challenging   for   fecal   samples   due   to   the   large   number   of  
different  chemicals  involved)  and  instigating  a  study  into  the  bacterial  differences.  
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Appendix E
Detection of colorectal cancer
(CRC) by urinary volatile
organic compound analysis
This Appendix contains a paper presenting a proof of principle of the effectiveness of
FAIMS at analysing urine samples to detect CRC. I developed the analysis procedure
for the FAIMS spectra, wrote the code to implement it and applied it to the data.
The trial was designed and otherwise implemented by the other authors.
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Abstract
Colorectal cancer (CRC) is a leading cause of cancer related death in Europe and the USA. There is no universally accepted
effective non-invasive screening test for CRC. Guaiac based faecal occult blood (gFOB) testing has largely been superseded
by Faecal Immunochemical testing (FIT), but sensitivity still remains poor. The uptake of population based FOBt testing in
the UK is also low at around 50%. The detection of volatile organic compounds (VOCs) signature(s) for many cancer
subtypes is receiving increasing interest using a variety of gas phase analytical instruments. One such example is FAIMS
(Field Asymmetric Ion Mobility Spectrometer). FAIMS is able to identify Inflammatory Bowel disease (IBD) patients by
analysing shifts in VOCs patterns in both urine and faeces. This study extends this concept to determine whether CRC
patients can be identified through non-invasive analysis of urine, using FAIMS. 133 patients were recruited; 83 CRC patients
and 50 healthy controls. Urine was collected at the time of CRC diagnosis and headspace analysis undertaken using a FAIMS
instrument (Owlstone, Lonestar, UK). Data was processed using Fisher Discriminant Analysis (FDA) after feature extraction
from the raw data. FAIMS analyses demonstrated that the VOC profiles of CRC patients were tightly clustered and could be
distinguished from healthy controls. Sensitivity and specificity for CRC detection with FAIMS were 88% and 60%
respectively. This study suggests that VOC signatures emanating from urine can be detected in patients with CRC using ion
mobility spectroscopy technology (FAIMS) with potential as a novel screening tool.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer
related death in Europe and the USA [1,2]. At present there is a
lack of effective, non-invasive screening tests for CRC. Current
methods utilise guaiac based faecal occult blood (gFOB) testing,
however, this has now largely been replaced by Faecal Immuno-
chemical Testing (FIT). Whilst this is an improvement, FIT still
shows relatively low sensitivity for CRC, 66–88%, depending on
the cut off values for haemoglobin (50–200 ng/ml), with a
specificity of 87–96% [3–5]. The sensitivity for advanced adenoma
is even lower at 27–41%, with a specificity of 91–97% [5]. The
uptake of screening utilising faecal samples is also an issue, with
approximately 50% of invited participants not accepting popula-
tion based FOBt screening in our locality.
Non-invasive testing of cancers, using Volatile Organic Com-
pounds (VOCs) and gases that emanate from urine, breath, stool
and blood, has received growing interest and has been an
expanding area of research in recent years. This work initially
started from the use of canines to detect cancers, which showed a
marked ability to discriminate cancer patients from healthy
individuals [6,7,8]. However, more recently a number of groups
have indicated that it is possible to use gas phase analytical
instruments, specifically gas chromatography and mass spectrom-
etry (GC-MS), selective-ion flow mass spectrometer (SIFT) and the
electronic nose (e-nose), to detect lung, breast, bladder and
prostate cancers [9,10,11,12]. For a detailed review on gas phase
biomarkers in Gastroenterology, please see Arasaradnam et al
[13].
In direct relation to colorectal cancer (CRC), recent work has
shown that it is possible to discriminate cancer from non-cancer
patients, but can also be used for the discrimination of lung, breast,
prostate and colorectal cancer from each other by analysing breath
samples [14]. This is further supported by recent work that has
also shown that CRC can be distinguished from controls with over
75% accuracy using GC-MS, again employing breath analysis
[15]. VOCs present in urine have also been shown to distinguish
CRC patients from control groups and other cancers (leukaemia
PLOS ONE | www.plosone.org 1 September 2014 | Volume 9 | Issue 9 | e108750
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and lymphoma), with GC-MS [16]. The electronic nose (Cyrano
320, Sensigent, USA) has also been shown to discriminate between
CRC and healthy controls when the VOCs profile in faeces are
analysed (85% sensitivity and 87% specificity). Additionally the e-
nose was able to discriminate between advanced adenomas and
healthy controls with 62% sensitivity and 86% specificity [5].
These studies support the existence of putative gas phase bio-
markers within biological output media for detecting CRC and
thus could be the basis of a rapid screening tool.
VOCs can exist in the gaseous phase and are present in exhaled
air, sweat, urine and faeces [17,18]. The mechanism for the
generation of VOCs is the subject of current research but they are
perturbed in many physiological and pathological states - affected
by diet and disease states. It is believed that the generation of
VOCs within the bowel are the result of colonic bacteria
undergoing fermentation of non-starch polysaccharides – fibre
consumed by the host. As such, they represent the complex
interaction of colonic cells, human gut microflora and invading
pathogens [19,20]. The study of the resultant products of
fermentation which we have termed ‘the fermentome’
[17,18,21,22] can be measured in urine. The latter is presumed
possible due to the altered gut permeability afforded in certain gut
diseases [23]. We believe that VOCs represent a bio-signature that
represents the sum of the multifactorial influences (genetics,
environmental factors including diet and disease states) affecting
an individual. The aim of this study was to test the potential of
FAIMS – a novel highly sensitive technology to differentiate
between CRC and healthy controls using only urine samples.
Table 1. Demographic data for CRC and control patients.
N=133 CRC Controls
Number 83 50
Mean Age (years) 60 (17) 47 (16)
Sex: M/F 53:30 21:29
Mean BMI 27 (7) 26 (5)
Current Smokers (% of whole population) 6.0% 1.5%
Alcohol: Greater than recommended units/week (% of whole population) 5.3% 3.8%
Figures in parenthesis are standard deviations (SD).
doi:10.1371/journal.pone.0108750.t001
Figure 1. Log of raw data from the FAIMS instrument for a colorectal cancer patient. Intensity is in arbitrary units of ion count.
doi:10.1371/journal.pone.0108750.g001
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Materials and Methods
2.1 Subjects
One hundred and thirty three individuals were recruited
prospectively for this study. Eighty-three of these patients had
histologically confirmed colorectal cancer and fifty were healthy
individuals who had a recent normal colonoscopy. The mean age
of the CRC patients was 60 years (SD 17 years), 53 (64%) were
male. The demographics of the subjects are shown in Table 1.
2.2 Study Design
This was a case control study where patients were recruited
from outpatient clinics at University Hospital Coventry &
Warwickshire, UK. Urine was then collected in standard universal
Sterilin specimen containers (Newport, UK) and frozen immedi-
ately to 280uC, for subsequent batch analysis.
2.3 Analysis
Samples were thawed at room temperature overnight, aliquoted
into appropriate sample bottles and analysed using the FAIMS
experimental methods described below.
2.3.1 FAIMS. For FAIMS analysis, a commercial instrument
was utilised (Lonestar, Owlstone, UK, employing an ATLAS
sampling system and split flow box). This system achieves
separation of chemical components on the basis of differences in
the electric field dependence of ionised chemical mobilities.
FAIMS allows gas molecules to be separated and analysed at
atmospheric pressure and room temperature, unlike similar
traditional analytical techniques. After a sample is ionised, it is
composed of ions of various sizes and types. These are introduced
between two metal plates and an asymmetric high voltage
waveform is applied to these plates, subjecting the ionized
molecules to high electric fields. The difference in movement of
these molecules within this high electric field can be measured,
thus resulting in a separation of the complex mixture.
A sample of 5 ml of urine is aliquoted into a 20 ml glass vial and
placed inside the ATLAS sampler. The sampler heats the sample
to (in our case) 4060.1uC, when the sample reaches the correct
temperature (typically 10 min), clean synthetic air is passed over
the sample and into the Lonestar FAIMS instrument. The flow
rate over the sample is 500 ml/min and increased to 2 L/min by
additional clean air before being passed into the instrument. The
Lonestar is set up to scan between 0 and 90% dispersion field (the
dispersion field represents the magnitude of the electric field) in 51
steps and a compensation voltage of between 26 V and +6 V in
512 steps. The compensation voltage is used to remove the effect
of the drift produced by the high electric field, thus only molecules
that have a specific mobility exit the plates at that point. Figure 1
shows a typical FAIMS ‘plume’ produced from a CRC patient’s
urine sample plotted on a log scale.
2,3.2 GC-MS. For GC-MS analysis, separate aliquots of 5 ml
are taken from each sample to run through a Bruker Scion SQ
GC-MS instrument. Each aliquot was agitated and heated to 60uC
for 5 minutes, before the contents of its headspace are extracted
using a Combi-PAL ITEX automated pre-concentrator system.
The volatiles contained in the ITEX were then released by heating
to 250uC, and injected into the instrument at a split ratio of 1:20
with helium carrier gas. The Restek Rxi-624Sil column (20 m
length, 0.18 mm ID, 1.0 um df) fitted to the GC was kept at a
constant 50uC for 1 minute before being increased up to 280uC at
a rate of 20uC/min, separating out the constituent VOCs in terms
of molecular weight and polarity. After an initial detection to
produce a chromatogram, the VOC molecules are fragmented by
the mass spectrometer and detected to produce corresponding
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mass spectra. These are correlated with the GC chromatogram
peaks, and checked against a National Institute of Standards and
Technology library (NIST 2013) of chemical compounds. This
was perfrimed in order to gain additional insight into the specific
chemical groups that make up the volatile headspace of the urine
samples in those with CRC.
2.4 Statistical Methods
Data analysis for FAIMS results is performed using Fisher
Discriminant Analysis. This allows for the simple interpretation of
complex data to determine if differences in groups can be detected.
The data was processed in Matlab (Mathworks Inc., USA,
R2013b). For analysis, both the positive and negative ion count
matrices of each sample were concatenated into a single 52,224
element vector (or 1D array). These were then wavelet
transformed using a Daubechies D4 wavelet, a technique
commonly used in data compression and has the ability to
separate out subtle signals within a dataset. Data points within the
52,224 elements suitable for discrimination are then identified.
This is achieved by calculating the within class scatter (Ssi) and
the between class scatter [(sm)
2/(Ssi)
2] for each point within the
vector (thus the same datapoints (or variable) from all the sample
datasets are examined and the within class as well as between class
scatter calculated across all the samples), to generate two further
1D arrays, again formed of 52,224 data points. Different
thresholds are then set for within class and between class scatter
and the variables that are within these thresholds are then used for
data processing by fisher discriminant analysis (FDA; a pre-
classified linear technique). To test the validity of the FDA, five
samples from each group (CRC and controls) were removed
before the FDA was performed. Then, based on the FDA results of
the remnant, a prediction is made on the group of the unknown
Figure 2. Fisher Disciminant Analysis (FDA) of FAIMS data in patients with CRC and controls.
doi:10.1371/journal.pone.0108750.g002
Table 3. GC-MS peaks for the CRC patients and corresponding National Institute of Standards and Technology (NIST) targets for
these peaks.
Average GC Retention Time (min) Major MS Peaks Common NIST targets
1.4 42, 43, 45, 56, 58 Acetaldehyde, Ethylene Oxide, Oxalic Acid
1.53 42, 44, 55, 67 Dimethyl Diazene, Cyclobutyl Amine, Oxepane
1.75 42, 43, 58 Acetone
2.95 39, 43, 44, 58, 71, 86 2-Pentanone, 3-methyl-2-Butanone, 2,3-Butanedione
4.56 43, 58, 71 4-Heptanone, 3-Heptanone, 2,4-dimethyl-3-Pentanone
4.7 44, 51, 63, 78, 104 Acetyloxime-Pyridine Carboxaldehyde, Hydrocinnamoyl-Bezene-ethanamine,
Styrene, Dimethyl-Thiourea
4.77 39, 40, 60, 72, 99 Allyl Isothiocyanate, Isothiocyanato-cyclopropane, 2-cyano-acetamide
5.31 42, 44, 56, 75, 94, 118, 133, 151 Methoxy-phenyl-oxime, Ethylbenzoic acid (pentyl ester), Carbamic acid (methyl ester)
5.38 41, 43, 44, 57, 72 Hexen-1-ol, 4-methyl-1-hexene, Hexanal
doi:10.1371/journal.pone.0108750.t003
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samples. This prediction is based on a KNN (k-nearest neighbor)
method. This process is repeated ten times for each pair threshold
values until optimum thresholds, and thus set of variables, are
identified. This variable group is then used for the remainder of
the analysis process to calculate sensitivity and specificity. For
further details on analyses described in detail, please see
Covington et al [23].
2.5 Ethics
Scientific and ethical approval was obtained from local
Research & Development Department and Warwickshire Ethics
Committee 09/H1211/38. Written informed consent was ob-
tained from all patients who participated in the study.
Results
The demographic data of the cancer and non-cancer group are
described in Table 1. No statistically significant difference between
the groups was noted however, as expected there was male gender
predominance. Details of the tumour staging for the 83 CRC
patients are shown in Table 2.
The analysis of the FAIMS data for CRC patients and controls
was carried out using Fisher Discriminant Analysis, as described
above, and the results from the identified variables are shown in
Figure 2. Reclassification for CRC was correct in 74% of cases
(p,0.001). The sensitivity and specificity of the FAIMS analysis to
detect CRC were 88% and 60% respectively.
The CRC patients’ urine was also analysed by GC-MS, the
results can be found in table 3, along with a list of corresponding
chemicals from the National Institute for Standards and Tech-
nology (NIST) database. No unique chemical was identified in
those with CRC compared with controls.
Discussion
This study is the first to our knowledge to report the utility
FAIMS analyses for CRC detection in urine and supports previous
work by others using electronic nose [5] and GCMS [16]. This has
been achieved by investigating how gases and vapours (VOCs)
emanating from urine samples are disparate in those with CRC
compared with controls. Our findings also support previous work
where, VOC signature differences were noted in CRC patients
within different biological materials (faeces, breath and urine)
[5,15,16]. Our CRC cohort had a male sex predominance, as
would be expected for a population of CRC patients, whilst our
control group had a slight female predominance. This could raise
the prospect of sex bias within the cohort, however, whilst the
pattern of VOCs and by association, the fermentome, could
theoretically be affected by sex and age, data from our previous
published studies of IBD, bile acid malabsorption, pelvic cancer
and coeliac disease have not shown any propensity for age and sex
affecting the VOC signals [23,24,25,26,27].
De Meij et al showed that the e-nose could discriminate CRC
from healthy controls with 85% sensitivity and 87% specificity,
and could also distinguish advanced adenomas from healthy
controls with 62% sensitivity and 86% specificity [5]. Our study
has shown using urine specimens rather than faeces – with FAIMS
demonstrating a sensitivity of 88% and a specificity of 60%. This
has importance especially in our local population where uptake of
screening is poor due to the requirement to produce faecal
samples.
Ion mobility has a number of advantages over both GCMS and
e-nose: for example it is undertaking a physical measurement of
molecules instead of a chemical interaction (as would a traditional
e-nose) and secondly, the sensitivity is much higher i.e. parts per
billion to parts per trillion. This makes it an ideal platform for a
future screening tool especially as the sensitivity is high. Our
findings expand on previous research describing how both e-nose
and FAIMS technologies can be used to distinguish effects of
radiation in pelvic cancers [25] and inflammatory conditions e.g.
between Crohn’s disease and ulcerative colitis [26], in addition to
Bile acid malabsorption and Coeliac disease [23,27].
Genetic stool markers have received interest as a potential non-
invasive screening target for CRC. Lidgard et al [28] performed a
study of automated stool DNA analysis for b-actin, mutant kRAS,
aberrantly methylated BMP3 and NDRG4, and faecal haemo-
globin. This showed a sensitivity of 98% and 90% specificity for
CRC and 57–83% sensitivity for advanced adenomas depending
on size. Our study shows comparable sensitivity results, but at a
much lower process cost, and with urine rather than faecal
sampling.
The unique chemical fingerprint or ‘bio-odorant fingerprint’
produced by the different disease states, and healthy individuals,
shows the potential of this technology to screen for, and aid, in the
diagnosis of CRC. It also has the potential to aid in further
investigation of individuals with other gastrointestinal diseases.
Gases and vapours are thought to be produced by the process of
colonic fermentation involving a complex interaction between the
colonocyte cells, human faecal flora, mucosal integrity and
invading pathogens [17,18]. VOCs emitted from bodily fluids
thus have huge potential as putative biomarkers for use in the
assessment of gastrointestinal diseases. Alterations in the pattern of
VOCs are thought to reflect changes in the gastrointestinal
environment. This suggests a possible role for gut microflora
dysbiosis in the pathophysiology of CRC [29].
Conclusions
This study has shown that the VOC signature present in the
urine of patients with CRC, can be distinguished from healthy
controls using FAIMS. The sensitivity and specificity of FAIMS is
88% and 60% respectively for CRC. Whilst this is lower than the
gold standard of colonoscopy it is comparable with current faecal
stool testing including the guaiac and immunohistochemical
methods. The UK uptake for screening is low; 62%, 57% and
59% uptake in the first, second and third rounds of the national
screening programme [30], and around 50% currently in the local
population. One of the reasons for this is the nature of the
biological sample required. Offering an alternative and less
intrusive option, such as urine rather than faeces, is likely to be
far more acceptable to patients, and can be incorporated into
screening pathways for the future.
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